Home
Stampa
Home
Stampa
 
Auditorium Sala Oggioni
Sala Stucchi
Alabastro A
Alabastro B
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30

13:30 - 16:00 | Special Session

Incontro scuole RaccontART

17:00 - 18:00 | Satellite Symposium

Defining new patient-centric goals to improve long-term treatment success in HIV

18:00 - 20:00

ICAR 2022 Opening Session

14:30 - 16:30 | Pre-Conference advanced course

Focus on viral resistance and variability

14:30 - 16:30 | Pre-Conference advanced course

Clinical and point of care diagnostics for STIs in a PrEP service

14:30 - 16:30 | Pre-Conference advanced course

New psychoactive substances and chemsex. David Stuart Course

  • Auditorium Sala Oggioni
    13:30 - 16:00

    Special Session

    Incontro scuole RaccontART

    Con la sponsorizzazione di:

    Special Session

    Incontro scuole RaccontART

    ICAR dedica particolare attenzione alle tematiche legate alla prevenzione e al coinvolgimento della societa' civile e lancia, come ogni anno, il Contest Artistico RaccontART, giunto all'ottava edizione e destinato agli studenti degli Istituti Scolastici Superiori. RaccontART rappresenta un'occasione unica e preziosa di formazione e informazione in tema di HIV, Infezioni Sessualmente Trasmissibili e Covid-19. Questa sessione è dedicata alla presentazione delle Opere finaliste in concorso, selezionate dalle Giurie Artistica e Tecnico-Scientifica. I primi tre classificati verranno premiati durante l'Opening Session.

    Chairs: A. Caraglia, F. Ceccherini - Silberstein, D. Zagato

    13.30 - 13.40 Benvenuto dei Presidenti ICAR 2022: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi
    13.40 - 14.10 Introduzione e presentazione della Giuria Artistica e Tecnico-Scientifica
    14.10 - 15.45 Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici
    15.45 - 16.00 Conclusioni
    17:00 - 18:00

    Satellite Symposium

    Defining new patient-centric goals to improve long-term treatment success in HIV

    Con la sponsorizzazione non condizionante di:

    Satellite Symposium

    Defining new patient-centric goals to improve long-term treatment success in HIV

    Although 30 years of research and pharmacological innovation have transformed HIV infection into a chronic disease, the persistence of issues related to direct and indirect harm of the virus, life-long ART exposure, higher risk of comorbidities and host peculiarities mean that life-expectancy and QoL of PLWH are still significantly lower compared with general population. In this scenario, the definition of a new and broader concept of long-term treatment success able to meet not only the clinical goals but also needs and expectations of PLWH, becomes even more crucial. A "tailored" approach based on the complexities of the individual (often not manifested) together with the availability of ARVs optimized in terms of efficacy, genetic barrier, forgiveness, tolerability, and convenience are probably the key to reach this ambitious goal. Through an interactive talk, experts will discuss on current challenges and available strategies to fill these gaps, also with the support of real-life data.

    Chair: G. Di Perri

    17.00 - 17.15 How to define long-term treatment success for PLWH and which attributes are requested to ARV?
    M. Andreoni
    17.15 - 17.55 Round-table discussion on how to improve outcomes with current antiretroviral therapy:
    Conductor: A. Gori
      - How important are high genetic barrier, forgiveness and adherence?
    G. Di Perri
      - How to optimize the long-term treatment outcomes in experienced patients?
    R. Gagliardini
      - What is the added value of real-word evidence?
    L. Taramasso
    17.55 - 18.00 Take-home messages and conclusions
    G. Di Perri
    18:00 - 20:00

    ICAR 2022 Opening Session

    ICAR 2022 Opening Session

    Conduce: T. Cartolano

    Chairs: A. Antinori, M.G.L. Cernuschi, F. Maggiolo, M. Zazzi

    18.00 - 18.20 Introducing ICAR 2022. Chairs and Authorities' welcome addresses
    18.20 - 18.40 RaccontART contest Awards
    18.40 - 19.10 Mauro Moroni Memorial Lecture COVID-19 past, present and future. Will Covid ever retire?
    M. Andreoni
    19.10 - 19.40 HIV as a chronic disease: myth or truth?
    F. Maggiolo, S. Mattioli
    19.40 - 20.00 Opening session closing remarks
  • Sala Stucchi
    14:30 - 16:30

    Pre-Conference advanced course

    Focus on viral resistance and variability

    Pre-Conference advanced course

    Focus on viral resistance and variability

    RNA viruses show a great potential for genetic variation, rapid evolution and adaptation. Genetic variability may affect pathogenesis, epidemiology and the success of antiviral therapy. In the past months, several SARS-CoV-2 variants of concern (VOCs) have emerged and an intense monitoring of their circulation worldwide plays a crucial role not only in surveillance but also as part of containment and mitigation strategies. Different molecular methods to detect and characterize a specific viral variant have been developed. Many of these assays can accurately identify the variants, while others require confirmation by sequencing. Viral genetic variability is also responsible for drug resistance, a well known phenomenon in HIV infection. Despite successful antiretroviral therapy, a minority of people living with HIV (PLWH) still have difficulty in achieving and maintaining virological suppression, mainly due to HIV drug resistance, and a small group of them harbor multi-drug resistant viruses. In this scenario, the emergence of drug resistance mutations to the latest antiretroviral drugs should be carefully investigated. Nowadays, more than 90% of PLWH have undetectable viral load. ART optimization or simplification in this clinical setting can be critical, especially when previous ART history is complex or unknown. The current transition from Sanger sequencing to Next Generation Sequencing to detect archived HIV drug resistance mutations could offer novel treatment-relevant insights and improve the management of virologically suppressed patients.

    Chairs: R. Gagliardini, V. Micheli, O. Turriziani

    14.30 - 15.00 HIV drug resistance mutations to new antiretroviral drugs
    F. Saladini
    15.00 - 15.30 Detection of archived HIV drug resistance mutations in virologically suppressed individuals by different genotyping techniques: from Sanger to NGS
    M. Santoro
    15.30 - 16.00 Molecular assays to characterize SARS-CoV-2 viral variants
    S. Messali
    16.00 - 16.30 Discussion on Course issues
  • Alabastro A
    14:30 - 16:30

    Pre-Conference advanced course

    Clinical and point of care diagnostics for STIs in a PrEP service

    Pre-Conference advanced course

    Clinical and point of care diagnostics for STIs in a PrEP service

    The syndromic approach for the management of sexually transmitted infections (STIs) relies on the assessment of patient's general complaints: clinical evaluation represents the best and fastest way to choose the appropriate treatment. Laboratory tests provide the correct etiologic diagnosis but turn-around times could be an issue in a clinic dedicated to PrEP care, where a high burden of STIs and heavily interconnected sexual networks require a rapid handling. Overtreatment and spread of antimicrobial resistance are additional drawbacks if microbial diagnosis is not readily available. Point-of-care diagnostics could be helpful both in hospital- and community-based services for rapid diagnosis and epidemiological monitoring of people in PrEP.

    Chairs: V. Mazzotta, R. Rossotti

    14.30 - 15.00 Traditional versus point of care diagnostics for STIs: pros and cons
    A. Nava
    15.00 - 15.30 Clinical approach to the diagnosis of STIs, treatment criteria and concerns about microbial resistance
    S. Pittalis
    15.30 - 16.00 Management of STIs diagnosis in a community-based, peer-run PrEP service
    P.L.G. Vinti
    16.00 - 16.30 Discussion on Course issues
  • Alabastro B
    14:30 - 16:30

    Pre-Conference advanced course

    New psychoactive substances and chemsex. David Stuart Course

    Pre-Conference advanced course

    New psychoactive substances and chemsex. David Stuart Course

    Chemsex can be defined as the use of specific drugs (chems), in a sexualized context, by gay men and other men who have sex with men. Chemsex is associated with peculiar socio-cultural aspects of MSM sexuality. Chems use also varies in different geographical areas according to availability, affordability or other circumstances. Initially three substances only have been named as chems. Other substances now are added to chems. Chemsex adds ritual aspects, often driven by dating networks, to MSM sexual behavior. It is a complex phenomenon that involves different areas and can have different impact on different people and require different approaches. There is a need for more information about substances and how to reduce risks associated with their use, while for more problematic aspects (social, behavioral, psychologic, psychiatric, and medical), a therapeutic group's experience - supervised by a psychotherapist - can be an opportunity to cope with abuse.

    Chairs: G. Fracca, M. Lanza

    14.30 - 14.50 Definition and evolution of sexualized psychoactive substances' use in Italy
    F.M. Nimbi
    14.50 - 15.10 MPDV and free coke as chems. Harm reduction-
    M. Lanza
    15.10 - 15.30 Chemsex as social ritual among MSM
    G.M. Corbelli
    15.30 - 15.50 Chemsex addiction: dealing with the unconscious as a pathway for treatment
    G. Fracca
    15.50 - 16.30 Discussion on Course issues
 
Auditorium Sala Oggioni
Sala Stucchi
Alabastro A
Alabastro B
Bergamo Science Center
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30

09:00 - 10:00

Keynote Lectures

10:05 - 11:05 | Sponsored Symposium

Being pioneers of a new paradigm: what have we learned so far?

11:10 - 12:10 | Satellite Symposium

HIV: act in the present and challenge the future

12:15 - 13:15 | Symposium

New Insights and Challenges on Hepatitis and HIV Co-infections

14:30 - 15:30 | Sponsored Symposium

Long Term Treatment Success for PLWH: from clinical trials to real world experience with B/F/TAF

15:35 - 16:35 | Symposium

At the edge of PREP

16:40 - 17:40 | Symposium

Monoclonal antibodies and antiviral agents in COVID-19: rational for use and best candidates

17:45 - 18:45 | Symposium

Challenges in HIV cure: getting to zero reservoir

10:05 - 11:05 | Oral Communications

PrEP: new data and issues

11:10 - 12:10 | Oral Communications

Immunological efficacy of SARS-CoV-2 vaccine I

12:15 - 13:15 | Expert Meeting

Narrative Medicine applied to Vaccination during Covid-19 pandemic

13:15 - 14:30 | Special Session

How to use U=U to fight stigma

14:30 - 15:30 | Oral Communications

COVID-19: clinical management

15:35 - 16:35 | Oral Communications

Pathogenesis & Immunology

16:40 - 17:40 | Oral Communications

From HIV to SARS-CoV-2

17:45 - 18:45 | Oral Communications

Metabolic alterations: effect of drugs and diseases

10:05 - 11:05 | Satellite Symposium

Hepatitis Delta in HIV/HBV Infected Patients

11:10 - 12:00 | Oral Poster

COVID-19: treatment strategies II

12:15 - 13:15 | Sponsored Symposium

Cabotegravir + rilpivirine long-acting: are we ready for the new era?

13:15 - 14:15 | Oral Communications

Metabolic issues in effective HAART

14:30 - 15:30 | Expert Meeting

The new recombinant adjuvanted vaccine against Herpes Zoster: clinical data and recommendations

15:35 - 16:35 | Interactive Expert Meeting

Affairs of the heart in HIV: redundant or a key challenge?

16:40 - 17:40 | Expert Meeting

Evolving models of care in the management of Gram+ infectious diseases: the role of long-acting antibiotic therapies

17:45 - 18:45 | Oral Communications

Special issues in clinical HIV

11:10 - 12:00 | Oral Poster

Treatment of naive PLWH: current strategies and rapid start of ART

13:25 - 14:15 | Oral Poster

Predictors of COVID-19 severity

14:30 - 15:20 | Oral Poster

Viro-immunological correlates of COVID-19 severity

15:35 - 16:25 | Oral Poster

Neuropsychological complications in COVID-19

16:40 - 17:30 | Oral Poster

Cardiovascular diseases, osteoporosis but not only

17:45 - 18:35 | Oral Poster

Measuring HIV stigma and disclosure

10:05 - 10:55 | Oral Poster

COVID-19: treatment strategies I

11:10 - 12:00 | Oral Poster

PrEP: real life experience

12:15 - 13:05 | Oral Poster

Access to test and educational aspects

13:25 - 14:15 | Oral Poster

HCV eradication: general and key populations

14:30 - 15:20 | Oral Poster

Issues on mental health, sexual health and STIs

15:35 - 16:25 | Oral Poster

New issues on dual therapy

16:40 - 17:30 | Oral Poster

Vulnerable and key population: local experiences

17:45 - 18:35 | Oral Poster

Models of COVID-19 pathogenesis and response to vaccination

  • Auditorium Sala Oggioni
    09:00 - 10:00

    Keynote Lectures

    Keynote Lectures

    Chairs: M.G. Di Benedetto, A. Lazzarin

    09.00 - 09.30 Virus spillover
    G. Antonelli
    09.30 - 10.00 Innate immunity and COVID-19
    C. Garlanda
    10:05 - 11:05

    Sponsored Symposium

    Being pioneers of a new paradigm: what have we learned so far?

    Con il supporto di:

    Sponsored Symposium

    Being pioneers of a new paradigm: what have we learned so far?

    The life expectancy of people living with HIV (PLHIV) is now close to the one of HIV negative people. This important milestone has been achieved thanks to the continuous evolution of antiretroviral therapy (ART), the basis of which continuous improvement placed on providing optimal therapeutic options for long-term management. In this context, ART therapy has evolved in the direction of 2-drug regimens (2DR), which represent a new paradigm supported by solid evidence from clinical trials confirmed in real-life. In particular, dolutegravir/lamivudine (DTG/3TC) represents an important therapeutic option, both in the initial phase of treatment and in the switch from ARV. Starting from these assumptions, the session will focus on the learnings coming from the validation of this new paradigm which bases its foundations on robust data, and which means having an additional option to personalize treatment for PLHIV naïve and virologically suppressed. Regarding these aspects, the most recent data available for regimens containing dolutegravir and lamivudine (DTG / 3TC; DTG + 3TC) will be discussed.

    Chairs: S. Cicalini, R. Gulminetti

    10.05 - 10.15 Introduction
    10.15 - 10.30 The relevance of robust and valuable data
    P. Mohammed
    10.30 - 10.50 The meaning of personalizing treatments
    C. Mussini
    10.50 - 11.05 Questions & Answers
    11:10 - 12:10

    Satellite Symposium

    HIV: act in the present and challenge the future

    Con la sponsorizzazione non condizionante di:

    Satellite Symposium

    HIV: act in the present and challenge the future

    Since the introduction of ART there has been increased survival in PLWH; nowadays it is important to answer to needs of every single HIV-positive patient - requiring long-life antiretroviral treatments providing durability and tolerability- but also to consider the challenges raising from HIV-negative at-risk population. The aim of this Symposium is to deepen the challenge coming from the HIV vaccine as public health measure, focusing on clinical and social aspects. Furthermore, it is of utmost importance keep the focus in the present days for discussing the appropriate treatment strategies to adopt in daily practice for improving patients care.

    Chairs: A. Cingolani, G.M. Corbelli

    11.10 - 11.30 What we know about HIV Vaccine?
    S. Nozza
    11.30 - 11.50 PI-based learning
    S. Rusconi
    11.50 - 12.10 Discussion on Symposium issues
    12:15 - 13:15

    Symposium

    New Insights and Challenges on Hepatitis and HIV Co-infections

    Symposium

    New Insights and Challenges on Hepatitis and HIV Co-infections

    This symposium is aimed at providing new insights on three topics in the field of hepatitis and HIV coinfections. In particular, the first lecture will provide a comprehensive overview on novel anti-HBV drugs, targeting different phases of HBV life cycle, that should go beyond the concept of virological suppression and aim at achieving HBV functional cure. Particular attention will be dedicated to the challenges that virologists and clinicians will have to cope to reach this important end-point. With a decade left to reach the ambitious WHO goals for viral hepatitis elimination, many challenges still remain concerning the need to scale-up HCV testing and expand access to HCV treatment particularly in marginalized populations at risk for HCV infection. The importance of these aspects in elimination efforts, with an emphasis on micro-elimination strategies, will be explored in the second lecture of the symposium. Finally, the third lecture will be dedicated to HIV+CMV coinfection, an intriguing and crucial aspect contributing to HIV pathogenesis. Indeed, persistent CMV replication or reactivation have been demonstrated to fuel HIV reservoir and to exacerbate the process of inflammaging and immune-senescence.

    Chairs: N. Coppola, V. Svicher

    12.15 - 12.30 Novel anti-HBV drugs on the horizon
    S. Valentina
    12.15 - 12.30 Novel anti-HBV drugs on the horizon
    A.M. Geretti
    12.30 - 12.45 The road towards HCV elimination: is the WHO target achievable in time?
    M. Puoti
    12.45 - 13.00 What's new on HIV & CMV coinfection?
    M. Lichtner
    13.00 - 13.15 Discussion on Symposium issues
    14:30 - 15:30

    Sponsored Symposium

    Long Term Treatment Success for PLWH: from clinical trials to real world experience with B/F/TAF

    Simposio promozionale di:

    Sponsored Symposium

    Long Term Treatment Success for PLWH: from clinical trials to real world experience with B/F/TAF

    Despite all the advances in therapeutic strategies, HIV remains a complex disease that has a significant impact on the lives of PLWH. To address this complexity, Gilead emphasizes the importance of Long-Term Treatment Success (LTTS). The LTTS has the patient's long-term therapeutic success as its objective. This is achieved not only with the classic parameters of effectiveness and safety but also with a whole series of other aspects that impact the quality of life of the patient living with HIV. Long Term Treatment Success should be the goal for every clinician when facing PLWH. Every person living with HIV must be able to live their lives in the best possible way. The Symposium will analyze how B/F/TAF ensures Long Term Treatment Success both through 5-year follow-up data from clinical trials and with numerous Real World Evidence data from various Italian centers that will be discussed in a roundtable.

    Chair: A. Castagna

    14.30 - 14.45 Long term treatment success in the clinical trials: 5 years data with B/F/TAF
    S. Lo Caputo
    14.45 - 15.25 Experiences from Italian cohorts: Round Table
    Conductor: G. Madeddu
    Discussants: S. Cicalini, G. d’Ettorre, V. Esposito, L. Gazzola, N. Gianotti
    15.25 - 15.30 Discussion on Symposium issues
    15:35 - 16:35

    Symposium

    At the edge of PREP

    Symposium

    At the edge of PREP

    The efficacy of PREP as an HIV prevention tool is universally recognized. However, most literature data demonstrating PREP efficacy and effectiveness come from studies on MSM. Some aspects of PREP still need to be defined in order to understand its effectiveness and maximize its implementation. In this symposium we want to explore some aspects that still represent gray areas with regard to PREP, in particular the effectiveness and efficacy in populations less represented in clinical trials, such as women, transgender population, IVDU population, etc., with an eye both to real world experiences in these populations and to regulatory aspects of use, or how PREP can fit within protocols of vaccine prevention.

    Chairs: D. Calzavara, S. Mattioli

    15.35 - 15.45 Populations not represented in clinical trials: regulatory aspects
    W.R. Nutland
    15.45 - 15.55 Populations not represented in clinical trials: experiences on the field
    M.N.T. Appenroth
    15.55 - 16.10 Ethicality of PREP in vaccine protocols and beyond
    G.M. Corbelli
    16.10 - 16.25 Cost-efficacy of PREP
    E. Girardi
    16.25 - 16.35 Discussion on Symposium issues
    16:40 - 17:40

    Symposium

    Monoclonal antibodies and antiviral agents in COVID-19: rational for use and best candidates

    Symposium

    Monoclonal antibodies and antiviral agents in COVID-19: rational for use and best candidates

    The development of therapeutic monoclonal antibodies and direct antiviral agents is currently at the front line of fighting against the COVID-19 pandemic. However, the emergence of SARS-CoV-2 variants, as BA.1 and BA.2 lineages, inducing escape from most of monoclonal antibodies represents a great challenge. Furthermore, as additional variants of concern will likely continue to emerge, there is a high unmet medical need for therapeutics that, alone or in combination, can remain effective as the virus evolves. The Symposium will present the state of the art of virological, clinical and immunological research against COVID-19 with a look at the promising clinical data emerging from the use of monoclonal antibodies and the most recent clinical experiences in the field.

    Chairs: A. Antinori, M. Zazzi

    16.40 - 16.55 Neutralizing antibodies overcome SARS-CoV-2 BA.1 and BA.2 antigenic shift
    D. Corti
    16.55 - 17.10 Evolving clinical use and real-life strategies for early treatment of not-hospitalized COVID-19 patients
    V. Mazzotta
    17.10 - 17.25 Could monoclonal antibodies early exposure antagonize anomalies of innate and adaptive immune reponse in COVID-19?
    A. Bandera
    17.25 - 17.40 Discussion on Symposium issues
    17:45 - 18:45

    Symposium

    Challenges in HIV cure: getting to zero reservoir

    Symposium

    Challenges in HIV cure: getting to zero reservoir

    Despite sustained control of HIV replication is now achievable with convenient and well-tolerated antiretroviral treatments, the establishment of a lifelong persistent cellular reservoir precludes the eradication of the infection. Thus, characterizing and quantifying the intact viral reservoir is considered an essential prerequisite for the development and the clinical evaluation of curative strategies. Moreover, viral persistence has been demonstrated in several organs and tissues with the highest amount in lymph nodes, gastrointestinal tract, and central nervous system. Understanding the dynamics of drug penetration in the different cellular reservoirs is vital for increasing the efficacy of both antiretroviral therapy and investigational curative approaches. This symposium aims to show and discuss the recent results and advances in laboratory techniques and pharmacology that might lead to pave the way for the eradication of HIV infection.

    Chair: F. Ceccherini - Silberstein

    17.45 - 18.00 Characterizing and quantifying the HIV reservoir
    F.R. Simonetti
    18.00 - 18.15 Pharmacology of the HIV reservoir
    A. Calcagno
    18.15 - 18.45 Round table
    Discussants: A. Calcagno, A. De Maria, G. Nunnari, F. Simonetti, O. Turriziani
  • Sala Stucchi
    10:05 - 11:05

    Oral Communications

    PrEP: new data and issues

    Oral Communications

    PrEP: new data and issues

    Chairs: M.G. Di Benedetto, P. Meli

    10.05 - 10.15

    OC 1

    Impact of SIMIT PrEP eligibility criteria on retention in care and new sexually transmitted infections acquisition
    R. Rossotti1,5, G. Mulé2,5, A. Tavelli3, A. De Bona2,5, C. Muccini4,5, D. Moschese5,6, S. Bossolasco4,5, D. Calzavara5, A. Foschi5,6, V. Ferrara5, R. Repossi5, M. Cernuschi4,5, A. d’Arminio Monforte2,7
    1Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, 2Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, 3ICONA Foundation, Milan, 4Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, 5Milano Checkpoint, Milan, 6I Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, 7University of Milano, Milan

    10.17 - 10.27

    OC 2

    Sexually transmitted infection and adherence in an Italian access program of HIV pre-exposure prophylaxis (ItaPrEP)
    V. Mazzotta1, S. Lanini1, D. Calzavara2, A. Tavelli3, A. De Bona3, F. De Zottis1, V. Ferrara2, S. La Monica4, S. Mattioli5, A. Bianchi6, G. Mulè3, L. Badia5, S. Bossolasco2, E.Rozenn7, R. Bellagamba1, D. Tesoro3, R. Rossotti8, M. Pedone5, S. Nozza9, P. Tomasi5, L. Biasoli3, F. Gili7, M. Bonanni5, A. Copes3, A. Castagna9, A. Gori10, M. Puoti8, G.Rizzardini11, M. Andreoni12, C. Mastroianni13, R. Cauda4, V. Puro7, A. Cingolani4, G.M. Corbelli5, M. Cernuschi2,6, A. d’Arminio Monforte3, A. Antinori1
    1HIV/AIDS Unit, INMI L. Spallanzani IRCCS, Roma, 2Milano Checkpoint, Milano, 3ASST Santi Paolo e Carlo, University of Milano, 4Fondazione Policlinico A. Gemelli, Catholic University, Roma, 5PLUS aps (BLQ Checkpoint), Bologna, 6ASA Onlus, Milano, 7CRAIDS, INMI L. Spallanzani IRCCS, Roma, 8ASST Niguarda Hospital, Milano, 9HSR San Raffaele Scientific Institute, Milano, 10IRCCS Policlinico Ospedale Maggiore, Milano, 11ASST L. Sacco Hospital, Milano, 12Tor Vergata University, Roma, 13Sapienza University, Roma

    10.29 - 10.39

    OC 3

    Prevalence of anal HPV infection among PrEP users screened through a self-administered Point-of-Care test: data from a community-based PrEP programme in Milan
    L. Biasioli1,3, R. Rossotti1,4, A. Tavelli1,3, A. De Bona1,3, C. Tincati3, D. Calzavara1, P. Vinti1, C. Baiguera1,4, R. Repossi1, V. Ferrara1, S. Bossolasco1,2, C. Muccini1,2, D. Tesoro1,3, A. D’Arminio Monforte1,3, M. Cernuschi1,2 on behalf of the Milano Check Point Group
    1Milano Check Point, Milano, 2IRCCS San Raffaele Scientific Institute, Milano, 3ASST Santi Paolo e Carlo, Milano, 4ASST Niguarda Hospital, Milano

    10.41 - 10.51

    OC 4

    PrEP use disclosure to sexual partners, friends and relatives: a psycho-social analysis
    A. Bianchi1,2, A. Tavelli3, P.L. Vinti2, D. Calzavara2, V. Ferrara2, A. Antonino1,2, F. Rossi1,2, M. Massa2, A. De Bona3, D. Rossotti2,4, S. Bossolasco2,5, D. Canetti5, A. Foschi2,6, D. Tesoro3, G. Mulé2,3, R. Repossi1,2, N. Frattini1,2, E. Garavaglia1,2, C. Ferrara1,2, D. De Cia Warzanowski2, M. Cernuschi1,2,5
    1ASA. Associazione Solidarietà AIDS, Milan, Italy, 2Milano Checkpoint, Milan, 3San Paolo Hospital, Milan, Italy, 4ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, 5San Raffaele Hospital, Milan, Italy, 6Luigi Sacco Hospital, Milan, Italy

    11:10 - 12:10

    Oral Communications

    Immunological efficacy of SARS-CoV-2 vaccine I

    Oral Communications

    Immunological efficacy of SARS-CoV-2 vaccine I

    Chairs: A. Bandera, F. Castelli

    11.10 - 11.20

    OC 5

    Poor humoral immunogenicity to SARS-CoV-2 vaccination in people living with HIV (PLWH) with low CD4 count
    A. Vergori1, A. Cozzi-Lepri2, M. Giannella3, A. Tavelli4, A.M. Azzini5, L. Marconi3, S. Cicalini1, A. Rodanò4, S. Meschi1, M. Fusto1, A. Sartor6,G. Matusali1, S. Piconi7, G.Pellicano8, A. Cascio9, G. Levy-Hara10, A. Costantini11, G. Madeddu12, G. Marchetti4, P. Viale3, E. Tacconelli5, A. d'Arminio Monforte4, A.Antinori1 for the VAXICONA-ORCHESTRA Study Group
    1National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, 2CREME, Institute for Global Health, UCL, London, UK, 3Unit of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, 4Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy, 5Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy, 6Microbiology Unit, Udine University Hospital, Udine, Italy, 7Infectious Diseases Unit, A. Manzoni ASST Lecco, Lecco, Italy, 8Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy, 9Infectious and Tropical Diseases Unit, PROMISE, University of Palermo, Palermo, Italy, 10Instituto Alberto Taquini de Investigación en Medicina Traslacional, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina, 11Clinical Immunology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Marche Polytechnic University, Ancona, Italy, 12Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy

    11.22 - 11.32

    OC 6

    Humoral immunogenicity to SARS-CoV-2 mRNA vaccine third additional/booster shot in people living with HIV (PLWH) by current CD4 count
    A. Antinori1, A. Cozzi-Lepri2, A. Vergori1, A. Tavelli3, M. Giannella4, S. Cicalini1, L. Marconi4, V. Yellenki3, S. Meschi1, G. Pellicanò5, N. Carroccia4, G. Matusali1, A. Latini6, M. Lichtner7, S. Lo Caputo8, F.M. Fusco9, G. Marchetti3, E. Tacconelli10, A. d'Arminio Monforte3 for the VAXICONA-ORCHESTRA Study Group
    1National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, 2CREME, Institute for Global Health, UCL, London, UK, 3Unit of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, 4Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy, 5Dertment of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy, 6Department of Dermatology, San Gallicano Institute IRCCS, Roma, Italy, 7Santa M. Goretti Hospital, Sapienza University, Latina, Italy, 8Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, 9AORN Ospedali Dei Colli, Cotugno Hospital, Naples, Italy, 10Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy

    11.34 - 11.44

    OC 7

    Longitudinal characterization of interferon and antibody response following vaccination against SARS-CoV-2 in patients with HIV-1 infection
    M. Scordio1, F. Frasca1, L. Santinelli2, L. Maddaloni2, L. Sorrentino1, M. Fracella1, E.N. Cavallari2, A. Napoli2, L. Cinti2, P. Roberto2, G. Ceccarelli2, A. Gaeta2, G. Antonelli1,3, C. M. Mastroianni2, G. d’Ettorre2, C. Scagnolari1
    1Laboratory of Virology, Department of Molecular Medicine, Sapienza University, Rome, Italy, 2Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy, 3Microbiology and Virology Unit, Sapienza University Hospital “Policlinico Umberto I”, Rome, Italy

    11.46 - 11.56

    OC 8

    T-cell and humoral responses to mRNA-1273 vaccine up to 6 months in late presenter people living with HIV (PLWH)
    M. Augello, V. Bono, R. Rovito, M. Hadla, V. Yellenki, C. Tincati, A. d’Arminio Monforte, G. Marchetti
    Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy

    12:15 - 13:15

    Expert Meeting

    Narrative Medicine applied to Vaccination during Covid-19 pandemic

    Con il supporto di:

    Expert Meeting

    Narrative Medicine applied to Vaccination during Covid-19 pandemic

    Considering SARS-CoV-2 rapid spread and mortality rate, effective vaccines are needed to control the pandemic. Population is called to make a choice: to accept or refuse vaccination. Data of vaccination clinical trials have shown good results both in efficacy and safety, however long-term data are still to come; meanwhile the virus mutates, and the polarization between the Pro Vax and the No Vax groups, with a number in between identified as the Hesitancy group, is growing, despite the majority of people are Pro Vax. The aim of the Expert Meeting is to debate on different perceptions of people around vaccines and understand propensity to remain vaccinated against infectious diseases, taking advantage of the results of a research based on Narrative Medicine applied to COVID-19 vaccination.

    Moderator: S. Vella

    Discussants: M.G. Marini, F. Moccia, E. Volpato

      Narrative medicine and bioethicsto investigate citizenshipattitudeto Covid-19 vaccination
    M.G. Marini
      Narrative Medicine applied to Vaccination during Covid-19 pandemic
    E. Volpato
    13:15 - 14:30

    Special Session

    How to use U=U to fight stigma

    Special Session

    How to use U=U to fight stigma

    Undetectable=Untransmittable (U=U) concept represents a revolution for people living with HIV. It means the end of fear of transmitting the infection, even through unprotected sex. The end of stigma. In Italy, the Consensus Conference (published by sections L and M of Ministry of Health's CTS - Technical Scientifical Committee) formulated U=U concept in an extensive, clear, doubt free approach. This evidence has neither been acquired by many doctors, nor explained to many people living with HIV. There is no communication campaign directed to the general population. In this session we share different experiences, showing how U=U positively improved the social life of people living with HIV, and how on the other hand the absence of adequate information directed to the general population and institutions, contributes to maintain heavy stigma against HIV.

    Chairs: G.V. Calvino, A. Moznich

    14:30 - 15:30

    Oral Communications

    COVID-19: clinical management

    Oral Communications

    COVID-19: clinical management

    Chairs: M. Bassetti, R. Cauda

    14.30 - 14.40

    OC 13

    Home prescription treatment and mortality risk after hospitalization with symptomatic COVID- 19 disease
    A. Dessilani, A. Cozzi-Lepri, E. Franceschini, G. Guaraldi, V. Borghi, M. D. Di Trapani, M. Del Monte, F. Medioli, I. Baldisserotto, S. Esperti, A. Mazzocchi, J. Conti, A. Gallerani, N. Barp, A. Spadoni, V. Menozzi, C. Mussini
    Struttura Complessa di Malattie Infettive, AOU Policlinico di Modena, Modena

    14.42 - 14.52

    OC 14

    In vivo efficacy of monoclonal antibodies and direct antiviral agents against the SARS-CoV-2 BA.1 and BA.2 Omicron sublineages
    V. Mazzotta1,2, A. Cozzi Lepri3, F. Colavita1, S. Lanini1, R. Rosati1, E. Lalle1, C. Cimaglia1, I. Mastrorosa1, J. Paulicelli1, S. Vita1, E. Caraffa1, G. Matusali1, A. Vergori1, G.Giannico1, G. Maffongelli1, E. Milozzi1, D. Donno1, P. Vittozzi1, F. De Zottis1, P. Piselli1, E. Girardi1, A.R. Garbuglia1, F. Vaia1, E. Nicastri1, A. Antinori1
    1National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, 2PhD course in Microbiology, Immunology, Infectious Diseases, and Transplants (MIMIT), University of Rome Tor Vergata, Rome, Italy, 3Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK

    14.54 - 15.04

    OC 15

    Anemia is strongly associated with severity and mortality of COVID-19 in hospitalized patients
    F. Di Gennaro, G. Brindicci, M. Cormio, V. Guerra, A. Lugli, L. De Santis, A. Procopio, D.F. Bavaro, E. Milano, N. De Gennaro, G. De Iaco, R. Lattanzio, C.R. Santoro, A. Saracino
    Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari Italy

    15.06 - 15.16

    OC 16

    Clinical characteristics and outcomes of COVID-19 in vaccinated versus not-vaccinated hospitalized patients: data from an Italian reference hospital
    A. Mondi, I. Mastrorosa, A. Navarra, S. Lanini, A. D’Annunzio, F. Vaia, E. Girardi, A. Antinori
    National Institute for Infectious Diseases L. Spallanzani IRCCS, Rome, Italy

    15:35 - 16:35

    Oral Communications

    Pathogenesis & Immunology

    Oral Communications

    Pathogenesis & Immunology

    Chairs: C. Agrati, G.C. Marchetti

    15.35 - 15.45

    OC 17

    Impact of SARS-CoV-2 infection in a relevant three-dimensional human bronchial cell culture model of Cystic Fibrosis
    I. Pagani1, L. JV. Galietta2, N. Pedemonte3, V. Capurro3, A. Venturini2, C. Cigana4, B. A. Franco4, A. Bragonzi4, E. Vicenzi1
    1Viral Pathogenesis and Biosafety Unit, IRCCS-Ospedale San Raffaele, Milan, Italy, 2Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, NA, Italy, 3UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Genova, Italy, 4Infections and Cystic Fibrosis Unit, IRCCS-Ospedale San Raffaele, Milan, Italy

    15.47 - 15.57

    OC 18

    Oral immunity characterization in saliva from asymptomatic and severe COVID19 patients
    I. Saulle1,2, M. Garziano1,2, O. Utyro2, S. Lo Caputo3, M. Poliseno3, T.A. Santantonio3, M. Clerici1,4, M. Biasin2
    1Laboratory of Immunology, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, 2Laboratory of Immunobiology, Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, 3Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, 4Don C. Gnocchi Foundation, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Foundation, Milan, Italy

    15.59 - 16.09

    OC 19

    Therapeutic monoclonal antibody treatment restores immune homeostasis and did not prevent the expansion of anti-SARS-CoV-2 adaptive immune response in mild/moderate COVID-19 patients
    R. Casetti1, A. Sacchi1, V. Mazzotta2, F. Cristofanelli1, E. Cimini1, S. Notari1, G. Grassi1, V. Bordoni1, I. Mastrorosa2, M.L. Giancola2, A. Vergori2, M. Tempestilli1, S. Vita2, M. Rubino1, D. Mariotti1, S. Gili1, E. Lalle3, S. Meschi3, F. Colavita3, A.R. Garbuglia3, E. Girardi4, E. Nicastri2, A. Antinori2, C Agrati1
    1Cellular Immunology and Pharmacology Laboratory, INMI L Spallanzani, Rome, Italy, 2Clinical Department, INMI L Spallanzani, Rome, Italy, 3Virology Laboratory, INMI L Spallanzani, Rome, Italy, 4Scientific Directorate, INMI L Spallanzani, Rome, Italy

    16.11 - 16.21

    OC 20

    Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the early phases of chronic infection even in the setting of limited liver damage
    S. D'Anna1, L. Carioti1, L. Piermatteo1, A. Battisti1,2, L. Benedetti1, F. Ceccherini-Silberstein1, U.S. Gill2, P.T.F. Kennedy2, V. Svicher1, R. Salpini1
    1University of Rome Tor Vergata, Department of Experimental Medicine, Rome, 2Barts Liver Centre, Blizard Institute, Barts and The London SMD, QMUL, London

    16:40 - 17:40

    Oral Communications

    From HIV to SARS-CoV-2

    Oral Communications

    From HIV to SARS-CoV-2

    Chairs: A. Callegaro, F. Maggi

    16.40 - 16.50

    OC 21

    Intact proviral DNA and chromosome integration sites in peripheral blood lympho-monocytes of early treated acute HIV infections
    G. Rozera1, G. Sberna1, G. Berno1, C. Gruber1, N. Orchi2, V. Puro2, A. Mondi3, A. Antinori3, I. Abbate1
    1Virology Unit, 2AIDS Referral Center, 3HIV/AIDS Clinical Department of the National Institute for Infectious Diseases I.R.C.C.S. L. Spallanzani, Rome, Italy

    16.52 - 17.02

    OC 22

    Plasma, Intracellular and Lymph node Antiretroviral Concentrations and HIV DNA Change in Patients Treated During Primary HIV Infection: Results from the INACTION P25 Study
    A. De Nicolò1, E. De Vivo1, S. Dispinseri2, G. Marchetti3, M. Trunfio4, A. Ianniello1, A. D’Avolio1, A. Muscatello5, A. Gori5, S. Rusconi6,7, E. Bruzzesi8, A. Gabrieli9, D.P. Bernasconi10, S. Nozza11, A. Calcagno4 on behalf of the INACTION (Italian Network of Acute HIV Infection) study group
    1Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Turin, 2Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, 3Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, 4Unif of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, 5Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, 6UOC Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, 7University of Milan, Milan, 8Vita-Saluta San Raffaele University, Milan, 9Dipartimento di Scienze Biomediche e Cliniche, Ospedale L Sacco, Milan, 10Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4 School of Medicine and Surgery, University of Milano-Bicocca, Monza, 11Department of Infectious Diseases, IRCCS Ospedale san Raffaele, Milan, Italy

    17.04 - 17.14

    OC 23

    Efficacy, tolerability and pharmacokinetics of doravirine in the clinical setting
    S. Fantino1, M. Ferrara1, G. Trevisan1, G. Accardo1, F. Alladio1, E. Drappero1, S. Biffi1, A. Serra1, L. Trentini1, M. Tettoni1, E. De Vivo2, A. Ianniello2, J. Mula2, A. De Nicolò2, A. D’Avolio2, A. Calcagno1, G. Di Perri1, S. Bonora1
    1Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, 2Laboratory of Clinical Pharmacology and Pharmacogenetics,, Department of Medical Sciences, University of Torino, Torino

    17.16 - 17.26

    OC 24

    Are Minions useful in the lab workflow? Comparison between long and short sequencing in COVID-19 surveillance
    B. Bruzzone1, V. Ricucci1, V. De Pace1, F. Stefanelli1, N. Randazzo1, G. Garzillo2, M. Cavaletti3, S. Casali3, M. Rossi3, A. Domnich1, C. Trombetta2, A. Orsi1,2, G. Icardi1,2
    1Hygiene Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genoa, Italy, 2Department of Health Science, Genoa University, Genoa, Italy, 34bases Italia srl, Campospinoso, Pavia, Italy

    17.28 - 17.38

    OC 25

    In vitro activity of molnupiravir in combination with GC-376 or PF-07321332 against SARS-CoV-2
    A. Gidari1, S. Bastianelli1, S. Pierucci1, C. Busti1, S. Sabbatini2, G. Genga1, E. Svizzeretto1, A. Tommasi1, E. Schiaroli1, D. Francisci1
    1Department of Medicine and Surgery, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, Perugia, Italy, 2Department of Medicine and Surgery, Medical Microbiology Section, University of Perugia, Perugia, Italy

    17:45 - 18:45

    Oral Communications

    Metabolic alterations: effect of drugs and diseases

    Oral Communications

    Metabolic alterations: effect of drugs and diseases

    Chairs: V. Borghi, L.A.R. Rancilio

    17.45 - 17.55

    OC 26

    From NAFLD to MAFLD: implications of change in terminology in PWH
    L. Gozzi1, J. Milic2, S. Renzetti3, F. Motta2, A. Cervo1, G. Burastero1, V. Iadisernia1, B. Lebouche4, S. Al Hinai4, M. Deschenes4, M. Menozzi1, P. Raggi5, S. Calza3, C. Mussini1,2, G. Sebastiani4, G. Guaraldi1,2
    1Azienda Ospedaliero - Universitaria, Policlinico of Modena, Modena, Italy, 2University of Modena and Reggio Emilia, Modena, Italy, 3University of Brescia, Brescia, Italy, 4McGill University Health Centre, Montreal, Canada, 5University of Alberta, Edmonton, Canada

    17.57 - 18.07

    OC 27

    The pathway of NAFLD vs MAFLD toward significant fibrosis
    J. Milic1, S. Renzetti2, F. Motta1, L. Gozzi3, G. Besutti4, G. Burastero3, V. Iadisernia3, A. Dessilani3, M. Del Monte3, M. Faltoni3, S. Volpi3, B. Lebouche5, S. Al Hinai5, M. Deschenes5, S. Calza2, P. Raggi6, G. Mancini3, C. Mussini1,2, G. Sebastiani5, G. Guaraldi1,2
    1University of Modena and Reggio Emilia, Modena, Italy, 2University of Brescia, Italy, 3Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, 4Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy, 5McGill University Health Centre, Montreal, Canada, 6University of Alberta, Edmonton, Canada

    18.09 - 18.19

    OC 28

    With or Without TAF? What is the difference? Data from a real-life setting
    N. Squillace1, L. Taramasso2, E. Ricci3, B. Menzaghi4, G. De Socio5, G.Orofino6, B.M. Celesia7, E. Sarchi8, C. Molteni9, G. Pellicano’10, F. Conti11, F. Vichi12, A. Di Biagio2, P. Bonfanti1, for the CISAI Study Group
    1Infectious Diseases Unit ASST-MONZA, San Gerardo Hospital-University of Milano-Bicocca, Monza, 2Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa 3Fondazione ASIA Onlus, Buccinasco (MI), 4Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), 5Unit of Infectious Diseases, Santa Maria Hospital, Perugia, 6Division I of Infectious and Tropical Diseases, ASL Città di Torino, 7Unit of Infectious Diseases, Garibaldi Hospital, Catania, 8Infectious Diseases Unit, S.Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, 9Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, 10Infectious Diseases, G. Martino Hospital -University of Messina, Messina, 11Department of Infectious Diseases, Luigi Sacco Hospital, Milan, Italy, 12Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence

    18.21 - 18.31

    OC 29

    Impact of COVID-19 pandemic on incidence and prevalence of metabolic syndrome in PLWH
    R. Papaioannu Borjesson1, L. Galli2, C. Muccini1,2, A. Poli2, T. Clemente1, M. Bottanelli1, N. Gianotti2, S. Nozza2, A. Castagna1,2, V. Spagnuolo2
    1Vita-Salute San Raffaele University - Milan (Italy), 2Infectious Diseases Unit, San Raffaele Scientific Institute - Milan (Italy)

  • Alabastro A
    10:05 - 11:05

    Satellite Symposium

    Hepatitis Delta in HIV/HBV Infected Patients

    Con la sponsorizzazione non condizionante di:

    Satellite Symposium

    Hepatitis Delta in HIV/HBV Infected Patients

    Viral liver diseases are frequent comorbidities and major contributors to death in HIV-positive individuals on antiretroviral therapy.  Due to similarities in transmission routes, persons living with HIV (PLWH) are at risk for HDV infection. The lack of satisfactory treatment for hepatitis delta virus (HDV) infection has meant a major threat for developing cirrhosis and liver cancer in this population. Recent data gathered from HIV ICONA Cohort suggest that HDV infection among PLWH is underdiagnosed, although HDV entails a high risk of liver disease progression. Because effective drugs to treat HDV are now available, it is even more crucial increase awareness to identify patients at an early stage of liver disease. During the Symposium we will provide an exceptional overview of HDV disease among PLWD, from its diagnosis to its management, sharing the most up to date evidences of HDV treatment.

    Chair: M. Puoti

    10.05 - 10.10 Introduction
    10.10 - 10.30 Epidemiological characteristics of HDV infection in HIV patients - the ICONA Cohort
    A. d'Arminio Monforte
    10.30 - 10.50 Managing Viral Hepatitis D and new treatment option for HDV
    P. Lampertico
    10.50 - 11.05 Discussion on Symposium issues
    11:10 - 12:00

    Oral Poster

    COVID-19: treatment strategies II

    Oral Poster

    COVID-19: treatment strategies II

    Chairs: V. Cento, L. Sasset

    11.10 - 11.15

    OP 7

    Use of Sotrovimab in a cohort of Pregnant Women with a high risk of COVID 19 progression: a single-center experience
    L. Frallonardo1, A. Vimercati2, R. Novara1, D.F. Bavaro1, G. Brindicci1, C.R. Santoro1, I. Ferrante2, G. Chiarello2, C. Lepera2, M. Mongelli2, R. Cicinelli2, F. Di Gennaro1, E. Cicinelli2, A. Saracino1
    1Clinic of Infectious Diseases, University of “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, Italy, 2Clinic of Obstetrics & Gynaecology, University of “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, Italy

    11.17 - 11.22

    OP 8

    Remdesivir does not influence SARS-CoV-2 RNA viral load kinetics in nasopharyngeal swab specimens of COVID-19 hospitalized patients: a real-life experience
    L. Campogiani1,2, M. Iannetta1,2, A. Di Lorenzo1,2, M. Zordan1,2, L. Coppola1,2, M. Compagno1,2, V. Malagnino1,2, E. Teti1,2, M. Andreoni1,2, L. Sarmati1,2
    1Department of System Medicine, Tor Vergata University, Rome, Italy, 2Infectious Disease Clinic, Policlinico Tor Vergata, Rome Italy

    11.24 - 11.29

    OP 9

    Anti-spike monoclonal antibodies to prevent hospitalization in mild COVID-19: preliminary data of an ongoing large observational multicenter study (CONDIVIDIAMO)
    A. Soria1, G. Ghilardi2, F. Graziano3, S.V. Benatti4, G. Lapadula1,2, A. Ferraresi5, P. Brambilla5, D. Pocaterra6, M.E. Quiros Roldan7, M. Franzetti8, L. Bradanini9, A. Cappelletti1, A. Rugova1, ML. Borghesi1, S. Piconi9, S. Rusconi8,10, F. Castelli7, P. Morelli6, A. Pan5, M. Rizzi4, S. Galimberti3, M.G. Valsecchi3, P. Bonfanti1,2
    1San Gerardo Hospital ASST Monza, Monza, 2School of Medicine and Surgery University of Milano-Bicocca, Monza, 3Bicocca Bioinformatics Biostatistics and Bioimaging Center B4 School of Medicine and Surgery University of Milano-Bicocca, Monza, 4ASST Papa Giovanni XXIII, Bergamo, 5ASST Cremona, Cremona, 6Humanitas Clinical and Research Center, Milan, 7ASST Spedali Civili University of Brescia, Brescia, 8Legnano Hospital ASST Ovest Milanese, Legnano, 9ASST A Manzoni, Lecco, 10DIBIC "Luigi Sacco" Università degli Studi di Milano, Milan

    11.31 - 11.36

    OP 10

    Early Use of Short-Course Remdesivir and Monoclonal Antibodies May Reduce The Risk of Disease Progression in Hospitalized Patients With COVID-19: a Single Center Retrospective Study
    D.F. Bavaro1, L. Diella1, A. Belati1, G. Brindicci1, F. Balena1, D. Fiordelisi1, M.F. Mariani1, F. Signorile1, G. Metrangolo1, L. De Santis1, V. Spada1, M. Camporeale1, A. Dargenio1, G. Nicoletta2, F. Di Gennaro1, M. Dell’Aera2, A. Saracino1
    1Clinic of Infectious Diseases, University Hospital of Bari, Bari, Italy, 2Hospital Pharmacy Department, University Hospital of Bari, Bari, Italy

    11.38 - 11.43

    OP 11

    Continuous Positive Airway Pressure in SARS-CoV-2 associated Acute Respiratory Distress Syndrome: timing to maximize results
    R. Nevola1,3, A. Russo2, S. Scuotto2, S. Imbriani1, C. Aprea1, M. Abitabile1, D. Beccia1, C. Brin1, C. Carusone1, F. Cinone1, G. Cirigliano1, S. Colantuoni1, D. Cozzolino1, G.Cuomo1, M. Del Core1, K. Gjeloshi1, A. Marrone1, G. Medicamento1, L. Meo1, F. Nappo1, A. Padula1, P.C. Pafundi1, R. Ranieri1, C. Ricozzi1, L. Rinaldi1, C.P. Romano1, R. Ruocco1, C. Ruosi1, A. Salvati2, F.C. Sasso1, A. Sellitto1, P. Sommese1, A. Villani1, N. Coppola2, L.E. Adinolfi1
    1Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy, 2Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy, 3Internal Medicine and Hepatology Unit, Betania Evangelical Hospital, Naples, Italy

    11.45 - 11.50

    OP 12

    EpCOT: an open-label, controlled, randomized clinical trial on the efficacy of early prone-positioning in patients with mild pneumonia due to SARS-CoV-2
    M. Fezzi1, G. Lapadula1,2, L. Antolini1, A. Soria2, A. Rugova2, M. Rossi2, L. Bisi2, F. Sabbatini2, A. Cappelletti2, S. Limonta2, A. Ranzani2, I. De Benedetto2, N. Corti1,2, P. Bonfanti1,2
    1Università degli Studi di Milano Bicocca - Dipartimento di Medicina e Chirurgia, Monza, 2ASST Monza Ospedale San Gerardo, Monza

    12:15 - 13:15

    Sponsored Symposium

    Cabotegravir + rilpivirine long-acting: are we ready for the new era?

    Con il supporto di:

    Sponsored Symposium

    Cabotegravir + rilpivirine long-acting: are we ready for the new era?

    Advances in the efficacy of antiretroviral therapy led to a shift in treatment focus to emphasize convenience, tolerability, and overall acceptability of HIV therapy. This has culminated in the development of efficacious single-tablet daily oral regimens, which offer simplicity and convenience. Despite this, the need for life-long daily pill-taking can present substantial challenges that can be broadly grouped into three categories: adherence issues, emotional issues (including stigmatization concerns and the daily reminder of HIV status) and medical issues, such as difficulty swallowing, drug-food and drug-drug interactions, and pill burden. Innovations and treatment options that can fill the unmet needs of people living with HIV, such as long-acting non-oral regimens, could support patients to overcome treatment barriers and improve their quality of life. Objective of this symposium is to discuss the clinical trials data about Cabotegravir + Rilpivirine long-acting regimen, both in terms of efficacy and safety as well as Patient Reported Outcomes and treatment preference reported by patients.

    Chair: G. Rizzardini

    12.15 - 12.35 Cabotegravir + rilpivirine long-acting therapy: what the data tell us
    S. Nozza
    12.35 - 12.55 Patient reporting outcomes and treatment preferences
    A. Cingolani
    12.55 - 13.15 Questions & Answers
    13:15 - 14:15

    Oral Communications

    Metabolic issues in effective HAART

    Oral Communications

    Metabolic issues in effective HAART

    Chairs: E. Focà, C. Gervasoni

    13.15 - 13.25

    OC 9

    Role of Emtricitabile/Tenofovir Alafenamide/Bictegravir on metabolic and hepatic safety: data from Surveillance Cohort Long-term Toxicity Antiretrovirals/antivirals (SCOLTA) project
    N. Squillace1, E. Ricci2, B. Menzaghi3, G.V. De Socio4, G. Orofino5, B.M. Celesia6, F. Vichi7, A. Di Biagio8, L. Taramasso8, C. Molteni9, E. Sarchi10, L. Valsecchi11, G.F. Pellicanò12, P. Bonfanti1, for the CISAI Study Group
    1Infectious Diseases Unit ASST-MONZA, San Gerardo Hospital-University of Milano-Bicocca, Monza, 2Fondazione ASIA Onlus, Buccinasco (MI), Italy, 3Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Varese, 4Unit of Infectious Diseases, Santa Maria Hospital, Perugia, 5Division I of Infectious and Tropical Diseases, ASL Città di Torino, 6Unit of Infectious Diseases, Garibaldi Hospital, Catania, 7Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, 8Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, 9Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, 10Infectious Diseases Unit, S.Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, 111st Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy, 12Infectious Diseases, G. Martino Hospital -University of Messina, Messina

    13.27 - 13.37

    OC 10

    Machine learning algorithm to predict weight change in ART experienced PWH
    F. Motta1, J. Milic1, S. Barbieri1, L. Gozzi2, E. Aprile2, M. Belli2, M. Venuta2, G. Cuomo2, F. Carli2, G. Dolci2, V. Iadisernia2, G. Burastero2, C. Mussini1,2, F. Mandreoli3, G. Guaraldi1,2
    1Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, 2Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy, 3Department of Physics, Informatics and Mathematics, University of Modena and Reggio Emilia, Modena, Italy

    13.39 - 13.49

    OC 11

    In vitro model of adypocite differentiation under TAF, TDF and INSTIs selective challenge
    M.A. Carleo1, A. Perna2, A. Guida1, P. Rosario1, S. Mascolo1, A. Lucariello3, G. Palmiero1, V. Rizzo1, A. M. Rossomando1, A. Baldi4, A. De Luca5, P. Maggi6, V. Esposito1
    1Infectious Diseases and Gender Medicine Unit “D. Cotugno” Hospital – AO dei Colli, Naples Italy, 2Department of Medicine and Health Sciences “Vincenzo Tiberio”, University of Molise, Campobasso, Italy, 3Department of Sport Sciences and Wellness, University of Naples "Parthenope", Naples, Italy, 4Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Università degli Studi della Campania "L. Vanvitelli", Caserta, Italy, 5Department of Mental and Physical Health and Preventive Medicine, Section of Human Anatomy, University of Campania “Luigi Vanvitelli”, Naples, Italy, 6University of Campania “Luigi Vanvitelli”, Caserta Italy

    13.51 - 14.01

    OC 12

    Liver enzymes levels, metabolic and renal profile modifications after switching from TDF to TAF- based regimens among ART experienced PLWH in ICONA cohort
    M. Poliseno1, S. Lo Caputo1, A. Tavelli2, R. Gagliardini3, L. Gazzola2, A. Saracino4, T.A. Santantonio1, M. Puoti5, S. Cicalini3, A. Antinori3 , A. d'Arminio Monforte2, A. Cozzi-Lepri6
    1Unit of Infectious Diseases, University of Foggia, Foggia, Italy, 2Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, 3National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy, 4Operative Unit of Infectious Diseases, Hospital-University Polyclinic of Bari, Bari, Italy, 5Infectious Diseases Unit, Niguarda Hospital, Milan, Italy, 6Institute for Global Health UCL, University College London, London, UK

    14:30 - 15:30

    Expert Meeting

    The new recombinant adjuvanted vaccine against Herpes Zoster: clinical data and recommendations

    Con il supporto di:

    Expert Meeting

    The new recombinant adjuvanted vaccine against Herpes Zoster: clinical data and recommendations

    There is a substantial unmet medical need associated with herpes zoster (HZ) and its complications, particularly in older adults and those who are immunocompromised (IC). Current disease management of HZ is not optimal. Early treatment with antiviral drugs, initiated within 72 hours of rash onset, decreases the incidence of new lesion formation, accelerates healing and the resolution of acute pain. Populations at increased risk for developing HZ are those having a decline in immune function, including older adults or individuals who are IC. Individuals who are IC due to haematological malignancies (HM) and solid tumours, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), treatments such as chemo- or radiotherapy, haematopoietic stem cell transplantation (HSCT), immune suppression following organ transplantation or therapy with high doses of corticosteroids are also at increased risk of developing HZ. Individuals who are IC also have an increased risk of disseminated disease. The Recombinant Zoster Vaccine (RZV) is available in Italy since 2021. RZV has been shown to be highly effective at preventing shingles and post-herpetic neuralgia in adults older than 50 years. The vaccine is also effective at protecting adults older than 18 years who are at increased risk of herpes zoster. In the Recommendations of the Italian society for infectious and tropical diseases (SIMIT) for adult vaccinations document, published in 2021, SIMIT recommended RZV for the prevention of HZ and PHN in older adults (>65 yo) and for several categories of at higher risk subjects including HIV+ patients.

    Chair: C.M. Mastroianni

    14.30 - 14.45 Scientific and clinical profile of the new recombinant adjuvanted vaccine against HZ
    G. Gabutti
    14.45 - 15.00 The prevention of HZ in at higher risk subjects: the Recommendations of the Italian Society for Infectious and Tropical Diseases (SIMIT)
    M. Andreoni
    15.00 - 15.15 Vaccination against HZ directly offered in the Infectious Diseases center: the «Milan» experience
    G. Rizzardini
    15.15 - 15.30 Discussion on Expert Meeting issues
    15:35 - 16:35

    Interactive Expert Meeting

    Affairs of the heart in HIV: redundant or a key challenge?

    Con la sponsorizzazione non condizionante di:

    Interactive Expert Meeting

    Affairs of the heart in HIV: redundant or a key challenge?

    PLWH may be predisposed to higher risk of Cardiometabolic Disorders such as dyslipidemia, cardiovascular disease and diabetes. In fact, metabolic syndrome affects up to 52% of PLWH. In this interactive round table, innovative individualized treatment strategies for the management of PLWH at risk or with cardiometabolic disorders will be discussed.

    Moderator: C. Gervasoni

    Discussants: A.M. Cattelan, R. Gagliardini, A. Saracino

      Affairs of the heart in HIV: redundant or a key challenge?
    C. Gervasoni
    16:40 - 17:40

    Expert Meeting

    Evolving models of care in the management of Gram+ infectious diseases: the role of long-acting antibiotic therapies

    Expert Meeting

    Evolving models of care in the management of Gram+ infectious diseases: the role of long-acting antibiotic therapies

    The increase of multidrug resistance among Gram-positive pathogens, particularly among staphylococci and enterococci, represents a major health care problem, since it results in significant morbidity, mortality, and health care costs. The emergence of such resistant bacterial strains highlights the need to optimize treatment approaches. In this view, novel lipoglycopeptides endowed with long-term activity allowing single-shot administration would be extremely useful and may represent an attractive therapeutic option alternative for early hospital discharge, a cost-saving and a resource-saving approach. Furthermore, long-term intravenous antibiotic therapy poses a particular challenge, specially in this ongoing pandemic situation,  for treating patients classified as vulnerable or at highrisk for complications, such as PWID (persons who inject drugs) or those lacking social support, including frail elderly and/or those who are homeless or with an underlying psychiatric illness. This approach may offer improved quality of life for patients, considering benefits, such as no need for a central line for daily infusions, fast hospital discharge, and less need for laboratory monitoring.

    Chairs: F. De Iaco, C.M. Mastroianni

    16.40 - 16.45 Introduction
    C.M. Mastroianni
    16.45 - 17.05 Bacterial Infections in difficult-to-treat patients
    A.M. Cattelan
    17.05 - 17.25 Interaction between emergency medicine and infectious disease
    S. Di Maggio
    17.25 - 17.35 Questions & Answers
    F. De Iaco, C.M. Mastroianni
    17.35 - 17.40 Final considerations and take-home messages
    F. De Iaco
    17:45 - 18:45

    Oral Communications

    Special issues in clinical HIV

    Oral Communications

    Special issues in clinical HIV

    Chairs: P. Bonfanti, A. Saracino

    17.45 - 17.55

    OC 30

    Final immunovirological data from the p25- Italian Network of Acute HIV Infection (INACTION) cohort
    E. Bruzzesi1, A. Gabrieli2, D. Bernasconi3, G. Marchetti4, M. Trunfio5, D. Ripamonti6, A. Antinori7, N. Squillace8, R. Cauda9,10, M. Parisi11, A. Muscatello12, A. Bandera12,13, G.Tambussi11, S. Nozza11, S. Rusconi14 on behalf of INACTION study group
    1Vita-Salute San Raffaele University, Milan, Italy, 2Dipartimento di Scienze Biomediche e Cliniche, Ospedale L. Sacco, Milan, Italy, 3Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4 School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy, 4Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, 5Unif of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin,Italy, 6Infectious Disease Unit; ASST Papa Giovanni XXIII; Bergamo, Italy, 7National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS; Rome, Italy, 8Infectious Diseases Unit; Department of Internal Medicine; ASST San Gerardo; Monza, Italy, 9Istituto Clinica di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, 10UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 11Unit of Infectious Diseases, IRCCS Ospedale san Raffaele, Milan, Italy, 12Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan,Italy, 13School of Medicine and Surgery, University of Milan, Milan, Italy, 14UOC Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, Italy

    17.57 - 18.07

    OC 31

    Effect of 12-week cART on gut mucosal immunity and microbiome in PHI
    C. Tincati1, M. Hadla1, M. Falleni2, D. Tosi2, V. Yellenki1, R. Rovito1, V. Bono1, S. Rusconi3, A. Giacomelli4, A. Muscatello5, S. Dispinseri6, A. d’Arminio Monforte1, A. Calcagno7, S. Nozza6, A. Gori5, G. Marchetti1 for the Inaction (Italian Network of Acute HIV Infection) Study Group
    1Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, 2Pathology Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, 3UOC Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, 4Clinic of Infectious Diseases, Department of Biomedical and Clinical Sciences, L. Sacco Hospital, University of Milan, Milan, 5Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, 6Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, 7Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin

    18.09 - 18.19

    OC 32

    PLWH with advanced HIV disease are at higher risk for becoming difficult to treat: data from a large cohort of PLWH starting modern ART regimens
    R. Gagliardini1, A. Cozzi-Lepri2, A. Tavelli3, S. Rusconi 4,5, V. Spagnuolo6, A. Giacomelli7, G. Burastero8, C. Agrati1, M.M. Santoro9, G. Madeddu10, A. d'Arminio Monforte11, A. Antinori1
    1INMI Lazzaro Spallanzani IRCCS, Rome, Italy, 2Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, 3Icona Foundation, Milan, Italy, 4Unità Operativa Malattie Infettive, Ospedale Civile di Legnano, Legnano, Italy, 5Dipartimento di Scienze Biomediche e Cliniche “Luigi Sacco” Università degli Studi di Milano, Milan, Italy, 6IRCCS San Raffaele Scientific Institute, Infectious Diseases Unit, Milan, Italy, 7III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Ospedale Luigi Sacco, Milan, Italy, 8Infectious Disease Clinic, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, 9University of Rome Tor Vergata, Department of Experimental Medicine, Rome, Italy, 10Infectious Diseases Department of Medical, Surgical, and Experimental SciencesUniversity of Sassari, Italy
    11University of Milan, Department of Health Sciences, Milan, Italy

    18.21 - 18.31

    OC 33

    Weight change in obese and overweight PWH: the impact of SARS-CoV-2 pandemic
    S. Dettori1,2, S. Lerta1, L. Taramasso2, S. Bianchi1, F. Magnè2, S. Mora3, M. Giacomini3, M. Bassetti1,2, A. Di Biagio1,2
    1Department of Health Sciences (DISSAL), University of Genoa - Genoa, Italy, 2Infectious Diseases Unit, Ospedale Policlinico San Martino IRCCS - Genoa, Italy, 3Department of Informatics Bioengineering, Robotics, and Systems Engineering (DIBRIS), University of Genoa - Genoa, Italy

  • Alabastro B
    11:10 - 12:00

    Oral Poster

    Treatment of naive PLWH: current strategies and rapid start of ART

    Oral Poster

    Treatment of naive PLWH: current strategies and rapid start of ART

    Chairs: M.E. Quiros Roldan, L. Sighinolfi

    11.10 - 11.15

    OP 13

    Reasons for choosing DRV/cob/FTC/TAF in ART-naïve and ART-experienced patients: data from the Icona Cohort
    A. Tavelli1, D. Tomasoni2, N. Gianotti3, R. Gagliardini4, E. Bruzzesi3, P. Milini5, B. Menzaghi6, G. Lapadula7, P. Cinque8, L. Taramasso9, A. Antinori4, A. d'Arminio Monforte2
    1ICONA Foundation, Milan, Italy, 2Clinic of Infectious and Tropical Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, 3Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, 4National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy, 5Infectious Diseases Unit, Macerata Hospital, Macerata, Italy, 6Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, 7Clinic of Infectious Diseases, San Gerardo Hospital - ASST Monza, University of Milano-Bicocca, Monza, Italy, 8Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, San Raffaele Vita-Salute University, Milan, Italy, 9Infectious Diseases Unit, Ospedale Policlinico San Martino-IRCCS, Genoa, Italy

    11.17 - 11.22

    OP 14

    Blood telomere length in treatment-naive HIV-infected adults starting dolutegravir plus lamivudine versus triple regimen with two nucleosides
    F. Lombardi1, A. Sanfilippo2, M. Fabbiani3, A. Borghetti1, A. Ciccullo4, S. Di Giambenedetto1,2
    1Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Roma, Italia, 2Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica, Roma Italia, 3UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, Italia, 4Unità di Malattie infettive, Ospedale San Salvatore, L'Aquila, Italia

    11.24 - 11.29

    OP 15

    BIC/FTC/TAF in ART-naïve key populations: real-life data from the Icona cohort
    A. Tavelli1, G. Marchetti2, A. Vergori3, E. Quiros-Roldan4, V. Malagnino5, F. Vichi6, M. Lichtner7, S. Nozza8, R. Rossotti9, L. Sarmati5, A. Antinori3, A. d'Arminio Monforte2
    1Icona Foundation, Milan, Italy, 2Department of Health Sciences, Clinic of Infectious Diseases, 'San Paolo' Hospital, University of Milan, Milan, Italy, 3Clinical Department, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, 4Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy, 5Unit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy, 6Infectious Diseases Unit 1, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro, Florence, Italy, 7Infectious Diseases Unit, Santa Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy, 8Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, 9Department of Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

    11.31 - 11.36

    OP 16

    A pilot study of the impact of a rapid ART initiation in advanced HIV disease
    M. Camici, R. Gagliardini, S. Lanini, S. Ottou, A. Mondi, M.M. Plazzi, C. Pinnetti, A. Vergori, E. Grilli, F. De Zottis , I. Mastrorosa, V. Mazzotta, J. Paulicelli, R. Bellagamba, S.Cicalini, A. Antinori
    HIV/AIDS Clinical Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

    11.38 - 11.43

    OP 17

    Rapid ART initiation in a single-center italian cohort: an observational analysis
    R. Pincino1,3, L. Taramasso2, M. Berruti1, G. Cenderello1, M. Bassetti2,3, A. Di Biagio2,3
    1Infectious diseases unit, Borea Hospital, ASL-1 Imperiese, Sanremo, Italy, 2Infectious diseases unit, Policlinico San Martino Hospital, Genoa, Italy, 3Health and science department, Genoa University, Genoa, Italy

    11.45 - 11.50

    OP 18

    Viro-immunological effectiveness of different integrase strand-transfer inhibitor-based antiretroviral therapy regimens. A single center retrospective study
    M. Ceccarelli1,2,3, D. Scuderi4, R. Bruno1,3, G. Bruno5, A. Marino3,6, V. Moscatt3,7, Y. Russotto7, C. Micali7, E. Venanzi Rullo7, G. Nunnari7, B. Santi Cacopardo1, B.M. Celesia3
    1Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Catania, Catania, Italy, 2Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, Unit of Infectious Diseases, University of Messina, Messina, Italy, 3Unit of Infectious Diseases, ARNAS “Garibaldi”, “Nesima” Hospital, Catania, Italy, 4Unit of Infectious Diseases, “Cannizzaro” Hospital, Catania, Italy, 5Department of Medical and Surgical Sciences, Unit of Infectious Diseases, “Magna Graecia” University of Catanzaro, Catanzaro, Italy, 6Department of Biomedical and Biotechnological Sciences, Unit of Infectious Diseases, University of Catania, Catania, Italy, 7Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Messina, Messina, Italy

    13:25 - 14:15

    Oral Poster

    Predictors of COVID-19 severity

    Oral Poster

    Predictors of COVID-19 severity

    Chairs: G. Lapadula, P. Nasta

    13.25 - 13.30

    OP 31

    Hospitalization for COVID-19 or with SARS-CoV-2 infection during two different epidemic periods in Milan, Italy: data from Luigi Sacco Hospital registry
    A. Giacomelli1, A.L. Ridolfo1, L. Pezzati1,2, M. Piscaglia1,2, S. Caronni1,2, F. Sabaini1,2, L. Oreni1, F. Borgonovo1,2, M. Matone1,2, M. Galimberti1,2, M. Zacheo1,2, A. Civati1,2, A. Behring1,2, M. Schiavini1, G. Rizzardini1, S. Antinori1,2
    1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy, 2Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, Università degli Studi di Milano, Milan, Italy

    13.32 - 13.37

    OP 32

    Prognostic value of transaminases and bilirubin levels at admission to hospital on disease progression and mortality in patients with COVID-19 - an observational retrospective study
    R. Palladino, A. Russo, M. Pisaturo, P. Maggi, F.G. Numis, I. Gentile, V. Sangiovanni, V. Esposito, R. Punzi, G. Calabria, C. Rescigno, A. Salomone Megna, A. Masullo, E. Manzillo, G. Russo, R. Parrella, G. Dell’Aquila, M. Gambardella, A. Ponticiello, N. Coppola on behalf of CoviCam group
    Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, Infectious disease unit; University Federico II, Naples, Italy, Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, IV Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, IX Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, First Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, Infectious Diseease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D’Aragona Salerno, Italy, VIII Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, Infectious Diseases Unit, AO Avellino, Italy, Infectious Diseease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, Pneumology Unit, AORN Caserta, Italy

    13.39 - 13.44

    OP 33

    Early predictors of clinical deterioration in a cohort of outpatients with COVID-19 in Southern Italy: a multicenter observational study
    C. Monari1, M. Pisaturo1, P. Maggi2, M. Macera2, G. Di Caprio2, R. Pisapia3, V. Gentile1, M. Fordellone4, P. Chiodini4, N. Coppola1 on behalf of CoviCam group
    1Department of Mental Health and Public Medicine - Infectious Diseases Unit. University of Campania Luigi Vanvitelli, Naples, Italy, 2Infectious Disease Unit, AORN Caserta, 3Infectious Diseases Unit, AORN dei Colli, Naples, 4Medical Statistics Unit, University of Campania Luigi Vanvitelli, Naples, Italy

    13.46 - 13.51

    OP 34

    Risk factors for in-hospital mortality in COVID-19 patients with end stage renal diseases requiring manteinance hemodialysis
    A. Cingolani1, M. Ambrogio2, G. Micheli1, G. De Luca2, M. Chiuchiarelli1, A. Spasiano2, P. L. Salvo1, E. Rosati2, S.L. Cutuli3, E. Rando1, G. De Pascale3 and Nicola Panocchia2 for COVIDialysis-FPG Working Group: M. Ambrogio, G. De Luca, A. Spasiano, E. Rosati, N. Panocchia, R. Baccaro, M. Liberatori, A. Naticchia, F. D’Ascenzo, G. Grandaliano, G. Scoppettuolo, F. Damiano, P. Del Giacomo, F. Raffaelli, R. Losito, G. Maiuro, I. Izzi, A.Dusina, R. Passerotto, F. lamannna, S. Guerriero, B. Liguoro, F. Salvati, V. Iannone, R. Cauda
    1Infectious Diseases, 2Nefrology, 3Intensive Care Unit, Fondazione Policlinico A. Gemelli, IRCCS, Roma

    13.53 - 13.58

    OP 35

    Clinical characteristics and outcomes of COVID-19 hospitalized patients in the current pandemic phase
    E.P. Drago1, M. Poliseno1, M.A. Poli3, M. Altamura2, S.R. Bruno2, A. Calamo2, A. Giannelli2, G. Infante2, M. Mazzola2, S.B. Morella2, D. Moschetta2, M. Tarallo2, S. Lo Caputo1, T.A. Santantonio1, S. Carbonara2
    1Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Foggia, 2Infectious Disease Unit, Vittorio Emanuele II Hospital, Bisceglie, Barletta-Andria-Trani, 3Dermatology Unit, Department Internal Medicine, University of Bari

    14.00 - 14.05

    OP 36

    Laboratory and clinical biomarkers helps to predict severity of CT score in COVID19 patients: an observational study
    I. de Luca1, A. Russo1, F. Schettino2, M.A. Pisaturo1, P. Maggi1, F.G. Numis3, I. Gentile4, V. Sangiovanni5, V. Esposito6, R. Punzi7, G. Calabria8, C. Rescigno9, A. Salomone Megna10, A. Masullo11, E. Manzillo12, G. Russo13, R. Parrella14, G. Dell’Aquila15, M. Gambardella16, A. Ponticello17, A. Reginelli2, N. Coppola1 on behalf of CoviCam group
    1Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, 2Radiology Unit, Department of Precision Medicine, University of Campania “L. Vanvitelli”, Napoli, Italy, 3Emergency Unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, 4Infectious Disease Unit; University Federico II, Naples, Italy, 5Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, 6IV Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 7Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, 8IX Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 9First Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 10Infectious Diseease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, 11Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D’Aragona Salerno, Italy, 12VIII Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 13Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, 14Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, 15Infectious Diseases Unit, AO Avellino, Italy, 16Infectious Diseease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, 17Pneumology Unit, AORN Caserta, Italy

    14:30 - 15:20

    Oral Poster

    Viro-immunological correlates of COVID-19 severity

    Oral Poster

    Viro-immunological correlates of COVID-19 severity

    Chairs: I. Bon, I. Vicenti

    14.30 - 14.35

    OP 43

    PTX3 is a strong predictor of death among patients with COVID-19
    G. Lapadula1,2, R. Leone3, D.P. Bernasconi4, A. Biondi1,5, E. Rossi4, M. D'Angiò5, B. Bottazzi3, L.R. Bettini5, I. Beretta2, C. Garlanda3,6, M.G. Valsecchi4, A. Mantovani3,6,7, P. Bonfanti1,2 for the COVID-19 STORM Study Group
    1University of Milano-Bicocca, Milan, Italy, 2Department of Infectious Diseases, San Gerardo Hospital, Monza, Italy, 3Humanitas Clinical and Research Institute – IRCCS, Rozzano (MI), Italy, 4Bicocca Bioinformatics Biostatistics and Bioimaging Center - B4, University of Milano–Bicocca, Milan, Italy, 5Department of Pediatrics, European Reference Network (ERN) PaedCan, EuroBloodNet, MetabERN, Fondazione MBBM/Ospedale San Gerardo, Monza, Italy, 5Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy, 6William Harvey Research Institute, Queen Mary University, London, UK

    14.37 - 14.42

    OP 44

    The role of antigen load on viral clearance and severity in SARS-CoV-2 infection
    T. Clemente1,2, P.E. Rovatti3, M. Punta3,4, C. Muccini1,2, L. Galli2, C. Toffalori3, R. Papaioannu Borjesson1,2, M. Bottanelli1,2, C. Tresoldi5, F. Ciceri1,5,6, A. Castagna1,2, L. Vago3,6, V. Spagnuolo2, on the behalf of COVID-BioB Study Group
    1School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy, 2Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy, 3Unit of Immunogenetics, Leukemia Genomics and Immunobiology, San Raffaele Scientific Institute, Milan, Italy, 4Center for Omics Sciences, San Raffaele Scientific Institute, Milan, Italy, 5Immuno-hematology and Transfusion Medicine Unit, San Raffaele Scientific Institute, Milan, Italy, 6Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy

    14.44 - 14.49

    OP 45

    Dysregulation in IFN-omega levels and anti-IFN-omega neutralizing antibodies correlate with biochemical and hematological parameters predictive of disease severity in COVID-19 male patients
    F. Frasca1, M. Scordio1, L. Sorrentino1, M. Fracella1, L. Santinelli2, E. N. Cavallari2, C. Bitossi1, A. Viscido1, G. Ceccarelli2, A. Pierangeli1, O. Turriziani1, C. M. Mastroianni2, G. Antonelli1, G. d’Ettorre2, C. Scagnolari1
    1Laboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Italy, 2Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Italy

    14.51 - 14.56

    OP 46

    Characterization of IFN response in PBMC from children and adolescent after SARS-CoV-2 infection
    L. Sorrentino1, M.G. Conti2, G. Oliveto1, F. Frasca1, M. Fracella, M. Scordio1, A. D'Auria, M. Ardone1, M. Di Lieto1, L. Petrarca2, R. Nenna2, C. Scagnolari1, G. Antonelli1, F. Midulla2, A. Pierangeli1
    1Virology laboratory, molecular medicine department, Sapienza University, Rome, 2Maternal-Infantile and Urological Science Department, Sapienza University, Rome

    14.58 - 15.03

    OP 47

    Immunological profiles of SARS-CoV-2 infection: the link between cytokine storm, clinical severity and post-COVID syndrome
    A. Parente2, M. Iuliano1, R. Mongiovì1, B. Kertusha2, A. Carraro2, R. Marocco2, G. Mancarella2, C. Del Borgo2, T. Tieghi2, L. Fondaco2, G. Mangino1, G. Romeo1, M. Lichtner2
    1Dept. of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Italy, 2Dept. of Public Health and Infectious Disease, S. Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy

    15.05 - 15.10

    OP 48

    Respiratory and peripheral IFN response and frequency of T cell activation in COVID-19 patients
    L. Santinelli1, L. Maddaloni1, F. Frasca2, M. Scordio2, C.M. Lofaro1, L.Sorrentino2, M. Fracella2, E.N. Cavallari1, G. Ceccarelli1, A. Pierangeli2, C.M. Mastroianni1, G.Antonelli2,3, C. Scagnolari2, G. d’Ettorre1
    1Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, 2Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Italy, 3Microbiology and Virology Unit, Sapienza University Hospital “Policlinico Umberto I”, Rome, Italy

    15:35 - 16:25

    Oral Poster

    Neuropsychological complications in COVID-19

    Oral Poster

    Neuropsychological complications in COVID-19

    Chairs: B.M. Celesia, V. Spagnuolo

    15.35 - 15.40

    OP 55

    Dementia and COVID-19 outcomes: findings from a multicentric study in Campania region
    R. Astorri1, M. Pisaturo1, A. Russo1, P. Maggi2, F.G. Numis3, I. Gentile4, V. Sangiovanni5, V. Esposito6, R. Punzi7, G. Calabria8, C. Rescigno9, A. Salomone Megna10, A. Masullo11, E. Manzillo12, G. Russo13, R. Parrella14, G. Dell’Aquila15, M. Gambardella16, A. Ponticiello17, N. Coppola1 on behalf of CoviCam group
    1Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, 2Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, 3Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, 4Infectious disease unit; University Federico II, Naples, Italy, 5Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, 6IV Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 7Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, 8IX Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 9First Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 10Infectious Diseease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, 11Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D’Aragona Salerno, Italy, 12VIII Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 13Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, 14Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, 15Infectious Diseases Unit, AO Avellino, Italy, 16Infectious Diseease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, 17Pneumology Unit, AORN Caserta, Italy

    15.42 - 15.47

    OP 56

    COVID-19 neurocognitive impairment (COVID-19-NCI): an attempt for definition and clinical assessment
    G. Del Duca, A.C. Brita, I. Mastrorosa, A. Vergori, S. Lanini, M. Camici, M. Annalisa, C. Caligiuri, C. Pinnetti, A. Antinori
    Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy

    15.49 - 15.54

    OP 57

    Neuropsychological performance (NP) following COVID-19: prevalence and predictors
    A. Vergori1, G. Del Duca1, S. Lanini1, A.C. Brita2, C. Pinnetti1, I. Mastrorosa1, M. Camici1, A. Mondi1, V. Mazzotta1, P. Chinello1, P. Mencarini1, M.L. Giancola1, A. Abdeddaim1, E. Girardi3, F. Vaia4, A. Antinori1,5
    1Clinical Department, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, 2Psychology Unit, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, 3Scientific Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, 4General Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, 5Health Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy

    15.56 - 16.01

    OP 58

    Is plasma neurofilament light chain measurement relevant in long-COVID?
    M.A. Zingaropoli1, P. Pasculli1, T. Latronico2, F. Dominelli1, M. Guardiani1, E. Tortellini1, G. Saracino2, G.M. Liuzzi2, M. Lichtner1,3, C.M. Mastroianni1, M.R. Ciardi1
    1Department of Public Health and Infectious Diseases, Sapienza, University of Rome, 2Department of Biosciences, Biotechnology and Biopharmaceutics, Aldo Moro, University of Bari, 3Infectious Diseases Unit, SM Goretti Hospital, Latina, Sapienza, University of Rome

    16.03 - 16.08

    OP 59

    SARS-CoV-2 hampers Dopamine production in iPS-derived dopaminergic neurons
    G. Cappelletti1, E.M. Carsana2, G. Lunghi2, S. Breviario2, C. Vanetti1, A. Barnaba Di Fonzo3, M. Clerici3, M. Aureli2, C. Fenizia3
    1Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, 2Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy, 3Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

    16.10 - 16.15

    OP 60

    Early phase approach in SARS CoV-2 infection: a single center one-year real life experience
    D. Di Trento1, S. Garattini1, M. De Masi2, A. Gasperin1, A. Grimaldi1, S.G. De Maria1, S. Corazza1, S. Gismondi2, B. Bartolozzi2, D. Caianiello3, S. De Filippis1, B. Kertusha2, A.Carraro2, O. D’Onofrio2, G. Bagaglini4, G. Bonanni4, D. Alunni Fegatelli5, A. Spagnoli5, S. Di Somma6, C. Del Borgo2, M. Lichtner1
    1Department of Public Healt and Infectious Disease, “Sapienza University of Rome”, 2Infectious Disease Unit, SM Goretti Hospital Latina, 3General pratictioner, AUSL Latina, 4Pharmacy Service Unit, SM Goretti Hospital Latina, 5Statistic Department, “Sapienza University of Rome”, 6Department of Medical-Surgical Sciences and Translational Medicine, “Sapienza University of Rome”

    16:40 - 17:30

    Oral Poster

    Cardiovascular diseases, osteoporosis but not only

    Oral Poster

    Cardiovascular diseases, osteoporosis but not only

    Chairs: L. Calza, G. Mazzola

    16.40 - 16.45

    OP 67

    Weight gain in people living with HIV under antiretroviral therapy: do our strategies make a difference?
    C. Muccini1,2, D. Ceccarelli1, R. Lolatto1, V. Spagnuolo1, C. Oltolini1, A. Danise1, I. Mainardi1,2, R. Monardo1,2, A. Castagna1,2
    1Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, 2Vita-Salute San Raffaele University, Milan, Italy

    16.47 - 16.52

    OP 68

    PLWH (People Living With HIV): a single centre retrospective observational study on cardiovascular risk factors
    G. Gasparro1, B. Rossetti2, M. Ruggeri1,3, M. Tumbarello4,5
    1Corso Formazione Specifica in Medicina Generale AOU Meyer/Formas, Regione Toscana, Firenze, Italy, 2Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy, 3General Practitioner, Società Italiana di Medicina Generale e delle cure primarie, SIMG, Firenze, Italy, 4Dipartimento di Biotecnologie Mediche, Università degli Studi di Siena, Siena, Italy, 5UOC Malattie Infettive e Tropicali, Azienda Ospedaliero Universitaria Senese, Siena, Italy

    16.54 - 16.59

    OP 69

    Relationship between vitamin D deficiency and cardiovascular disease in virologically suppressed HIV-1-infected patients
    L. Calza1, V. Colangeli1, M. Borderi1, R. Riccardi1, F. Malerba1, I. Bon2, P. Viale1
    1Unit of Infectious Diseases, IRCCS S.Orsola Hospital, 2Unit of Microbiology, IRCCS S.Orsola Hospital, University of Bologna, Bologna, Italy

    17.01 - 17.06

    OP 70

    Effect of bisphosphonates on vertebral fractures in HIV infected males: a 7-years study
    L. Pezzaioli1, T. Porcelli1, S. Storti2, G. Tiecco2, M. degli Antoni2, S. Amadasi2, F. Castelli2, E. Quiros-Roldan2
    1Unit of Endocrinology and Metabolism, Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili Brescia, Brescia, Italy, 2Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali di Brescia, Brescia, Italy

    17.08 - 17.13

    OP 71

    Association between Health Literacy, care engagement and assessment of risk behaviours in an Italian cohort of people living with HIV
    V. Massaroni1, V. Delle Donne1, A. Borghetti2, S. Pierluigi2, F. Lamanna2, D. Farinacci2, A. Ciccullo3, G. Baldin4, S. Di Giambenedetto1,2
    1Infectious Diseases Institute, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy, 2UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 3UOC Infectious Diseases, Ospedale S. Salvatore, L’Aquila; Italy, 4Mater Olbia Hospital, Olbia, Italy

    17.15 - 17.20

    OP 72

    Mental health assessment in people living with HIV/AIDS (PLWHA): preliminary data from a referral HIV center
    F. Di Gennaro1, D. Montalbò2, R. Schiavoni1, G.G. Panico1, D.F. Bavaro1, L. Diella1, M. Di Tullio3, A. Calluso3, C.R. Santoro1, G. Brindicci1, F. Balena1, N. De Gennaro1, A. Belati1, D. Fiordelisi1, M. Sgambati2, A. Bertolino2, A. Saracino1
    1Clinic of Infectious Diseases, Department of Biomedical Sciences and Human Oncology, University of Bari, University of Bari "Aldo Moro", Bari, Italy, 2Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, Italy, 3C.A.M.A. – L.I.L.A, sezione Bari

    17:45 - 18:35

    Oral Poster

    Measuring HIV stigma and disclosure

    Oral Poster

    Measuring HIV stigma and disclosure

    Chairs: B.M. Celesia, T. Di Giovanni

    17.45 - 17.50

    OP 78

    Tackling the misunderstanding and stigma of HIV: a survey on 1007 Italian citizens
    D. Calzavara1, A. Tavelli1,2,3, A. d’Arminio Monforte1,2,3
    1Associazione Milano Check Point, Milano, 2ASST Santi Paolo e Carlo, Milano, 3Fondazione Icona

    17.52 - 17.57

    OP 79

    HIV-related stigma among Italian adults: results of an online survey
    V. Regine1, L. Pugliese1, B. Suligoi1, G. Briola2, A. Simonetti2, F. Marchionni2, V. Saturni2
    1Istituto Superiore di Sanità, Rome, 2Associazione Volontari Italiani del Sangue, Milan

    17.59 - 18.04

    OP 80

    Determinants of non disclosure of HIV status in PLWHIV to other than health care workers
    A. Cingolani1, A. Tavelli2, V. Calvino3, L. Cosmaro4, F. Bai5, C. Pinnetti6, D. Tesoro5, F. Castelli7, F. Maggiolo8, A. Antinori6, M. Cernuschi9, A. d'Arminio Monforte5
    1Policlinico Fondazione A. Gemelli, IRCCS, Roma, 2Fondazione ICONA, Milano, 3ANLAIDS Onlus, Roma, 4LILA Milano Onlus, Milano, 5Università degli studi di Milano, Milano, 6INMI L.Spallanzani, IRCCS, Roma, 7Università degli studi di Brescia, Brescia, 8ASST Giovanni XXIII, Bergamo, 9ASA onlus, Milano

    18.06 - 18.11

    OP 81

    Knowledge and impact of U=U among PLHIV, healthcare professionals and the general population in Italy: a qualitative study
    M. Oldrini1, M.L. Cosmaro1, S. Curridori1, S. Penon1, D. Savarino1, S. Mazzilli2, D. Paganini2, L. Tavoschi2
    1Fondazione LILA Milano – Lega Italiana per la Lotta contro l’AIDS, Milano, 2Dipartimento di Ricerca traslazionale e delle nuove tecnologie in Medicina e Chirurgia, Università di Pisa, Pisa

    18.13 - 18.18

    OP 82

    Do people living with HIV have a better knowledge of HIV and STIs compared to people without HIV? A survey study in Sardinia, Italy
    A. Colpani1, A. De Vito1, B. Zauli1, V. Fiore1, M.C. Meloni1, M. Fois1, A. Bitti1, S. Bacciu1, N. Leoni2, G. Angioni2, S. Babudieri1, G. Madeddu1
    1Unit of Infectious Disease, Department of Medical, Surgery, and Experimental Sciences, University of Sassari, Sassari, Italy, 2Infectious Diseases Unit, SS Trinità Hospital, Cagliari, Italy

    18.20 - 18.25

    OP 83

    Impact of HIV-related stigma on social support, mental health and quality of life in an Italian cohort of people living with HIV
    V. Delle Donne1, V. Massaroni1, A. Borghetti2, A. Dusina2, R.A. Passerotto2, R.J. Steiner2, A. Ciccullo3, G. Baldin4, S. Di Giambenedetto1,2
    1Infectious Diseases Institute, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy, 2UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 3UOC Infectious Diseases, Ospedale S. Salvatore, L’Aquila, Italy, 4Olbia Mater Hospital, Olbia, Italy

  • Bergamo Science Center
    10:05 - 10:55

    Oral Poster

    COVID-19: treatment strategies I

    Oral Poster

    COVID-19: treatment strategies I

    Chairs: C. Alteri, G. Cenderello

    10.05 - 10.10

    OP 1

    Real-life data on early treatment with antivirals in outpatients with mild COVID-19 symptoms
    A. Rugova1, G. Ghilardi2, G. Lapadula1,2, N. Squillace1, A. Cappelletti1, F. Sabbatini1, A. Ranzani1, M. Rossi1, F. Iannuzzi1, E. Pollastri1, P. Columpsi1, L. Bisi1, E. Colella1, S. Limonta1, I. De Benedetto1, N. Corti1,2, G.M. Migliorino1, S. Foresti1, A. Soria1, P. Bonfanti1,2
    1Clinic of Infectious Diseases San Gerardo Hospital ASST Monza, Monza, 2School of Medicine and Surgery University of Milano-Bicocca, Monza

    10.12 - 10.17

    OP 2

    Efficacy of licensed monoclonal antibodies and antiviral agents against the SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 and delta sub-lineage AY.4.2
    L. Fiaschi1, F. Dragoni1, E. Schiaroli2, A. Bergna3, B. Rossetti4, F. Giammarino1, C. Biba1, A. Gidari2, A. Lai3, C. Nencioni4, D. Francisci2, M. Zazzi1, I. Vicenti1
    1Department of Medical Biotechnologies, University of Siena, Siena, Italy, 2Department of Medicine and Surgery, Clinic of Infectious Diseases, University of Perugia, Perugia, Italy, 3Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, 4Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy

    10.19 - 10.24

    OP 3

    Sarilumab plus standard of care versus standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE Study)
    I. Mastrorosa1, R. Gagliardini1, F.V. Segala2, A. Mondi1, P. Lorenzini1, C. Cerva1, E. Taddei2, F. Bai3, M. Negri 2, C. Pinnetti1, S. Cicalini1, R. Murri2, V. Mazzotta1, M. Camici1, S. Mosti1, T. Bini3, A. Beccacece1, E. Milozzi1, M. Iannetta4, M. Fusto1, M.M. Plazzi1, M. Lichtner5, M. Fantoni2, M. Andreoni4, L. Sarmati4, R. Cauda2, E. Nicastri1, A. D’Arminio Monforte3, F. Palmieri1, A. Cingolani2, A. Antinori1
    1Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy, 2Fondazione Policlinico A. Gemelli IRCCS- Università Cattolica S. Cuore, Rome, Italy, 3Azienda Ospedaliera San Paolo, Milan, Italy, 4University of Rome Tor Vergata, Rome, Italy, 5Sapienza University of Rome, Italy, Polo Pontino

    10.26 - 10.31

    OP 4

    Safety and efficacy of antiviral agents in SARS-CoV-2 infected patients: a real-life experience
    A. De Vito, A. Colpani, A. Bitti, V. Manca, B. Zauli, M.C. Meloni, M. Fois, L. Denti, S. Bacciu, C. Marcia, I. Maida, S. Babudieri, G. Madeddu
    Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy

    10.33 - 10.38

    OP 5

    Efficacy of Early Antiviral Therapies among High-Risk Patients with Mild to Moderate COVID-19
    S. Amadasi1, M. Degli Antoni1, P. Grechi2, A. Tregambe2, S. Arsuffi1, F. Pennati1, M.A. Forleo1, F. Castelli1, E. Quiros-Roldan1
    1Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, 2Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia

    10.40 - 10.45

    OP 6

    Real life experience on the use of anti-SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression among inpatients and outpatients: a monocentric experience
    C. Leanza1, S. Di Bari1, N. Perrotta2, L.A. Fiorito2, R. Gentile3, V. Cioffi2, G. Casini2, F. Cogliati Dezza1, D. Fago1, C. Ajassa1, G. Iaiani1, R. Lobello2, E.M. Proli2, C.M. Mastroianni1, G. Russo1
    1Infectious Diseases Unit, AOU Policlinico Umberto 1st Sapienza University, Rome, Italy, 2Pharmacy, AOU Policlinico Umberto 1st, Rome, Italy, 3Pharmacy, G. D’annunzio University, Chieti Pescara, Italy

    11:10 - 12:00

    Oral Poster

    PrEP: real life experience

    Oral Poster

    PrEP: real life experience

    Chairs: F. Leserri, M. Marra

    11.10 - 11.15

    OP 19

    PrEP in Italy: how many people access it and what kind of services are offered?
    M. Stizioli1, G.M. Corbelli2, M. Falaguasta1, E. Nittolo1
    1PrEP in Italia, 2Plus Roma

    11.17 - 11.22

    OP 20

    HIV Pre-Exposure Prophylaxis (PrEP): the experience of the outpatient clinic of Perugia
    G. Gamboni, C. Gabrielli, C. Papalini, C. Pallotto, G. De Socio, F. Paciosi, A. Zoffoli, S.Tordi, E. Schiaroli, D. Francisci
    Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy

    11.24 - 11.29

    OP 21

    Impact of a pre-exposure prophylaxis program on HIV and other sexually transmitted infections over the last three years in a third level hospital: the experience from Padua
    F. Barbaro, S. Cavinato, M. Mazzitelli, L. Sasset, D. Leoni, A. Cattelan
    Unità Operativa Complessa Malattie Infettive e Tropicali, Azienda Ospedale Università Padova, Padova, Italy

    11.31 - 11.36

    OP 22

    Pre-Exposure Prophylaxis (PrEP) Service in Bergamo: three-year experience
    S. Venturelli, F. Borghi, L. Baldassari, D. Ripamonti, F. Maggiolo, M. Rizzi
    ASST Papa Giovanni XXIII, Bergamo

    11.38 - 11.43

    OP 23

    HIV Pre-exposure Prophylaxis in a Large Teaching Hospital in Milan: the CSL-PrEP Cohort experience
    A.R. Raccagni1, R. Lolatto2, L. Galli2, F. Alberton1, E. Bruzzesi1, D. Canetti2, M. Strano1, M. Ripa2, A. Castagna1,2, S. Nozza2
    1Vita-Salute San Raffaele University, Milan, Italy, 2Infectious Diseases Unit IRCCS San Raffaele, Milan, italy

    11.45 - 11.50

    OP 24

    The Italian experience of Pre-Exposure Prophylaxis (PrEP) users and serum creatinine variation: a two centers retrospective analysis
    M. Menozzi1, S. Volpi1, G.J. Burastero1, S. Colombaioni1, B. Fontana1, E. Martini1, M. Martini Fasce2, L. Labate2, A. Di Biagio3, C. Mussini1
    1Infectious Disease Clinic, University Hospital of Modena, Italy, 2Infectious Diseases Unit, Ospedale Policlinico San Martino IRCCS – Genoa, Italy, 3Department of Health Sciences (DISSAL), University of Genoa – Genoa, Italy

    12:15 - 13:05

    Oral Poster

    Access to test and educational aspects

    Oral Poster

    Access to test and educational aspects

    Chairs: A. Bianchi, G. D'Offizi

    12.15 - 12.20

    OP 25

    HIV testing in community-based centers and MSM premises: different settings, same needs
    A. Bianchi1,2, D. Zagato1, D. Calzavara2, R. Repossi1,2, P. Testoni1,2, A. Antonino1,2, G. Fracca1, F. Rossi1,2, A.J. Gallucci2,3, I. Gotti2,4, N. Frattini1,2, R. Rossotti2,6, G. Pigliapochi2, P. Russo2,3, M. Albiani2, M. Cernuschi1,2,5
    1ASA Associazione Solidarietà AIDS Onlus, Milan, Italy, 2Milano CheckPoint, Milan, Italy, 3CIG Arcigay Milano, Milan, Italy, 4Anlaids Sez. Lombarda, Milan, Italy, 5San Raffaele Hospital, Milan, Italy, 6ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

    12.22 - 12.27

    OP 26

    HIV testing: are we missing some opportunities?
    M. Mazzitelli, L. Sasset, D. Leoni, F. Barbaro, A.M. Cattelan
    Infectious and Tropical Diseases Unit, Azienda Ospedale Università Padova, Italy

    12.29 - 12.34

    OP 27

    Population of the Bergamo Check-Point. A first analysis of Cobatest data
    I. Mercurio1, C. Pellegris2, P. Meli2, E. Zanetti2, F. Maggiolo3, F. Radici4, R. Carissoli4
    1Croce Rossa Italiana – Comitato di Bergamo, 2Società Cooperativa Sociale Don Giuseppe Monticelli, 3ASST Papa Giovanni XXIII, 4Arcigay Bergamo Cives

    12.36 - 12.41

    OP 28

    Veneto Region “RECALL” project to discover HCV+people: the experience of the “Osservatorio Infettivologico“ in Verona
    V. Del Punta, M. Fiscon, G. Giammarresi, S. Nardi, M. Malena
    UOS Osservatorio Infettivologico Aziendale Azienda ULSS 9 Scaligera

    12.43 - 12.48

    OP 29

    Prejudice and perceived HIV risk among High School Students
    C. Pellegris1, I. Mercurio1, P. Meli1, E. Zanetti1, F. Maggiolo2, I. Fontana3
    1Società Cooperativa Sociale Don Giuseppe Monticelli, 2ASST Papa Giovanni XXIII, 3Ufficio Scolastico Territoriale Bergamo

    12.50 - 12.55

    OP 30

    Pilot experience of comprehensive sexuality education among Italian adolescents: preliminary results from the EduForIST project, April 2022
    A. Chinelli1, D. Martinelli2, L. Ceccarelli1, E. Torri1, R. Galipò3, P. Meli4, A. Camposeragna5, L.Rancilio6, M. Farinella7, L. Colaprico8, M. Oldrini9, M.C. Salfa10, A. Cellini11, M. Ubbiali12, A. Caraglia13, L. Mortari12, A.T. Palamara11, B. Suligoi10, L. Tavoschi1
    1University of Pisa, Department of Translational Research on New Technologies in Medicine and Surgery, 2University of Foggia, Department of Medical and Surgical Sciences, 3ANLAIDS - National Association for the Fight against AIDS, Rome, 4CICA - Italian Coordination of HIV/AIDS Housing Homes, Bergamo, 5CNCA - National Coordination of the Hospitality Community, Rome, 6Caritas Ambrosiana, Milan, 7Circolo di cultura omosessuale Mario Mieli, Rome, 8Italian Red Cross, Rome, 9LILA - Italian league for the fight against AIDS, Rome, 10Italian National Institute of Health, Rome, 11Sapienza University of Rome, 12University of Verona, Department of Human Sciences, 13Ministry of Health, Department of Prevention, Rome

    13:25 - 14:15

    Oral Poster

    HCV eradication: general and key populations

    Oral Poster

    HCV eradication: general and key populations

    Chairs: P. Colletti, M. Cusini

    13.25 - 13.30

    OP 37

    Long-term outcomes in GT3 HCV/HIV co-infected subjects treated with DAAs: impact on metabolic profile
    A. Siribelli1, D. Ceccarelli2, E. Messina2, C. Bertoni1, R. Lolatto2, G. Morsica2, C. Uberti-Foppa1,2, A. Castagna1,2, H. Hasson2
    1Vita-Salute University, Milan, Italy, 2Dept. of Infectious Diseases, San Raffaele Hospital, Milan, Italy

    13.32 - 13.37

    OP 38

    Chronic Hepatitis C cascade of care in Prisoners. Is there still some work to be done? Analysis of two penitentiaries in northern Italy
    A. Cambianica1, V. Marchese1, F. Pennati1, A. Faustinelli1, M. Tonni2, F. Roda2, A. Spinetti1, S. Zaltron1, S. Fiorentini3, E. Quiros-Roldan1, F. Castelli1, E. Focà1
    1Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, 2Unit of Prison Health ASST Spedali Civili Hospital, Brescia, Italy, 3Unit Of Microbiology and Virology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

    13.39 - 13.44

    OP 39

    HCV point of care screening in people tested for SARS-CoV-2 in a social-housing neighbourhood of Milan, Italy
    M. Beltrami1,2, G. Pagani3, F. Conti1,2, L. Pezzati1,2, G. Casalini1,2, R. Rondanin4, A. Prina4, A. Zagari5, M. Galli1,2, A. Giacomelli1
    1Malattie Infettive III Divisione, ASST FBF-Sacco, Milan, Italy, 2Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Università degli Studi di Milano, Milan, Italy, 3Malattie Infettive, Ospedale Nuovo di Legnano, ASST Ovest Milanese, Legnano, Italy, 4Medispa S.r.l., Milan, Italy, 5Direzione Socio-Sanitaria, ASST FBF-Sacco, Milan, Italy

    13.46 - 13.51

    OP 40

    Hepatitis C virus (HCV) micro-elimination in the hospital setting: the results of the HCV Caserta hospital project
    V. Messina1, M. Pisaturo2, L. Alessio2, A. Russo2, E. Tripaldelli3, A. Petruzziello3, A. Annechiaro4, M.R. Romano5, P. Maggi1,2, N. Coppola2
    1Infectious Disease Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, 2Department of Mental and Physical Health and Preventive Medicine, Infectious Diseases section, University of Campania Luigi Vanvitelli, Naples, 3Clinical Pathology, AORN Sant'Anna e San Sebastiano, Caserta, Italy, 4Direzione Sanitaria,AORN Sant'Anna e San Sebastiano, Caserta, Italy, 5Regione Campania, Naples, Italy

    13.53 - 13.58

    OP 41

    Patients’ reported experiences with direct acting antiviral therapy in an integrated model of hepatitis C care and treatment
    L. Ceccarelli1,2, G. Moretti2, I. Corazza2, L. Tavoschi1, M. Vainieri2
    1Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, 2Management and Healthcare Laboratory, Sant’Anna School of Advanced Studies, Pisa, Italy

    14.00 - 14.05

    OP 42

    Characterisation of viral infections in a cohort of migrants living in southern italy
    S. Capuano1,9, M. Pisaturo1,7, A. Loredana1,7, L. Occhiello1, M. Macera1,4, M. Starace1, E. Cordua1, L. Onorato1, G. Scotto8, G. Di Caprio3,7, F. Calò1,6, C. Sagnelli1,5, N. Coppola1
    1Department of Mental and Physical Health and Preventive Medicine, Infectious Diseases section, University of Campania Luigi Vanvitelli, Naples, 2L. Vanvitelli University Hospital, Naples, 3UOC of Infectious Diseases, AORN Sant&Anna and San Sebastiano, Caserta, 4Abraham Tent; Reception Center, Caserta, 5Missionary Sisters of Charity Center, Naples, 6Center for the Protection of Immigrant Health, Naples, 7Social center “ex-canapificio”, Caserta, 8UOC of Infectious Diseases, Foggia, 9Social center “ex-opg Je so Pazz”, Napoli

    14:30 - 15:20

    Oral Poster

    Issues on mental health, sexual health and STIs

    Oral Poster

    Issues on mental health, sexual health and STIs

    Chairs: R. Galipò, D. Ripamonti

    14.30 - 14.35

    OP 49

    Predictors of mental and sexual health after COVID-19 Pandemic in a group of MSM living with HIV
    F.M. Nimbi1, G.M. Corbelli2, G. Giovanardi1, A. Tanzilli1, V. Lingiardi1
    1Dept. Dynamic, Clinical and Health Psychology, Sapienza University of Rome, 2Plus Roma – APS, Rome

    14.37 - 14.42

    OP 50

    Single nucleotide polymorphisms affecting neuroinflammation biomarkers in different clinical groups of HIV-affected patients
    J. Cusato1, M. Antonucci1, A. Palermiti1, A. Manca1, J. Mula1, V. Avataneo1, M. Trunfio2, G. Di Perri2, A. D’Avolio1, A. Calcagno2
    1Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, 2Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy

    14.44 - 14.49

    OP 51

    Treatment response in syphilis reinfection among People living with HIV: high baseline titer and delayed assessment affects the risk of serological-non-response
    G. Tiecco, V. Marchese, S. Storti, M. Degli Antoni, M. Gulletta, F. Viola, E. Focà, F. Castelli, E. Quiros-Roldan
    Division of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

    14.51 - 14.56

    OP 52

    Increasing incidence of Mycoplasma genitalium infection in PLWHIV and PrEP users
    R. Rossotti1, A. Nava2, C. Baiguera1, F. D’Amico1, E. Inglese2, C. Rogati1, D. Fanti1, N.B. Bana1, C. Vismara2, M. Puoti1
    1Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, 2Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

    14.58 - 15.03

    OP 53

    Alteration of IFN pathways in anal cells from HIV-1/HPV co-infected men
    M. Fracella1, M. Scordio1, L. Sorrentino1, F. Frasca1, G. Oliveto1, A. Viscido1, L. Santinelli2, E.N. Cavallari2, G. D'Ettorre2, P. Gozzo2, G. Antonelli1, C. Scagnolari1, A. Pierangeli1
    1Department of Molecular Medicine, Virology Laboratory, Sapienza University of Rome, Rome, 2Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome

    15.05 - 15.10

    OP 54

    Efficacy of late HPV vaccination in young HIV+ MSM
    E. Cavallari1, L. Santinelli1, L. Maddaloni1, M. Ridolfi1, M. Scordio2, A. Pierangeli2, G. Ceccarelli1, C.M. Mastroianni1, G. d'Ettorre1
    1Department of Public Health and Infectious Diseases "Sapienza" University of Rome, Rome, 2Department of Molecular Medicine "Sapienza" University of Rome, Rome

    15:35 - 16:25

    Oral Poster

    New issues on dual therapy

    Oral Poster

    New issues on dual therapy

    Chairs: M. De Gennaro, S. Nozza

    15.35 - 15.40

    OP 61

    Efficacy and Durability of Dual Antiretroviral Regimens as switch therapy in treatment-experienced People Living with HIV (PLWH): data from the ARCA cohort
    M. Poliseno1, A. Borghetti2, F. Conti3, G. Di Teodoro4,5, F. Lombardi6, L. Montemurro1, L. Pezzati3, A. Shallvari5,7, A. Bezenchek5,7, V. Borghi8, S. Rusconi3,9
    1U.O. Malattie Infettive Universitaria, University of Foggia, Foggia, Italy, 2Policlinico Gemelli, Roma, Italy, 3Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milano, Italy, 4Dipartimento di Ingegneria informatica automatica e gestionale A. Ruberti, Sapienza Università di Roma, Roma, Italy, 5EuResist Network GEIE, Roma, Italy, 6Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Roma, Italy, 7InformaPRO SRL, Roma, Italy, 8Clinica Malattie Infettive, Azienda Ospedaliero Universitaria di Modena, Modena, Italy, 9OC Malattie Infettive, ASST Ovest Milanese, Ospedale di Legnano, Milano, Italy

    15.42 - 15.47

    OP 62

    Characterization of virologically suppressed HIV infected individuals potential eligible to the long-acting combination of cabotegravir plus riplivirine: results from the Italian ARCA cohort
    A. Cervo1, A. Russo2, D. Di Carlo3, A. De Vito4, L. Fabeni5, S. D’Anna6, L. Duca6, A. Colpani4, M. Fois4, B. Zauli4, G. Mancarella7, A. Carraro7, A. Bezenchek8, A. Cozzi-Lepri9, M.M. Santoro6
    1Infectious Diseases Clinic, University Hospital of Modena, Italy, 2Infectious Diseases Unit, Department of Mental Health, University of Campania “Luigi Vanvitelli”, Naples, Italy, 3Pediatric Clinical Research Center "Romeo and Enrica Invernizzi", Department of Biomedical and Clinical Sciences "L. Sacco" University of Milan, Italy, 4Unit of Infectious Diseases, Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy, 5National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, 6University of Rome “Tor Vergata”, Rome, Italy, 7Infectious Disease Unit, Sapienza University of Rome - Polo Pontino, Latina, Italy, 8InformaPRO SRL, Rome, Italy; EuResist Network GEIE, Rome, Italy, 9Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, London, UK

    15.49 - 15.54

    OP 63

    Long acting cabotegravir plus rilpivirine compassionate use program: a narrative description of the Italian experience
    R. Rossotti1, G. Orofino2, B. Canovari3, R. Viglietti4, F. D’Amico1, N.B. Bana1, L. Carani2, M.C. Moioli1, F. Barchiesi3, M. Puoti1,5
    1Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, 2Unit of Infectious Diseases, "Divisione A," Amedeo di Savoia Hospital, Turin, 3Unit of Infectious Diseases, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, 4UOC Infezioni Sistemiche e dell'Immunodepresso, AORN Ospedali dei Colli, PO D. Cotugno, Naples, 5School of Medicine, University of Milano Bicocca, Milan

    15.56 - 16.01

    OP 64

    Immunological recovery in PLWHIV starting dolutegravir plus lamivudine as first-line regimen: data from the ODOACRE cohort
    A. Ciccullo1, A. Dusina2, A. Borghetti2, M.V. Cossu3, D. Farinacci4, F. Lamanna4, R.A. Passerotto4, F. Lombardi4, A. Capetti3, G. Baldin2,5, S. Di Giambenedetto2,4
    1UOC Malattie Infettive, Ospedale San Salvatore, L'Aquila, Italia, 2UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia, 3Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, 4Università Cattolica del Sacro Cuore, Roma, Italia, 5Ospedale Mater Olbia, Olbia, Italia

    16.03 - 16.08

    OP 65

    Comparison of efficacy and tolerability of Dolutegravir / Rilpivirine and Dolutegravir / Lamivudine in experienced HIV-1 positive patients switched from a three-drug regimen based on Non-Nucleoside Reverse Transcriptase Inhibitors: a multicenter cohort study in Italy
    F. Lagi1, A. Giacomelli2, V. Borghi3, A. Ciccullo4, L. Taramasso5, G. Madeddu6, G. D’Ettorre7, A. Giacometti8, F. Ducci9, A. De Vito6, R. Pincino10, S. Di Giambenedetto4, C. Mussini3, S. Antinori2, G. Sterrantino9
    1Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy, 2Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy, 3Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy, 4UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, 5Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS, Genoa, Italy, 6Infectious Diseases Operative Unit, University Hospital of Sassari, Sassari, Italy, 7Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, 8Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Ancona, Italy, 9Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 10Infectious Diseases Unit, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

    16.10 - 16.15

    OP 66

    Comparing the efficacy and tolerability of dolutegravir plus rilpivirine versus dolutegravir plus lamivudine in a multicenter cohort
    A. Ciccullo1, G. Baldin2,3, M.V. Cossu3, A. Giacomelli4, F. Lagi5, F. Lamanna6, D. Farinacci6, V. Iannone6, R.A. Passerotto6, A. Capetti3, G. Sterrantino5, S. Antinori4, S. Di Giambenedetto2,6
    1UOC Malattie Infettive, Ospedale San Salvatore, L’Aquila, Italy, 2UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, 3Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, 4UOC Malattie Infettive III, DIBIC Luigi Sacco, University of Milan, Milan, Italy, 5Division of Tropical and Infectious Diseases, "Careggi" Hospital, Florence, Italy, 6Catholic University of the Sacred Heart, Rome, Italy

    16:40 - 17:30

    Oral Poster

    Vulnerable and key population: local experiences

    Oral Poster

    Vulnerable and key population: local experiences

    Chairs: E. Girardi, A. Moznich

    16.40 - 16.45

    OP 73

    Community-Based Centers (CBCs): sexual health needs and prevention knowledge among MSM in Lazio
    G.M. Corbelli1, V. Lingiardi2, F.M. Nimbi2
    1Plus Roma – APS, Rome, 2Dept. of Dynamic, Clinical and Health Psychology, Sapienza University of Rome

    16.47 - 16.52

    OP 74

    Injecting drug use, irrespective of harm reduction measures, is strongly associated with HCV infection: results of a structured questionnaire administered during HCV screening sessions in low threshold harm reduction services
    A. Soria1, G. Ghilardi1, M. Comolatti1, M. Di Gennaro1, C. Gaboardi2, A. De Pace3, P. Di Gloria2, C. Bregamo2, R. Gallizzi2, A. Barni3, MG. Marconi4, GM. Migliorino1, P. Bonfanti1,5, G. Lapadula1,5
    1Infectious Diseases San Gerardo Hospital ASST Monza, Monza, 2Cooperativa Lotta Contro L’Emarginazione, Monza, 3Comunità Nuova, Monza, 4ATS Brianza, Monza, 5University of Milano-Bicocca, Monza

    16.54 - 16.59

    OP 75

    High prevalence of HCV infection among people screened in unconventional low threshold settings: results of an outreach program of screening and linkage to care for people using drugs
    A. Soria1, G. Lapadula1,2, M. Comolatti1, M. Di Gennaro1, C. Gaboardi3, A. De Pace3, P. Di Gloria3, C. Bregamo3, R. Gallizzi3, A. Barni4, MG. Marconi5, G. Scaffidi6, M. Bramani-Araldi6, A. Caruso6, D. Leto7, A. Cardia7, P. Fortuna8, G. Galimberti8, S. Torlasco9, C. Fanzaga10, M. Belloni10, E. Chiesa11, GM. Migliorino1, P. Bonfanti1,2
    1Infectious Diseases San Gerardo Hospital ASST Monza, Monza, 2University of Milano-Bicocca, Monza, 3Cooperativa Lotta Contro L’Emarginazione, Monza, 4Comunità Nuova, Monza, 5ATS Brianza, Monza, 6SerD Carate-Brianza ASST Brianza, Carate-Brianza, 7SerD Limbiate ASST Brianza, Limbiate, 8SerD Monza ASST Monza, Monza, 9Corpo Italiano Soccorso Ordine di Malta Monza Brianza, Monza, 10Servizi Sociali Comune di Monza, Monza, 11Casa Circondariale di Monza, Monza

    17.01 - 17.06

    OP 76

    Descriptive analysis and retention in care of a cohort of HIV-positive migrants (AMIGO: A HIV-positive MIGrants cohort at AOU Careggi)
    F. Lagi1, S.T. Kiros1, M. Turco3, B. Borchi1, F. Bartalesi1, P. Corsi1, E. Gotuzzo4, G. Sterrantino2, A. Bartoloni1,2
    1SOD Malattie Infettive e Tropicali, AOU Careggi, 2Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi Di Firenze, Firenze, 3Sezione di Dermatologia, Dipartimento di Scienze della Salute, Università degli studi di Firenze, Firenze, 4Universitad Peruana Cayetano Heredia, Lima, Peru

    17.08 - 17.13

    OP 77

    A qualitative survey on facilitating factors and barriers to access and continuum of care: point of view of HIV-positive transgender migrant women living in Florence
    F. Lagi1, C. Gatteschi2, M. Tilli3, N. Zocco4, A. Avarello1, S. Bellini5, S. Contanessi4, M.R. Zigliani5, M. Stagnitta4, L. Mariano4, E. Gazzarri4, L. Belloni6, A. Bartoloni1,3, G. Sterrantino3, F. Ierardi2
    1SOD Malattie Infettive e Tropicali, AOU Careggi, Firenze, 2Agenzia Regionale di Sanità di Toscana, 3Dipartimento di medicina Speriementale e Clinica, Università degli studi di Firenze, Firenze, 4CAT Coperativa sociale Firenza, 5Lega Italiana Lotta all’ AIDS, LILA, 6Centro di riferimento regionale criticità relazionali, AOU Careggi, Firenze

    17:45 - 18:35

    Oral Poster

    Models of COVID-19 pathogenesis and response to vaccination

    Oral Poster

    Models of COVID-19 pathogenesis and response to vaccination

    Chairs: A. Riva, C. Tincati

    17.45 - 17.50

    OP 84

    Human iPSC-derived motor neurons are productively infected by SARS-CoV-2
    G. Cappelletti1, C. Colombrita2, F. Limanaqi1,5, D. Trabattoni1, C. Moscheni1, A. Tosoni6, M. Nebuloni1,6, S. Santangelo2,3, V. Silani2,4, A. Ratti2,3, M. Biasin1
    1Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Italy, 2Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy, 3Department of Medical Biotechnology and Translational Medicine, University of Milan, Italy, 4Department of Pathophysiology and Transplantation, “Dino Ferrari” Center, University of Milan, Italy, 5Department of Pathophysiology and Transplantation, Milan, Italy, 6Pathology Unit, L. Sacco Hospital, Milan, Italy

    17.52 - 17.57

    OP 85

    SARS-CoV-2 infection of airway epithelium triggers endothelial cells activation
    D. Mariotti, G. Matusali, F. Colavita, C. Agrati, V. Bordoni
    INMI L. Spallanzani, Roma

    17.59 - 18.04

    OP 86

    Specific CD4+ and CD8+ T cell response of SARS-CoV-2 S epitopes using tetramers & monocyte dysregulation in fully vaccinated donors and recovered patients
    A. Parente2, M. Iuliano1, R. Mongiovì1, B. Kertusha2, A. Carraro2, R. Marocco2, G. Mancarella2, S. Garattini2, F. Izzo2, C. Del Borgo2, T. Tieghi2, L. Fondaco2, G. Mangino1, M. Lichtner2, G. Romeo1
    1Dept. of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Italy, 2Dept. of Public Health and Infectious Disease, S. Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy

    18.06 - 18.11

    OP 87

    Immune responses after three doses of BNT162b2 mRNA vaccine in a cohort of HIV-vertically transmitted patients
    C. Vanetti1, M. Stracuzzi2, F. Cicilano1, V. Rubinacci2,4, C. Fenizia3, G. Meraviglia2, Clerici3,5, M. Biasin1, G.V. Zuccotti2,4, V. Giacomet2, D. Trabattoni1
    1University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, 2Ospedale L. Sacco, University of Milan, Department of Pediatric Infectious Diseases, Milan, 3University of Milan, Department of Pathophysiology and Transplantation, Milan, 4Ospedale dei Bambini V. Buzzi, Department of Paediatrics, Milan, 5IRCCS Fondazione Don Carlo Gnocchi

    18.13 - 18.18

    OP 88

    Comparison between QuantiFERON SARS-CoV 2 kit and Activation Induced Cell Markers (AIMs) assay in 21 non-vaccinated patients with late COVID19 infection
    A. Gatti1, M. De Paschale2, P. Clerici2, M.P. Faggioli3, A. Tamburello3, L. Castelnuovo3, M. Franzetti4, § S. Rusconi4,, A. Mazzone3
    1Haematology Laboratory - Transfusion Center, 2Microbiology Unit, 3Internal Medicine Unit, 4Infectious Diseases Unit, Legnano Hospital, Milano, Italy, §Department of Biomedical and Clinical Sciences DIBIC “Luigi Sacco”, University of Milan, Italy

    18.20 - 18.25

    OP 89

    An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein
    M.C. Bellocchi1, L. Carioti1, R. Scutari1, M. Iannetta2, L. Piermatteo1, M. Alkhatib1, S. Tedde2, L. Duca1, L. Coppola2, V. Malagnino2, A. Crea2, L. Ansaldo2, S. D’Anna1, M.M. Santoro1, A. Bertoli1,2, A. Di Lorenzo2, R. Salpini1, V. Svicher1, E. Teti2, N. Braccialarghe2, R.A. Cavasio2, L. Sarmati2, M. Andreoni2, F. Ceccherini-Silberstein1
    1University of Rome Tor Vergata, Rome, Italy, 2University Hospital of Rome Tor Vergata, Rome, Italy

 
Auditorium Sala Oggioni
Sala Stucchi
Alabastro A
Alabastro B
Bergamo Science Center
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30

09:00 - 10:00

Keynote Lectures

10:05 - 11:05 | Symposium

Comorbidities of contemporary relevance

11:10 - 12:10 | Sponsored Symposium

Remdesivir: key-role in COVID-19 management

12:15 - 13:15 | Symposium

A practical approach to HIV patients' management

13:15 - 14:15 | Symposium

Immunological control over HIV : from models of spontaneous control to immunotherapeutic approaches

14:15 - 15:15 | Symposium

COVID-19 from early treatment to long-term care

15:20 - 16:20 | Symposium

Update on antiretroviral therapy: answers and suggestions during a pandemic era

16:25 - 16:40

ICAR 2022 Special Awards and Closing Remarks

16:25 - 16:45

ICAR 2022 Special Awards and Closing Remarks

10:05 - 11:05 | Expert Meeting

Heavily-treatment experienced (HTE) patients: who are they? And how should be managed?

11:10 - 12:10 | Oral Communications

Resistance to antiretroviral

12:15 - 13:15 | Oral Communications

HIV and SARS-CoV-2: two intersecting epidemics

13:15 - 14:15 | Oral Communications

Diabetes, cardiovascular diseases and STIs. A wide range of comorbidities

14:15 - 15:15 | Oral Communications

Dual therapy in naive and switched PLWH

15:20 - 16:20 | Oral Communications

Complexities of SARS-CoV-2 infection

10:05 - 10:35 | Special Session

Update on current monkeypox multi-country outbreak in Europe

10:40 - 12:10 | Symposium

The Italian Fast-Track Cities Network

12:15 - 13:15 | Expert Meeting

Redefining management and treatment goals in antiretroviral triple therapy: results of a Delphi Consensus

13:15 - 14:15 | Oral Communications

Immunological efficacy of SARS-CoV-2 vaccine II

14:15 - 15:15 | Oral Communications

Mental health and predictors of AIDS and non-AIDS defining co-pathologies

15:20 - 16:20 | Oral Communications

Insights on epidemiological and clinical management of hepatitis viruses

10:05 - 10:55 | Oral Poster

COVID-19: considerations of special populations

11:10 - 12:00 | Oral Poster

HIV and SARS-CoV-2: from in vivo to in vitro

12:15 - 13:05 | Oral Poster

Acute COVID-19 and post COVID-19 syndrome

13:15 - 14:05 | Oral Poster

Open questions about ART efficacy

14:20 - 15:10 | Oral Poster

Prevention and access to services during COVID pandemic

15:20 - 16:10 | Oral Poster

Immunopathogenesis of HIV

10:05 - 10:55 | Oral Poster

Toxicity of antiretroviral therapy

12:15 - 13:05 | Oral Poster

Immunological efficacy of COVID-19 vaccination in vulnerable populations

13:15 - 14:05 | Oral Poster

Immunological complexity in COVID-19

14:20 - 15:10 | Oral Poster

SARS-CoV-2: from in vivo to in vitro

15:20 - 16:15 | Round Table

Preventing an fighting emerging infections: the monkeypox paradigma between information and stigma

  • Auditorium Sala Oggioni
    09:00 - 10:00

    Keynote Lectures

    Keynote Lectures

    Chairs: M.L. Cosmaro, M. Galli

    09.00 - 09.30 Anti-HIV therapy as a guide to treat COVID-19
    C.F. Perno
    09.30 - 10.00 Comparing the Mental Health Trajectories of PLWH during the pandemic period with the prepandemic situation: impact of geographic differences and different access to health care facilities
    F. Lampe
    10:05 - 11:05

    Symposium

    Comorbidities of contemporary relevance

    Symposium

    Comorbidities of contemporary relevance

    In recent years, the comorbidities of HIV infection, initially associated with side effects of ART, have turned into pathological conditions more often related to aging and lifestyles. Among ART side effects, weight gain remains a concern especially in PWH receiving integrase inhibitors, and mechanisms are still unclear. Beyond ART, sexually transmitted infections are among those more clinically relevant in PWH because of their high frequency and transmissibility, despite most can be prevented or treated. In this context, HPV infection is of particular interest because it is implicated in the development of tumors, which remain a relevant cause of mortality in PWH.

    Chairs: P. Maggi, B. Marchini

    10.05 - 10.20 Pathogenetic aspects of weight gain under ART
    L. Taramasso
    10.20 - 10.35 Evolving concepts in Sexually Transmitted Infections
    G. Villa
    10.35 - 10.50 HPV infection and its consequences: where we stand now
    N. Squillace
    10.50 - 11.05 Discussion on Symposium issues
    11:10 - 12:10

    Sponsored Symposium

    Remdesivir: key-role in COVID-19 management

    Simposio promozionale di:

    Sponsored Symposium

    Remdesivir: key-role in COVID-19 management

    Remdesivir, the first antiviral drug authorized in Europe for the treatment of COVID-19, has demonstrated its efficacy in three randomized controlled clinical trials, including the gold-standard ACTT-1 study, and, increasingly, in numerous evidences from the real practice. Recent international real-world retrospective analyses on large data sets and a meta-analysis of the most important real-world publications confirmed that hospitalised COVID-19 patients treated with remdesivir had a statistically significant reduction in mortality and improved survival compared to matched controls. Moreover, the PINETREE phase III study on moderate COVID-19 patients revealed high efficacy of remdesivir in reducing hospitalization or mortality rate compared to placebo, results that granted the new recent EMA indication for high risk moderate patients. This Symposium will be an opportunity to give an overview of the evolving patient profile, to present a scientific update on remdesivir efficacy data and to discuss centres organization to manage the treatment of COVID-19 outpatients. The three talks composing the Symposium will then try to address the most important topics regarding COVID-19 patient management with remdesivir.

    Chair: R. Bruno

    11.10 - 11.15 Introduction
    R. Bruno
    11.15 - 11.30 The evolution of the COVID-19 patient profile 
    P. Viale
    11.30 - 11.45 Remdesivir in the severe patient: new evidences from the Real World
    M. Falcone
    11.45 - 12.00 Remdesivir in the high risk moderate patient:  efficacy profile and patient management
    E. Nicastri
    12.00 - 12.10 Discussion on Symposium issues
    12:15 - 13:15

    Symposium

    A practical approach to HIV patients' management

    Symposium

    A practical approach to HIV patients' management

    The objectives of this symposium are to provide both clinical management insights on «late presentation in HIV» identifying the unmet needs of specific vulnerable patients, such as migrants, pregnant women, trans individuals, adolescents, and to increase the level of awareness for the HIV management in these specific populations. The program will also include new immuno-pharmacology concepts that may have a role in the future HIV therapy as well as a lecture on some new therapeutic approaches to tubercolosis that can impact the future management of people with HIV.

    Chairs: A. Gori, F. Vichi

    12.15 - 12.30 Management of Late presentation in vulnerable populations - Interactive clinical case
    C. Pinnetti
    12.30 - 12.45 Chasing inflammation: is there a role of the immunomodulant agents in HIV? - Interactive clinical case
    G.C. Marchetti
    12.45 - 13.00 New therapeutic approaches to tuberculosis in people living with HIV
    A. Matteelli
    13.00 - 13.15 Discussion on Symposium issues
    13:15 - 14:15

    Symposium

    Immunological control over HIV : from models of spontaneous control to immunotherapeutic approaches

    Symposium

    Immunological control over HIV : from models of spontaneous control to immunotherapeutic approaches

    The symposium is intended to address different aspects of the immune control over HIV. In particular, a comprehensive review of the latest notions on known human and animal models of spontaneous control over HIV will be provided. The interaction of the virus with specific cell subpopulations, and in particular stem cell memory cells, will also be illustrated. The most novel specific immunotherapeutic approaches to overcome HIV infection will also be thoroughly reviewed during the symposium.

    Chairs: C. Agrati, A. Cossarizza

    13.15 - 13.30 HIV and stem cell memory cells: from pathogenesis to therapeutic approaches
    L. Manganaro
    13.30 - 13.45 Immunotherapy as a tool towards cure interventions
    M.S. Clerici
    13.45 - 14.00 Models of spontaneous control over HIV infection
    G. Poli
    14.00 - 14.15 Discussion on Symposium issues
    14:15 - 15:15

    Symposium

    COVID-19 from early treatment to long-term care

    Symposium

    COVID-19 from early treatment to long-term care

    This symposium will offer insights in the early and late management of COVID-19. On one end, we will discuss risk stratification of vulnerable individuals who qualify for early treatment of SARS COV-2 infection. On the other end, we will discuss pathogenesis and care of Post-Acute COVID Syndrome (PACS). A clinical case presentation of a vaccinated individual living with HIV will offer the framework to discuss risk stratification for early treatment of immunologically vulnerable populations, as well as how to assess and manage post-acute COVID Syndrome.

    Chairs: G. Rizzardini, M. Rizzi

    14.15 - 14.30 From risk stratification to early treatment. How to keep a patient with SARS-CoV-2 out of hospital?
    D. Peppa
    14.30 - 14.45 From acute to post-acute SARS-CoV-2 disease: can we prevent or reverse PACS?
    S.G. Deeks
    14.45 - 15.15 Panel discussion - Clinical models in managing PACS. Is resilience our goal?
    Discussants: S. Deeks, G. d’Ettorre, A. M. Geretti, G. Guaraldi, D. Peppa, A. Vergori
    15:20 - 16:20

    Symposium

    Update on antiretroviral therapy: answers and suggestions during a pandemic era

    Symposium

    Update on antiretroviral therapy: answers and suggestions during a pandemic era

    Antiretroviral therapy (TARV) has changed the life expectancy of people living with HIV infection and has drastically improved the quality of life of people we care for. The high efficacy of TARV is still hampered by the impossibility of clearing the viral reservoir. Nevertheless, new drugs for modern needs are flourishing and will reach the clinical arena. These compounds will be instrumental for the rapid start of TARV, even in the context of the COVID-19 pandemic, and in the challenge of treating HTE individuals, a polymorphic situation where novel answers are eagerly awaited.

    Chairs: T. Bini, P.M. Cinque

    15.20 - 15.35 New drugs for modern needs: from phase II trials up to now
    A. Di Biagio
    15.35 - 15.50 Rapid start in COVID-19 era: what is needed?
    C. Mussini
    15.50 - 16.15 Clinical case: Novel strategies for HTE people
    Presenter: D. Canetti
    Discussants: D. Ripamonti, S. Rusconi
    16.15 - 16.20 Discussion on Symposium issues
    16:25 - 16:40

    ICAR 2022 Special Awards and Closing Remarks

    ICAR 2022 Special Awards and Closing Remarks

    Chairs: A. Antinori, M.G.L. Cernuschi, A. d'Arminio Monforte, F. Maggiolo, M. Zazzi

    16.25 - 16.40 ICAR 2022 Special Awards:
      -ICAR-CROI Awards
      -ICAR Scientific Committee Awards
      -SIMIT Awards to Best Oral Communications for young researchers
    16.40 - 16.45 ICAR 2022 Closing remarks
    16:25 - 16:45

    ICAR 2022 Special Awards and Closing Remarks

    ICAR 2022 Special Awards and Closing Remarks

    Chairs: A. Antinori, M.G.L. Cernuschi, A. d'Arminio Monforte, F. Maggiolo, M. Zazzi

    16.25 - 16.40 ICAR 2022 Special Awards:
      -ICAR-CROI Awards
      -ICAR Scientific Committee Awards
      -SIMIT Awards to Best Oral Communications for young researchers
    16.40 - 16.45 ICAR 2022 Closing remarks
  • Sala Stucchi
    10:05 - 11:05

    Expert Meeting

    Heavily-treatment experienced (HTE) patients: who are they? And how should be managed?

    Con la sponsorizzazione non condizionante di:

    Expert Meeting

    Heavily-treatment experienced (HTE) patients: who are they? And how should be managed?

    Despite the availability of new classes of antiretroviral (ARV) therapy with improved efficacy, some usually heavily-treatment experienced (HTE) patients eventually experience treatment failure due to various factors including viral resistance, drug toxicity, drug intolerance, and poor adherence. Long-term ARV therapy use could lead to decreased efficacy of multiple classes of ARVs, requiring increasingly tailored regimens, and few, if any, remaining ARV options remaining. Therefore, it is important to consider new ARVs with different mechanism of action in the therapeutic approach of these patients: in this context, the oral attachment inhibitor has demonstrated efficacy in adults with multidrug resistant HIV-1 infection in urgent need of new treatment due to resistance, safety, or tolerability issues with their current regimens.

    Moderator: S. Lo Caputo

    Discussants: A. Castagna, C.F. Perno

      Heavily-treatment experienced (HTE) patients: who are they? And how should be managed?
    11:10 - 12:10

    Oral Communications

    Resistance to antiretroviral

    Oral Communications

    Resistance to antiretroviral

    Chairs: A. Cascio, M.A. Di Pietro

    11.10 - 11.20

    OC 34

    Evaluation of integrase resistance and its predictors in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings
    M.M. Santoro1, D. Armenia2, C. Charpentier3, A. Bertoli4, F. Forbici5, V. Calvez6, D. Descamps3, F. Ceccherini-Silberstein1, A.G. Marcelin6, P. Flandre7, on behalf of the ANRS-MIE AC43 group and the Italian HIV-drug resistance group
    1University of Rome “Tor Vergata”, Rome, Italy, 2Saint Camillus International University of Health Sciences, Rome, Italy, 3Paris University, AP-HP, Hôpital Bichat-Claude-Bernard, IAME, Paris, France, 4Polyclinic of Rome “Tor Vergata”, Rome Italy, 5National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, 6Sorbonne Université, AP-HP, Hôpital Pitié Salpêtrière, INSERM UMR-S1136, Paris, France, 7Sorbonne Université, INSERM UMR-S1136, Paris, France

    11.22 - 11.32

    OC 35

    Efficacy of dolutegravir versus darunavir in first-line regimens according to resistance mutations and viral subtype
    P.F. Salvo1, D. Farinacci1,2, A. Ciccullo3, V. Borghi4, P. Laghetti5, S. Rusconi6, A. Saracino7, W. Gennari4, B. Bruzzone8, I. Vicenti9, A. Callegaro10, A. Di Biagio11, M. Zazzi9, A. Borghetti2
    1Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, 2UOC Malattie Infettive, Fondazione Policlinico Universitario A.Gemelli IRCCS, Roma, 3Malattie Infettive, Ospedale San Salvatore, L'Aquila, 4Clinica delle Malattie Infettive e Tropicali, Università di Modena e Reggio Emilia, Modena, 5Microbiologia e Virologia, Università degli Studi di Bari, Bari, 6UOC Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, 7Clinica Malattie Infettive, Università degli Studi di Bari, Bari, 8UO Igiene, Ospedale Policlinico San Martino, Genova, 9Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, 10UO Microbiologia e Virologia, ASST Papa Giovanni XXIII, Bergamo, 11Clinica di Malattie Infettive, Ospedale Policlinico San Martino, Dipartimento di Scienze della Salute (DISSAL), Università di Genova, Genova

    11.34 - 11.44

    OC 36

    Clinical and virological outcomes of difficult to treat patients in a large cohort of PLWH starting modern ART regimens
    R. Gagliardini1, A. Tavelli2, S. Rusconi3,4, A. Costantini5, S. Cicalini1, F. Maggiolo6, V. Spagnuolo7, E. Quiros Roldan8, S. Lo Caputo9, A. d'Arminio Monforte10, A. Antinori1, A. Cozzi-Lepri11
    1INMI Lazzaro Spallanzani IRCCS, Rome, Italy, 2Icona Foundation, Milan, Italy, 3Unità Operativa Malattie Infettive, Ospedale Civile di Legnano, Legnano, Italy, 4Dipartimento di Scienze Biomediche e Cliniche “Luigi Sacco” Università degli Studi di Milano, Milan, Italy, 5Clinical Immunology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Marche Polytechnic University, Ancona, Italy, 6ASST Papa Giovanni XXIII, Bergamo, Italy, 7IRCCS San Raffaele Scientific Institute, Infectious Diseases Unit, Milan, Italy.
    8Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy, 9Infectious Diseases Unit, University of Foggia, Foggia, Italy, 10University of Milan, Department of Health Sciences, Milan, Italy, 11Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL

    11.46 - 11.56

    OC 37

    Durability of Mega ART in a large cohort of treatment experienced people living with HIV: Data from ARCA database
    L. Labate1,2, B. Rossetti3, C. Russo1,2, M. Bottanelli4,5, C. Cassol6,7, F. Bracchitta8, L. Graziani9, M. Tilli9, I. Rancan6,7, C. Malcontenti10, S. Mora11, R. Papaioannu4,5, A. Bezenchek12,13, A. Shallvari12,13, A. Di Biagio1,2
    1Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neuroscience, Genoa, Italy, 2Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, 3Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy, 4Vita-Salute San Raffaele University- Milan (Italy), 5Infectious Diseases Unit, San Raffaele Scientific Institute-Milan (Italy), 6Department of Medical Biotechnologies, University of Siena, Siena, Italy, 7Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, 8Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, L. Sacco University Hospital, Milan, Italy, 9Department of Experimental & Clinical Medicine, University of Florence, Florence, Italy, 10SOD Malattie Infettive e Tropicali AOU Careggi, Firenze, 11Department of Informatics, Bioengineering, Robotics and System Engineering, University of Genoa, Genoa, Italy, 12INFORMAPRO Srl, Rome, Italy, 13EURESIST Network GEIE, Rome, Italy

    12:15 - 13:15

    Oral Communications

    HIV and SARS-CoV-2: two intersecting epidemics

    Oral Communications

    HIV and SARS-CoV-2: two intersecting epidemics

    Chairs: M. Breveglieri, S. Lo Caputo

    12.15 - 12.25

    OC 38

    The Cascade of HIV Care (CoC) of Milan as compared to Italy: data derived from the COA Registry and the Icona cohort- Milan Fast Track City
    A. d’Arminio Monforte1,3,7, A. Navarra2, A. Tavelli3,7, B. Suligoi4, V. Regine4, L. Pugliese4, L. Timelli5, A. Caraglia5, M. Oldrini6, L. Cosmaro3,7, D. Calzavara7, M. Cernuschi3,7, G. Rizzardini8, A. Gori3,9, S. Antinori10, M. Puoti3,11, A. Castagna3,12, E. Girardi2,3
    1ASST Santi Paolo e Carlo, Unità Malattie Infettive e Tropicali, Milano, Italia, 2Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani"- IRCCS, Roma, Italia, 3Fondazione Icona, Milano, Italia, 4Istituto Superiore di Sanità, Roma, Italia, 5Ministero della Salute, Roma, 6Fondazione LILA Milano, Milano, Italia, 7Milano Check Point, Milano, Italia, 8ASST Fatebenefratelli-Sacco, Divisione 1 Malattie Infettive, Milano, Italia, 9IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Clinica di Malattie Infettive, Milano, Italia, 10ASST Fatebenefratelli-Sacco, Divisione 3 Malattie Infettive, Milano, Italia, 11ASST Grande Ospedale Metropolitano Niguarda, Unità Malattie Infettive, Milano, Italia, 12IRCCS Ospedale San Raffaele, Unità di Malattie Infettive, Milano, Italia

    12.27 - 12.37

    OC 39

    Effect of COVID-19 pandemic on the HIV cascade of care at a Provincial level
    F. Maggiolo1, R. Teocchi1, P. Meli2, D. Valenti3, F. Radici4, I. Mercurio5, A.P. Callegaro6
    1ASST Papa Giovanni XXIII, 2Comunità Emmaus & Caritas Bergamasca, 3Associazione FROM, 4Arcigay Bergamo Cives, 5CRI-Comitato di Bergamo, 6ASST Bergamo Est, Bergamo

    12.39 - 12.49

    OC 40

    SARS-CoV-2 infection and vaccination coverage among fragile populations in a Local Health Area of Northern Italy
    G. Maifredi1, I. Izzo2, C. Gasparotti1, C.V. Sileo1, S. Storti2, M. Degli Antoni2, G. Tiecco2, S. Amadasi2, E. Focà2, F. Castelli2, E. Quiros-Roldan2
    1ATS Brescia (Brescia Health Protection Agency), Brescia, Italy, 2Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali di Brescia, Brescia, Italy

    12.51 - 13.01

    OC 41

    New diagnosis of HIV among transgender women sex-workers across time: results from a multi-year street-based intervention (2017-2020)
    G. Lapadula1,2, E. Beretta1, P. Columpsi1, M. Comolatti1, N. Corti2, S. Limonta1, A. Rugova1, A. Ranzani1, A. Soria1, N. Squillace1, E. Lungu3, A. Monopoli3, V. Cristiano3, P. Bonfanti1,2
    1School of Medicine, University of Milano-Bicocca, Milan, Italy, 2San Gerardo Hospital, ASST Monza, Monza, Italy, 3ALA Milano Onlus, Milan, Italy

    13:15 - 14:15

    Oral Communications

    Diabetes, cardiovascular diseases and STIs. A wide range of comorbidities

    Oral Communications

    Diabetes, cardiovascular diseases and STIs. A wide range of comorbidities

    Chairs: T. Bini, G. Orofino

    13.15 - 13.25

    OC 42

    Incident diabetes in course of antiretroviral therapy
    L. Taramasso1, N. Squillace2, E. Ricci3, B. Menzaghi4, G. Orofino5, G.V. De Socio6, C. Molteni7, C.V. Martinelli8, G. Madeddu9, F. Vichi10, L. Valsecchi11, B.M. Celesia12, P. Maggi13, F. Conti14, G.F. Pellicanò15, A. Cascio16, E. Sarchi17, R. Gulminetti18, G. Parruti19, L. Calza20, K. Falasca21, A. Di Biagio1,22, P. Bonfanti2 on behalf of CISAI Study Group
    1Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, 2Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, 3Fondazione ASIA Onlus, Buccinasco (MI), Italy, 4Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, 5Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, 6Clinic of Infectious Diseases, Department of Medicine, Azienda Ospedaliera di Perugia, Santa Maria Hospital, Perugia, 7Infectious Disease Unit, Ospedale A. Manzoni, Lecco, Italy, 8SOD Malattie Infettive e Tropicali AOU Careggi, Florence, Italy, 9Unit of Infectious and Tropical Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, 10Infectious Diseases Department, SOC 1, USLCENTROFIRENZE, Santa Maria Annunziata Hospital, Florence, Italy, 11Infectious Disease Unit (I Divisione), ASST Fatebenefratelli Sacco, Milan, Italy, 12Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi, Catania, Italy, 13Department of Infectious Disease, University of Campania Luigi Vanvitelli, Naples , Italy, 14Infectious Diseases Unit, Department of Biomedical and Clinical Sciences 'Luigi Sacco', Università degli Studi di Milano, Milan, Italy, 15Department of Human Pathology of the Adult and the Developmental Age 'G. Barresi', Unit of Infectious Diseases, University of Messina, 16Infectious and Tropical Diseases Unit- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) - University of Palermo, Palermo, Italy, 17Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, 18Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia Italy, 19Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy, 20Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna, Bologna, Italy, 21Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy, 22Department of Health Sciences, Infectious Disease Clinic, University of Genoa, Genoa, Italy

    13.27 - 13.37

    OC 43

    Treatment with integrase inhibitors among antiretroviral naïve patients is not associated with increased risk of diabetes mellitus
    G. Lapadula1,2, A. Soria2, G. Micheli3, M.V. Cossu4, A. De Vito5, G. Guaraldi6, A. Castagna7, A. Di Biagio8, S. Cicalini9, P. Bonfanti1,2, A. Cozzi-Lepri, A. d’Arminio Monforte for ICONA cohort Study
    1School of Medicine, University of Milano Bicocca, Milano, Italy, 2Clinic of Infectious Diseases, San Gerardo Hospital, ASST Monza, Monza, Italy, 3Università Cattolica del Sacro Cuore, Infectious Diseases Unit, Roma, Italy, 41st Division of Infectious Diseases, 'Luigi Sacco' University Hospital, Milan, Italy, 5Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, 6Unit of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, 7University “Vita Salute”, San Raffaele Hospital, Milano, Italy, 8Unit of Infectious Diseases, University of Genoa, Genoa, Italy, 9National Institute for Infectious Diseases “L. Spallanzani”, Rome, Italy

    13.39 - 13.49

    OC 44

    Non-Alcoholic to Metabolic Associated Fatty Liver Disease: Cardiovascular Implications of a Change in Terminology in Patients Living With HIV
    J. Milic1, S. Renzetti2, F. Motta2, L. Gozzi3, A. Cervo3, G. Burastero3, V. Iadisernia3, G. Franceschi3, M. Faltoni3, S. Volpi3, A. Mazzocchi3, C. Mussini2,3, G. Sebastiani4, S.Calza2, P. Raggi5, G. Guaraldi1,3
    1University of Modena and Reggio Emilia, Modena, Italy, 2University of Brescia, Brescia, Italy, 3Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, 4McGill University Health Centre, Montreal, Canada, 5University of Alberta, Edmonton, Canada

    13.51 - 14.01

    OC 45

    Syphilis infection and re-infection in PLWH and PrEP users: new insights into epidemic dynamics
    R. Rossotti1,5, D. Tesoro2,5, L. Gazzola2, A. Tavelli3, A. De Bona2,5, V. Licari4, F. D’Amico1, C. Baiguera1, D. Calzavara5, N.B. Bana1, V. Ferrara5, R. Repossi5, M. Cernuschi5,6, M. Puoti1,4, A. d’Arminio Monforte2,7
    1Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, 2Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, 3ICONA Foundation, Milan, 4University of Milano-Bicocca, Milan, 5Milano Checkpoint, Milan, 6Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, 7University of Milano, Milan

    14:15 - 15:15

    Oral Communications

    Dual therapy in naive and switched PLWH

    Oral Communications

    Dual therapy in naive and switched PLWH

    Chairs: S. Carbonara, B.M. Celesia

    14.15 - 14.25

    OC 50

    Adherence rates and forgiveness to uncomplete adherence to 3TC/DTG
    F. Maggiolo1, D. Valenti1,2, R. Teocchi3, L. Comi1, E. Di Filippo1
    1UOC Infectious Diseases, 2FROM foundation, 3Informatics department, ASST Papa Giovanni XXII, Bergamo Italy

    14.27 - 14.37

    OC 51

    12-Month immunological changes in patients randomized to switch either to BIC/TAF/FTC or DTG/3TC (DEBATE study)
    A. Cossarizza1, M. Mattioli1, A. Paolini1, A. Neroni1, S. De Biasi1, D. Lo Tartaro1, R. Borella1, L. Fidanza1, L. Gibellini1, B. Beghetto2, E. Roncaglia2, G. Nardini2, M. Menozzi2, G. Cuomo2, M. Di Gaetano2, G. Orlando2, V. Borghi2, C. Mussini1,2
    1University of Modena and Reggio Emilia, School of Medicine, 2AOU Policlinico di Modena

    14.39 - 14.49

    OC 52

    Switch to doravirine with dolutegravir dual regimen compared to other dual dolutegravir-based regimes in clinical practice: a 96-week analysis
    R. Rossotti1, F. D’Amico1, A. Nava2, A. Raimondi1, D. Fanti2, N.B. Bana1, E. Inglese2, L.G. Chianura1, M.C. Moioli1, C. Vismara2, M. Puoti1
    1Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, 2Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

    14.51 - 15.01

    OC 53

    Clinical and virological characteristics of people living with HIV who fail to maintain virological suppression after switching to dolutegravir-based two drug regimens. Results from the prospective observational ARCA cohort
    L. Taramasso1, R. Gagliardini2, C. Sepulcri3, A. Shallvari4, W. Gennari5, F. Lombardi6, S. Di Giambenedetto6,7, F. Maggiolo8, I. Vicenti9, V. Borghi10, V. Micheli11, D. Francisci12, E. Pontali13, S. Rusconi14, R. Maserati15, P. Laghetti16, B. Bruzzone17, S.T. Kiros18, A. Di Biagio1,3, ARCA collaborative group
    1Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, 2HIV/AIDS Unit, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, 3Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, 4InformaPRO S.r.l., Rome, Italy, 5Clinical Microbiology, Ospedale Civile di Baggiovara-Policilinico di Modena, Modena, Italy, 6Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, 7Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy, 8Infectious Disease Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, 9Department of Medical Biotechnologies, University of Siena, Siena, Italy, 10Clinica Malattie infettive, Azienda Ospedaliero Universitaria di Modena, 11Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco L. Sacco Hospital, Milan, Italy, 12Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, 13Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, 14Infectious Disease Unit, ASST Ovest Milanese, Legnano (MI), Italy; Department of Biomedical and Clinical Sciences DIBIC L. Sacco, University of Milan, Milan, Italy, 15Dipartimento Scienze mediche e malattie infettive, Fondazione IRCCS Policlinico "San Matteo", Pavia, Italy, 16Clinic of Infectious Diseases, University Hospital Policlinico, University of Bari, Bari, Italy, 17Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, 18Infectious Disease Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy

    15:20 - 16:20

    Oral Communications

    Complexities of SARS-CoV-2 infection

    Oral Communications

    Complexities of SARS-CoV-2 infection

    Chairs: P. Bonfanti, A. Saracino

    15.20 - 15.30

    OC 58

    Prevalence and epidemiological, clinical and microbiological characteristics of bacterial infections in a large cohort of patients admitted for COVID-19 in Campania: a multicentre cohort study
    L. Onorato1, M. Palamone1, P. Maggi2, F.G. Numis3, I. Gentile4, V. Sangiovanni5, V. Esposito6, R. Punzi7, G. Calabria8, C. Rescigno9, A. Salomone Megna10, A. Masullo11, E. Manzillo12, G. Russo13, R. Parrella14, G. Dell’Aquila15, M. Gambardella16, A. Ponticiello17, M. Pisaturo1, N. Coppola1, on behalf of CoviCam group
    1Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, 2Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, 3Emergency Department, PO Santa Maria delle Grazie, Pozzuoli, Italy, 4Infectious Diseases Unit; University Federico II, Naples, Italy, 5Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, 6IV Infectious Diseases Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 7Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, 8IX Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 9First Infectious Diseases Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 10Infectious Diseeases Unit, A.O. San Pio, PO Rummo, Benevento, Italy, 11Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D’Aragona Salerno, Italy, 12VIII Infectious Diseases Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 13Infectious Diseases Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, 14Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, 15Infectious Diseases Unit, AO Avellino, Italy, 16Infectious Diseeases Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, 17Pneumology Unit, AORN Caserta, Italy

    15.32 - 15.42

    OC 59

    Evaluation of SARS-CoV-2 reinfection risk during the different COVID-19 variants’ spread
    S. Leone, A. Agresta, G. De Carli, C. De Santis, M.C. Fusco, V. Vantaggio, M. D’Amato, G. Pitti, E. Girardi, F. Vairo
    National Institute for Infectious Diseases "L.Spallanzani" IRCCS

    15.44 - 15.54

    OC 60

    Pre-existent socio-economic status and its role in PASC syndrome: results from the VASCO study (VAriabili Socioeconomiche e COVID-19), on the “Surviving-COVID” Cohort, from Bergamo (Italy)
    S.V. Benatti1, S. Venturelli1, R. Buzzetti2, F. Binda1, L. Soavi1, L. Belotti1, A.M. Biffi1, M.S. Spada1, M. Casati1, M. Rizzi1
    1ASST Papa Giovanni XXIII, Bergamo, 2Clinical Epidemiologist, freelance, Bergamo

    15.56 - 16.06

    OC 61

    Depressive Symptoms Among Covid-19 Survived Patients One Year After Hospital Discharge: Prevalence and Factors Associated
    P. Vassalini1, R. Serra2, L. Tarsitani2, G. Ceccarelli1, A.E. Koukopoulos2, C. Borrazzo1, C. Di Nicolantonio2, C. Tosato1, F. Cherubini1, F. Alessandri3, C.M. Mastroianni1, G. d'Ettorre1
    1Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, 2Department of Human Neurosciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, 3Intensive Care Unit, Department of General and Specialist Surgery "Paride Stefanini", Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

  • Alabastro A
    10:05 - 10:35

    Special Session

    Update on current monkeypox multi-country outbreak in Europe

    Special Session

    Update on current monkeypox multi-country outbreak in Europe

    10.05 - 10.35 Update on current monkeypox multi-country outbreak in Europe
    A. Antinori
    10:40 - 12:10

    Symposium

    The Italian Fast-Track Cities Network

    Con la sponsorizzazione non condizionante di:

    Symposium

    The Italian Fast-Track Cities Network

    The Fast-Track Cities initiative (FTCI) is a global partnership between cities and municipalities around the world and four core partners: the International Association of Providers of AIDS-Care (IAPAC), the Joint United Nations Programme on HIV/AIDS (UNAIDS), the United Nations Human Settlements Programme (UN-Habitat) and the City of Paris. Launched on World AIDS Day 2012, the Network has grown to include more than 330 Cities and municipalities that are committed to attain the UNAIDS 95-95-95 targets by 2030. The aim of the Symposium is to focus on the Italian Fast-Track Cities state of the art as now 12 Italian townships are potentially involved. Even if FTCI is mostly a locally organized micro-program, sharing good practice and ideas may improve the effect of single realities and may lead to common actions able to engrave deeply on the HIV epidemics.

    Chairs: A. d'Arminio Monforte, S. Patrucco

    10.40 - 10.55 The Global Network example of good practice
    B. Audoin
    10.55 - 11.10 FTC experience from the municipality point of view
    M. Messina
    11.10 - 11.40 Italian Fast Track Cities calls Ukraine
    B. Audoin
    11.40 - 11.50 Common projects already in place and sharing of Cobatest data
    M.L. Cosmaro, P. Meli
    11.55 - 12.10 Future common projects and actions. FTCI delegates
    12:15 - 13:15

    Expert Meeting

    Redefining management and treatment goals in antiretroviral triple therapy: results of a Delphi Consensus

    Con la sponsorizzazione non condizionante di:

    Expert Meeting

    Redefining management and treatment goals in antiretroviral triple therapy: results of a Delphi Consensus

    Modern antiretroviral therapy (ART) offers several treatment options characterized by high efficacy and tolerability, and new strategies with less drug regimens and new drugs are now available for the treatment of HIV infection.  As definitive data on the long-term success of these new strategies are lacking, a panel of Experts in the care of HIV infection expressed their consensus on which could be the best strategy to achieve and maintain long-term virological and clinical success for PLWH in course of antiretroviral therapy, using Delphi methodology. The main consensus statements developed will be presented and discussed during this Expert Meeting.

    Chair: A. Di Biagio

    12.15 - 12.30 Optimizing the ARV treatment focusing on long-term effectiveness and a person-centred approach: consensus guidance using Delphi process
    A. Di Biagio
    12.30 - 13.10 Round table - Delphi Consensus results:
    Discussants: M. Borderi, S. Di Giambenedetto, G. Guaraldi, P. Maggi
    - Clinical efficacy: ART-monitoring strategy
    - Immunology and Pharmacology
    - Long-term safety
    - Quality of life assessment
    13.10 - 13.15 Final considerations
    A. Di Biagio
    13:15 - 14:15

    Oral Communications

    Immunological efficacy of SARS-CoV-2 vaccine II

    Oral Communications

    Immunological efficacy of SARS-CoV-2 vaccine II

    Chairs: A. Castagna, S. Parisi

    13.15 - 13.25

    OC 46

    Monitoring saliva and plasma neutralizing activity induced by the administration of a third BNT162B2 vaccine dose
    M. Garziano1,2, O. Utyro3, S. Strizzi1, C. Vanetti1, I. Saulle1, C. Conforti1, F. Cicilano1, M. Clerici1,2, M. Biasin1
    1Department of Biomedical and Clinical Sciences “L. Sacco”, University of Milan, Milan, Italy, 2Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, 3Department of Medical surgical and experimental sciences University of Sassari

    13.27 - 13.37

    OC 47

    Lower neutralization level against SARS-CoV-2 Omicron (BA.1) variant than against reference strain after a third dose of mRNA vaccine in PLWH
    A. Vergori1, A. Cozzi Lepri2, G. Matusali3, F. Colavita3, S. Cicalini1, P. Gallì4, A.R. Garbuglia3, M. Fusto1, V. Puro5, E. Girardi6, F. Vaia7, A. Antinori1,4
    1HIV/AIDS Unit, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, 2Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, 3Virology Unit, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, 4Health Direction,National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, 5Risk Management Unit, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, 6Scientific Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, 7General Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy

    13.39 - 13.49

    OC 48

    T-cell responses to SARS-CoV-2 Spike protein after 3 doses of BNT162b2 mRNA vaccination in healthy individuals, cross-recognize Alpha, Delta and Omicron variants of concern
    M. Iannetta, A. Di Lorenzo, A. Imeneo, A. Lodi, L. Ferrari, I. Fato, B. Massa, P.G. Pace, I. Spalliera, P. Vitale, B. Rossi, T. Mulas, L. Campogiani, L. Coppola, M. Compagno, V. Malagnino, E. Teti, M. Andreoni, L. Sarmati
    Department of System Medicine Tor Vergata University, Rome

    13.51 - 14.01

    OC 49

    CD4 cell count is critical for specific T cell-mediated response in PLWH before and after third dose of COVID-19 vaccine
    E. Tortellini1, M.A. Zingaropoli1, G. Mancarella1,2, R. Marocco2, A. Carraro1,2, M. Jhamour2, V. Perri1, M. Guardiani1, F. Dominelli1, A. Napoli3, A. Gaeta1, F. Mengoni1, P. Zuccalà2, V. Belvisi2, B. Kertusha1,2, A. Parente1,2, C. Del Borgo2, V. Vullo1, M.R. Ciardi1, C.M. Mastroianni1, M. Lichtner1,2 and LATINA COVID-19 Group
    1Department of Public Health and Infectious Diseases, Sapienza University of Rome, 2Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, 3Department of Molecular Medicine, Sapienza University of Rome

    14:15 - 15:15

    Oral Communications

    Mental health and predictors of AIDS and non-AIDS defining co-pathologies

    Oral Communications

    Mental health and predictors of AIDS and non-AIDS defining co-pathologies

    Chairs: M. Farinella, P. Maggi

    14.15 - 14.25

    OC 54

    Relation between genetic polymorphisms or variants and cognitive impairment in a group of HIV-infected people
    M. Degli Antoni1, I. Zanella2, E. Zacchi2, C. Fornari1, B. Fumarola1, E. Focà1, F. Castelli1, E. Quiros-Roldan1
    1University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, 2Department of Molecular and Translational Medicine, University of Brescia and Clinical Chemistry Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia

    14.27 - 14.37

    OC 55

    A higher CPE score in PLWH with HAND switched to a less neurotoxic regimen is associated to improved memory test (MARAND-X study)
    A. Lazzaro1, D. Vai2, A. Barco3, G. Stroffolini4,5, V. Pirriatore6, G. Guastamacchia2, M. Nigra7, V. Ghisetti8, M.C. Tettoni4, M. Trunfio4, A. Trentalange4, S. Bonora4, G. Di Perri4, A. Calcagno4
    1Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Roma Italy, 2Unit of Neurology, Maria Vittoria Hospital, ASL Città di Torino, Turin, Italy, 3Infectious Diseases Unit, Ospedale Maggiore della Carità, Novara, Italy, 4Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy 5Department of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy, 6SC Tropical and Infectious Disease ASL Città di Torino, 7Biochemistry and Immunology Laboratory, Maria Vittoria Hospital, ASL “Città di Torino”, Turin, Italy, 8Microbiology and Molcular Biology Laboratory, Amedeo di Savoia Hospitasl, ASL Città di Torino, Turin, Italy

    14.39 - 14.49

    OC 56

    Pre-ART platelet-to-lymphocyte ratio and the risk of serious non-AIDS-events, AIDS-events and mortality in PLWH starting first-line ART
    P. Saltini1,2,3, A. Cozzi-Lepri4, G. Bozzi1, G. Marchetti5, L. Taramasso6, S. Mazzanti7, V. Rizzo8, A. Antinori9, C. Mussini10, A. Gori1,2,3, A. D'Arminio Monforte5, A. Bandera1,2,3
    1Infectious Diseases Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy, 2Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy, 3Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milano, Italy, 4Institute for Global Health UCL, University College London, London, UK, 5Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Italy, 6Infectious Diseases Unit, San Martino Policlinico Hospital, IRCCS for Oncology and Neuroscience, Genoa, Italy, 7Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Ancona, Torrette, Italy, 8Immunodeficiency and Gender Related Infectious Diseases Unit, Department of Infectious Disease and Infectious Emergencies, AORN dei Colli, P.O. Cotugno, Naples, Italy, 9Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS, Rome, Italy, 10Clinic of Infectious Diseases, University of Modena, Modena, Italy

    14.51 - 15.01

    OC 57

    Association between HIV-1 DNA and clinical outcome in people living with HIV
    M. Bottanelli1, D. Ceccarelli2, R. Lolatto2, L. Galli2, M. Guffanti2, R. Dell’Acqua2, G. Ponta1, G. Mori1, A. Castagna1,2, C. Muccini1,2
    1School of Medicine and Surgery, Vita Salute San Raffaele University, Milan, Italy, 2Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy

    15:20 - 16:20

    Oral Communications

    Insights on epidemiological and clinical management of hepatitis viruses

    Oral Communications

    Insights on epidemiological and clinical management of hepatitis viruses

    Chairs: R. Bruno, G. Gaiera

    15.20 - 15.30

    OC 62

    Serum HBsAg and highly-sensitive HBV-DNA quantification can predict HBsAg loss after nucleo(s)tide analogue systematic discontinuation in non-cirrhotic patients with chronic hepatitis B
    L. Piermatteo1, R. Salpini1, S. D’Anna1, A.F. Guerra2, G. Tomassoli2, G. Abbati2, A. Pietrangelo2, P. Ventura2, V. Svicher1,3
    1Department of Experimental Medicine, University of Rome “Tor Vergata, 2Internal Medicine and Centre for Hemochromatosis, University Hospital of Modena, University of Modena and Reggio Emilia, Italy, 3Department of Biology, University of Rome “Tor Vergata"

    15.32 - 15.42

    OC 63

    Hepatitis D virus infection in a large cohort of immigrants in Southern Italy a multicenter, prospective study
    E. Cordua1, M. Pisaturo1,2,7, L. Alessio2,7, M. Starace1, A. Di Fraia1, C. Monari2,7, L. Onorato2,7. C. Sagnelli1,2,5, S. De Pascalis2, L. Gualdieri6, C. Minichini1, G. Di Caprio3,4, L. Occhiello1,6, G. Scotto8, M. Macera2,7, N. Coppola1,2
    1Department of Mental and Physical Health and Preventive Medicine, Infectious Diseases section, University of Campania Luigi Vanvitelli, Naples, 2L. Vanvitelli University Hospital, Naples, 3UOC of Infectious Diseases, AORN Sant'Anna and San Sebastiano, Caserta, 4"Abraham's Tent" Reception Center, Caserta, 5Missionary Sisters of Charity Center, Naples, 6Center for the Protection of Immigrant Health, Naples, 7Social center “ex-canapificio”, Caserta, 8UOC of Infectious Diseases, Foggia

    15.44 - 15.54

    OC 64

    Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays
    R. Salpini1, S. D’Anna1, M. Alkhatib1, L. Piermatteo1, A. Tavelli2, E. Quiros3, A. Cingolani4, C. Papalini5, S. Carrara6, V. Malagnino7, M. Puoti8, L. Sarmati7, A. d’Arminio Monforte9, F. Ceccherini Silberstein1, V. Svicher1 for the Icona Foundation Study Group
    1Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, 2ICONA Foundation, 3University Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, 4Unit of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli-Università Cattolica Del Sacro Cuore, Rome, Italy, 5Infectious Diseases Clinic, Department of Medicine, University of Perugia, Perugia, Italy, 6Microbiology Biobank and Cell Factory Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani', Rome, Italy, 7Unit of Infectious Diseases, University Hospital Tor Vergata, Rome, Italy, 8Dipartimento Medicina e Chirurgia, Università degli studi di Milano Bicocca, Milan, Italy, 9Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Italy

    15.56 - 16.06

    OC 65

    Hepatitis C testing, linkage to care and treatment during COVID-19 era in a north-east Italian hospital: what can we still need to do to improve elimination?
    E. Garlatti Costa1, M. Da Re2, D. Villalta2, M. Tonizzo1
    1SC Medicina Interna, Azienda sanitaria Friuli Occidentale, Pordenone, 2SSD Immunologia Allergologia, Azienda sanitaria Friuli Occidentale, Pordenone

  • Alabastro B
    10:05 - 10:55

    Oral Poster

    COVID-19: considerations of special populations

    Oral Poster

    COVID-19: considerations of special populations

    Chairs: V. Giacomet, F. Vichi

    10.05 - 10.10

    OP 90

    Impact of patients’ characteristics and comorbidities on in-hospital mortality during the first three waves of COVID-19 pandemic. Results from the Brescia HUB project
    E. Focà1, S. Calza2, S. Piva3, I. Ettori1, F. Rasulo3, C. Agabiti Rosei4, C. Aggiusti5, B. Cerudelli6, F. Quadri7, M. Metra8, M. Castellano9, M. Nardin10, C. Ricci11, R. Badolato12, F. Odicino13, R. Orabona13, F. Scolari14, L.R. Tomasoni1, F. Marinoni15, A.M. Roccaro16, C. Rossi17, F. Castelli1
    1Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, 2Unit of Biostatistics and Bioinformatics, University of Brescia, Brescia, Italy, 3Unit of Anesthesiology and Critical Care Medicine, ASST Spedali Civili, Italy, 4Second Unit of Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, 5Unit of Emergency Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, 6Unit of Neurology, University of Brescia and ASST Spedali Civili, Brescia, Italy,
    7Unit of Pneumology, ASST Spedali Civili, Brescia, Italy, 8Unit of Cardiology, University of Brescia and ASST Spedali Civili, Brescia, Italy, 9Unit of Internal Medicine and Endocrinology, University of Brescia and ASST Spedali Civili, Brescia, Italy, 10Third Unit of Internal Medicine, ASST Spedali Civili, Italy, 11Unit of Gastroenterology University of Brescia and ASST Spedali Civili, Brescia, Italy, 12Unit of Pediatrics, Children's Hospital University of Brescia and ASST Spedali Civili, Brescia, Italy, 13Unit of Gynecology and Obstetrics, University of Brescia and ASST Spedali Civili, Brescia, Italy, 14Unit of Nephrology and Dialysis, University of Brescia and ASST Spedali Civili, Brescia, Italy, 15Unit of Planning and Management Control Service, ASST Spedali Civili, Brescia, Italy, 16Unit of Clinical Research and Phase I Studies, ASST Spedali Civili, Brescia, Italy, 17Chief Medical Officer Institution, ASST Spedali Civili, Brescia, Italy

    10.12 - 10.17

    OP 91

    SARS-CoV-2 infection and COVID-19 disease in PLWH
    F. Maggiolo1, D. Valenti2, M. Arosio1, D. Guarneri1, M. Rizzi1, A.P. Callegaro3
    1ASST Papa Giovanni XXIII, 2Associazione FROM, 3ASST Bergamo Est, Bergamo, Italy

    10.19 - 10.24

    OP 92

    Evolution of SARS-CoV-2 Variants of Concerns (VOC) over a period of Delta and Omicron variants co-circulation: impact on clinical outcomes among patients (pts) hospitalized for COVID-19 in an Italian reference hospital in the first trimester of 2022
    A. Mondi, I. Mastrorosa, C. Cimaglia, P. Piselli, G. Matusali, F. Carletti, L. Fabeni, E. Specchiarello, G. Giannico, E. Milozzi, E. Biliotti, S. Di Bari, P. Chinello, A. Beccacece, P.Vittozzi, S. Mosti, N. Tetaj, L. Marchioni, S. Ianniello, E. Nicastri, A.R. Garbuglia, F. Vaia, E. Girardi, A. Antinori
    National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy

    10.26 - 10.31

    OP 93

    New issues in SARS-CoV-2 vaccination response among Health-care workers: slow responders and peri-vaccination infections
    S. Arsuffi1, E. Focà1, E. Sansone2, T. Diaferia2, E. Sala2, F. Castelli1, G. De Palma2, E. Quiros-Roldan1
    1Unit of Infectious and tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, 2University Department of Occupational Health and Industrial Hygiene, DSMC, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy

    10.33 - 10.38

    OP 94

    Antibody response in women vaccinated against SARS-CoV-2 during pregnancy and respective babies at birth
    A. Pani1, A. Proto2, S. Agliardi1, O.M. Gagliardi1, S. Renica1, F. di Ruscio1, C. Vismara3, D. Campisi3, F. Scaglione1, S. Martinelli2
    1Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy, 2Neonatology and Neonatal Intensive Care Unit, Niguarda Hospital, Milan, Italy, 3Microbiology Unit, Niguarda Hospital, Milan, Italy

    10.40 - 10.45

    OP 95

    Predictors of mortality in a cohort of oldest old subjects hospitalized for COVID-19
    M. Mazzitelli, M. Biasin, M. Trevenzoli, S. Lo Menzo, S. Marinello, A. Ferrari, L. Sasset, M. Brundu, S. Gardin, M. Cola, A.M. Cattelan
    Infectious and Tropical Diseases Unit, Azienda Ospedale Università, Padova

    11:10 - 12:00

    Oral Poster

    HIV and SARS-CoV-2: from in vivo to in vitro

    Oral Poster

    HIV and SARS-CoV-2: from in vivo to in vitro

    Chairs: D. Cattaneo, F. Saladini

    11.10 - 11.15

    OP 102

    Trends of HIV-1 drug resistance and APOBEC editing in PBMC compartment over the last decade
    D. Armenia1, R. Gagliardini2, C. Alteri3,4, V. Svicher5, V. Cento6, V. Borghi7, A. Vergori2, S. Cicalini2, F. Forbici2, L. Fabeni2, A. Bertoli5,8, W. Gennari7, V. Malagnino8, M. Andreoni8, C. Mussini7, A. Antinori2, C.F. Perno4, M.M. Santoro5, F. Ceccherini-Silberstein5
    1UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy, 2National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy 3University of Milan, Milan, Italy, 4Bambino Gesù Children’s Hospital, Rome, Italy, 5University of Rome “Tor Vergata”, Rome, Italy, 6Humanitas Research Hospital, IRCCS, Milan, Italy, 7University of Modena and Reggio Emilia, Modena, Italy, 8Polyclinic of Rome “Tor Vergata”, Rome Italy

    11.17 - 11.22

    OP 103

    Trend over time of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) and their drivers: cohort study from ARCA
    I. Rancan1,2, C. Cassol1,2, L. Graziani3, M. Tilli3, C. Malcontenti4, C. Russo5,6, M. Bottanelli7,8, F. Bracchitta9, R. Papaioannu7,8, L. Labate5,6, S. Mora12, A. Bezenchek10,11, A. Shallvari10,11, A. Di Biagio5,6, B, Rossetti13
    1Department of Medical Biotechnologies, University of Siena, Siena, Italy, 2Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, 3Department of Experimental & Clinical Medicine, University of Florence, Florence, Italy, 4SOD Malattie Infettive e Tropicali AOU Careggi, Florence, Italy, 5Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neuroscience, Genoa, Italy, 6Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, 7Vita-Salute San Raffaele University, Milan, Italy, 8Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy, 9Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, L. Sacco University Hospital, Milan, Italy, 10INFORMAPRO Srl, Rome, Italy, 11EURESIST Network GEIE, Rome, Italy, 12Department of Informatics, Bioengineering, Robotics and System Engineering, University of Genoa, Genoa, Italy, 13Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy

    11.24 - 11.29

    OP 104

    Sotrovimab-emergent resistance in immunocompromised COVID-19 patients
    F. Novazzi1,2, D. Focosi3, F. Drago Ferrante1, S. Boutahar1, A. Genoni1, F. Dentali2, D. Dalla Gasperina2, A. Baj1,2, F. Maggi1,2
    1Laboratory of Microbiology, ASST SetteLaghi, Varese, Italy, 2Department of Medicine and Surgery, University of Insubria, Varese, Italy, 3North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy

    11.31 - 11.36

    OP 105

    Tenofovir plasma and intracellular pharmacokinetics in INSTI-based regimens
    M. Ferrara1, G. Accardo1, S. Fantino1, G. Trevisan1, F. Alladio1, E. Drappero1, M. Tettoni1, E. De Vivo2, A. Ianniello2, J. Mula2, A. De Nicolò2, A. D’Avolio2, G. Di Perri1, A. Calcagno1, S. Bonora1
    1Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, 2Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Torino, Torino

    11.38 - 11.43

    OP 106

    Potent antiviral activity of new generation HIV-1 maturation inhibitors on human primary cells
    L. Duca1, P. Saccomandi1, L. Piermatteo1, R. Salpini1, C. Stacchiotti1, S. Aquaro2, C.F. Perno3, V. Svicher1, F. Ceccherini-Silberstein1
    1Università degli Studi di Roma Tor Vergata, Dipartimento di Medicina Sperimentale, Roma, Italia, 2Università della Calabria, Dipartimento di Farmacia e Scienze della Salute e della Nutrizione, Arcavacata di Rende (CS), Italia, 3Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Roma, Italia

    11.45 - 11.50

    OP 107

    Evaluation of the in vitro combinatorial activity of Ibalizumab and HIV-1 antivirals
    F. Giammarino, N. Bartolini, L. Fiaschi, F. Dragoni, I. Vicenti, M. Zazzi, F. Saladini
    Department of Medical Biotechnologies, University of Siena, Italy

    12:15 - 13:05

    Oral Poster

    Acute COVID-19 and post COVID-19 syndrome

    Oral Poster

    Acute COVID-19 and post COVID-19 syndrome

    Chairs: E. Focà, M. Lichtner

    12.15 - 12.20

    OP 108

    Long-COVID syndrome data from 126,752 patients: a systematic review and meta-analysis
    F. Di Gennaro1, A. Belati1, O. Tulone2, L. Diella1, D.F. Bavaro1, R. Bonica2, V. Genna2, L. Smith3, M. Trott3, M. Barbagallo2, L.J. Dominguez1, N. Veronese2, A. Saracino1
    1Department of Biomedical Sciences and Human Oncology, Section of Infectious Diseases, University of Bari, Bari, Italy, 2Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy, 3Faculty of Sport Sciences, University of Murcia, Murcia, Spain

    12.22 - 12.27

    OP 109

    Post-Acute Sequelae of COVID-19 (PASC): An Italian Experience
    P. Pasculli1, M.A. Zingaropoli1, F. Ciccone1, F. Paribeni1, R. Merz1, F. Dominelli1, G. Siccardi1, S. Pellegrini1, G. Galardo2, C.M. Mastroianni1, M.R. Ciardi1
    1Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, 2Medical Emergency Unit, Sapienza, University of Rome, Policlinico Umberto I, Rome, Italy

    12.29 - 12.34

    OP 110

    A multidisciplinary model to screen and treat the post-COVID-19 Syndrome
    N. Squillace1, V. Cogliandro1, E. Rossi2, G. Bellelli3,9, G. Foti4,9, M. Pozzi4, F. Luppi5,9, M. Lettino6, M.G. Strepparava7,9, C. Ferrarese8,9, E. Pollastri1, A. Rugova1, E. Ricci10, P. Bonfanti1,9 for the STORM Long-COVID Team
    1Infectious Disease Unit, San Gerardo hospital, ASST-Monza, Italy, 2Bicocca Center of Bioinformatics, Biostatistics and Bioimaging, University of Milano-Bicocca, Monza, Italy, 3Acute Geriatric Unit, San Gerardo hospital, ASST-Monza, Italy, 4Anesthesia and Intensive Care Unit, San Gerardo hospital, ASST-Monza, Italy, 5Respiratory Disease Unit, San Gerardo hospital, ASST-Monza, Italy, 6Cardiology Division, San Gerardo Hospital, ASST-Monza, Monza, Italy, 7Department of Mental Health, Clinical Psychology Unit, San Gerardo Hospital, ASST-Monza, Monza, Italy, 8Neurology Unit, San Gerardo hospital, ASST-Monza, Italy, 9School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy, 10Fondazione ASIA

    12.36 - 12.41

    OP 111

    Long term complications of COVID-19 in patients hospitalized in Clinica Malattie Infettive, Ospedali Riuniti, Ancona
    B. Candelaresi, S. Mazzanti, L. Brescini, V. Barocci, M. Di Pietrantonio, P. Mantini, S. Olivieri, F. Pallotta, F. Ginevri, G. Cesaretti
    Clinica Malattie Infettive, Ospedali Riuniti, Ancona

    12.43 - 12.48

    OP 112

    Outcome of patients with chronic liver disease hospitalized for SARS-CoV-2: a single centre matched cohort
    M. Ranzenigo1, C. Bertoni1, D. Ceccarelli2, L. Galli2, E. Messina2, H. Hasson2, A. Siribelli2, R. Lolatto2, A. Castagna1,2, C. Uberti-Foppa1,2, G. Morsica2
    1Vita-Salute University, Milan, Italy, 2Dept. of Infectious Diseases, San Raffaele Hospital, Milan, Italy

    12.50 - 12.55

    OP 113

    Characterization of three waves of covid 19 occurring in southern Italy: results of a multicentre cohort study
    V. Pattapola1, M. Pisaturo1, P. Maggi2, A. Russo1, R. Astorri1, F.G. Numis3, I. Gentile4, V. Sangiovanni5, V. Esposito6, R. Punzi7, G. Calabria8, C. Rescigno9, A. Salomone Megna10, A. Masullo11, E. Manzillo12, G. Russo13, R. Parrella14, G. Dell’Aquila15, M. Gambardella16, A. Ponticiello17, N. Coppola1 on behalf of CoviCam group
    1Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania ''L.Vanvitelli'', Napoli, Italy, 2Infectious Diseases Unit, A.O. S Anna e S. Sebastiano Caserta, Italy, 3Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, 4Infectious disease unit; University Federico II, Naples, Italy, 5Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, 6IV Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 7Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, 8IX Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 9First Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 10Infectious Diseease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, 11Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D’Aragona Salerno, Italy, 12VIII Infectious Disease Unit, AORN dei Coli, PO Cotugno, Naples, Italy, 13Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, 14Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, 15Infectious Diseases Unit, AO Avellino, Italy, 16Infectious Diseease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, 17Pneumology Unit, AORN Caserta, Italy

    13:15 - 14:05

    Oral Poster

    Open questions about ART efficacy

    Oral Poster

    Open questions about ART efficacy

    Chairs: M. Borderi, R. Gulminetti

    13.15 - 13.20

    OP 120

    Blood telomere length gain in virologically suppressed patients switching to dolutegravir plus lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study
    F. Lombardi1, A. Sanfilippo2, M. Fabbiani3, A. Borghetti1, A. Ciccullo4, S. Di Giambenedetto1,2
    1Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Roma, Italia, 2Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica, Roma Italia, 3UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, Italia, 4Unità di Malattie infettive, Ospedale San Salvatore, L'Aquila, Italia

    13.22 - 13.27

    OP 121

    Real-life use of Doravirine in treatment-experienced people living with HIV: an Italian multicentre study
    M. Mazzitelli1, M. Degli Antoni2, F. Castelli2, D. Ripamonti3, G. Zuglian3, G. Lapadula4, M. Fabbiani5, A. Ferraresi6, C. Putaggio1, A.M. Cattelan1, E. Quiros-Roldan2
    1Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, 2Department of Infectious and Tropical Diseases, ASST Spedali Civili General Hospital and University of Brescia, Brescia, 3Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, 4University of Milan Bicocca, Monza, 5Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, 6Division of Infectious Diseases, Cremona Hospital, Cremona

    13.29 - 13.34

    OP 122

    Forgiveness to imperfect adherence to bictegravir/emtricitabine/tenofovir alafenamide
    F. Maggiolo1, D. Valenti1,2, R. Teocchi3, L. Comi1, E. Di Filippo1, M. Rizzi1
    1UOC Infectious Diseases, 2FROM foundation, 3Informatics department, ASST Papa Giovanni XXII, Bergamo Italy

    13.36 - 13.41

    OP 123

    Evaluation of metabolic safety profile in naive and virologically suppressed HIV-1 infected individuals starting/switching to a bictegravir single-tablet-regimen in a real-life setting
    M. Trizzino, C. Gioè, E. Di Marco, A. Mancuso, M. Tolomeo, A. Cascio
    Infectious and Tropical Disease Unit, AOU Policlinico "P. Giaccone", Palermo, Italy

    13.43 - 13.48

    OP 124

    Real-world effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in women living with HIV: subgroup analysis from ICONA-BIC
    A. d'Arminio Monforte1, A. Tavelli2, A. Cingolani3, C. Mussini4, S. Piconi5, A. Calcagno6, G. Orofino7, S. Cicalini8, A. Castagna9, F. Ceccherini Silberstein10, A. Gori11, A. Antinori8
    1Department of Health Sciences, Clinic of Infectious Diseases, 'San Paolo' Hospital, University of Milan, Milan, Italy, 2Icona Foundation, Milan, Italy, 3Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy, 4Infectious and Tropical Diseases Unit, Azienda Ospedaliero Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy, 5Infectious Diseases, ASST Lecco, Lecco, Italy, 6Unit of Infectious Diseases, Ospedale Amedeo di Savoia, Department of Medical Sciences, University of Turin, Turin, Italy, 7"Divisione A" Unit of Infectious Diseases, Ospedale Amedeo di Savoia, ASL Città di Torino, Italy, 8Clinical Department, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, 9Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, 10Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, 11Clinic of Infectious Diseases, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

    13.50 - 13.55

    OP 125

    Tolerability, viro-immunological, metabolic effects, and costs of switching to BIC/TAF/FTC in a cohort of people living with HIV: a 48-week analysis
    M. Mazzitelli1, M. Trunfio2, D. Mengato3, C. Putaggio1, L. Sasset1, D. Leoni1, E. Castelli1, A.M. Cattelan1
    1Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, 2Infectious Disease Unit, Department of Medical Sciences at Amedeo di Savoia Hospital, University of Torino, Torino, Italy, 3Hospital Pharmacy Department, Padua University Hospital, Padua, Italy

    14:20 - 15:10

    Oral Poster

    Prevention and access to services during COVID pandemic

    Oral Poster

    Prevention and access to services during COVID pandemic

    Chairs: D. Calzavara, N. Gianotti

    14.20 - 14.25

    OP 132

    Narratives at the time of SARS-CoV-2 vaccination
    M.G. Marini1, E. Volpato2,3, L. Reale1, M. Portaro4, A. Uglietti4
    1Fondazione ISTUD, Milan (Italy), 2Department of Psychology, Università Cattolica del Sacro Cuore, Milan (Italy), 3IRCCS Fondazione Don Carlo Gnocchi, Milan (Italy), 4Infectious Diseases&Vaccines Medical Affairs Department, Janssen-Cilag SpA, Cologno Monzese (MI) (Italy)

    14.27 - 14.32

    OP 133

    Vaccine-preventable diseases in PLWH: adherence to recommendations in a single center in Northern Italy
    F. Pennati, V. Marchese, R. Zilocchi, S. Arsuffi, I. Polesini, F. Gaffurini, D. Castelli, E. Quiros Roldan, F. Castelli, E. Focà
    Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy

    14.34 - 14.39

    OP 134

    Impact of COVID-19 pandemic on sexual exposure and post-exposure prophylaxis (PEP) prescription appropriateness in a large Hospital, Northern Italy
    S. Arsuffi1, D. Minisci1, F.Pennati1, I. Polesini1, S. di Luglio1, E. Quiros-Roldan1, S. Calza2, F. Castelli1, E. Focà1
    1Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, 2Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

    14.41 - 14.46

    OP 135

    Looking for 90-90-90 goals: a real life experience during SARS-CoV-2 pandemia
    G. Brucci1,2, S. Dettori1,2, V. Busin3, L. Taramasso2, A. Vena1,2, F. Mina3, S. Beltramini3, D. Malucelli4, S. Mora5, M. Giacomini5, M. Bassetti1,2, A. Di Biagio1,2
    1Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, 2Infectious Diseases Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy, 3Pharmacy Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy, 4Deenova srl, Piacenza, Italy, 5Department of Engineering and Informatics University of Genoa, Genoa, Italy

    14.48 - 14.53

    OP 136

    The impact of COVID-19 pandemic on access to HIV services at urban context-based health facilities supported by CUAMM in collaboration with UNICEF, in Beira Mozambique
    N. Ronzoni1,2, C. Di Chiara1, V. Casigliani2, E. Barbieri1, A. Agazzi1, A. Zin1, A. Merolle2, F. Chenene2, V. Cinturao2, E. Occa2, D. Donà1, G. Putoto3, C. Giaquinto1
    1Department for Women’s and Children’s Health, University of Padua, Italy, 2Doctors with Africa CUAMM, Beira 2100, Mozambique, 3Operational Research Unit, Doctors with Africa CUAMM, Italy, 4Department of translational research and new technologies in medicine and surgery - University of Pisa, Italy

    14.55 - 15.00

    OP 137

    HAV, HBV and HPV vaccination coverage rate in a community-based pre-exposure prophylaxis program in Milan
    C. Muccini1,2, A. Tavelli1,3, R. Rossotti1,4, D. Calzavara1, P. Vinti1, A. De Bona1,3, S. Bossolasco1,2, D. Canetti1,2, D. Tesoro1,3, G. Mulè1,3, A. Foschi1,5, R. Repossi1, V. Ferrara1, A. D’Arminio Monforte1,3, M. Cernuschi1,2
    1Milano Checkpoint, Milano, 2IRCCS San Raffaele Scientific Institute, Milano, 3ASST Santi Paolo e Carlo, Milano, 4ASST Niguarda Hospital, Milano, 5ASST Fatebenefratelli Sacco

    15:20 - 16:10

    Oral Poster

    Immunopathogenesis of HIV

    Oral Poster

    Immunopathogenesis of HIV

    Chairs: V. Mazzotta, G. Nunnari

    15.20 - 15.25

    OP 144

    Distinctive features of immune markers of activation and exhaustion in adolescents and young adults people living with HIV infected perinatally vs. adult age
    L. Taramasso1, C. Dentone1, D. Fenoglio2,3, T. Altosole2, A. Parodi2, I. Cama4, C. Campi4,5, S. Garbarino4, M. Piana4,5, S. Mora6, M. Giacomini6, L. Labate7, G. Filaci2,3, M. Bassetti1,7, A. Di Biagio1,7
    1Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, 2Department of Internal Medicine-Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Italy, 3Biotherapy Unit, IRCCS Policlinico San Martino, 4MIDA, Dipartimento di Matematica, Università degli studi di Genova, Genova, Italy, 5LISCOMP, IRCCS Ospedale Policlinico San Martino, Genova, Italy, 6Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genova, Genova, Italy, 7Department of Health Science (DISSAL), University of Genova and Infectious Disease Clinic, Policlinico San Martino Hospital, Genova, Italy

    15.27 - 15.32

    OP 145

    Lack of HIV Type 1 Antibody seroconversion in Acutely Infected Individuals Treated with Early Antiretroviral Therapy
    A. Bertoldi1, A. Primavera1, M. Tamburello2, A. Morellini2, V. Ferraro2, S. Vituliano2, V. D’Urbano2, T. Lazzarotto1, L. Calza3, I. Bon1
    1Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, 2Section of Microbiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy, 3Clinics of Infectious Diseases, Department of Medical and Surgical Sciences, School of Medicine, University of Bologna, Bologna, Italy

    15.34 - 15.39

    OP 146

    Evaluation of HCMV specific T-cell responses in PLwHIV and their correlation with the immune-virological status and clinical parameters
    M. Iannetta, A. Lodi, L. Ferrari, A. Imeneo, A. Di Lorenzo, I. Fato, B. Massa, I. Spalliera, B. Rossi, M. Zordan, L. Campogiani, L. Coppola, V. Malagnino, E. Teti, M. Andreoni, L. Sarmati
    Department of System Medicine Tor Vergata University, Rome

    15.41 - 15.46

    OP 147

    Crosstalk between gut microbiota and T cell responses in ART-treated HIV-1 infected patients
    L. Santinelli1, L. Maddaloni1, A. Lazzaro1, P. Vassalini1, F. Frasca2, C.M. Lofaro1, S. Caiazzo1, G. Ceccarelli1, G. Antonelli2,3, C.M. Mastroianni1, C. Scagnolari2, G. d’Ettorre1
    1Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, 2Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Italy, 3Microbiology and Virology Unit, Sapienza University Hospital “Policlinico Umberto I”, Rome, Italy

    15.48 - 15.53

    OP 148

    Large proportion of new HIV diagnoses sustained by non-B subtypes – clinical and immunological correlates
    G. Bozzi1, P. Saltini1, G. Butta2, C. Bobbio1, A. Muscatello1, S. Ludovisi1, A. Gori1,3, A. Bandera1,3, L. Manganaro1,2
    1Infection Diseases Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico - Milan, Italy, 2Virology Unit, INGM-Istituto Nazionale di Genetica Molecolare - Milan, Italy, 3Department of Pathophysiology and Transplantation, University of Milan - Milan, Italy

  • Bergamo Science Center
    10:05 - 10:55

    Oral Poster

    Toxicity of antiretroviral therapy

    Oral Poster

    Toxicity of antiretroviral therapy

    Chairs: C. Gervasoni, R. Gulminetti

    10.05 - 10.10

    OP 96

    Efficacy and safety of switching to lamivudine/dolutegravir in HIV-1-infected patients aged over 65 years
    L. Calza1, V. Colangeli1, M. Borderi1, R. Riccardi1, F. Malerba1, I. Bon2, P. Viale1
    1Unit of Infectious Diseases, 2Unit of Microbiology, IRCCS S.Orsola Hospital, University of Bologna, Bologna, Italy

    10.12 - 10.17

    OP 97

    Specific neurodevelopmental consequences of dolutegravir exposure in a zebrafish embryo model and rescue with early folate treatment
    S. Ferretti1, E. Quiros-Roldan1, I. Zanella2, F. Castelli1, E. Massardi3, G. Borsani3, G. Tiecco1, S. Storti1, D. Zizioli3
    1Division of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, 2Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy, 3Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

    10.19 - 10.24

    OP 98

    Causes of HIV treatment interruption during the last 20 years: a multi-cohort real-life study
    A. De Vito1, E. Ricci2, B. Menzaghi3, G. Orofino4, C. Martinelli5, N. Squillace6, L. Taramasso7, G.V. De Socio8, C. Molteni9, F. Conti10, L. Valsecchi11, C. Costa12, B.M. Celesia13, G. Parruti14, G. Pellicanò15, E. Sarchi16, A. Cascio17, G. Cenderello18, K. Falasca19, A. Di Biagio7, P. Bonfanti6, G. Madeddu1
    1Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, 2Fondazione ASIA Onlus, Buccinasco (MI), Italy, 3Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, 4Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, 5SOD Malattie Infettive e Tropicali, AOU Careggi, Firenze, Italy, 6Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, 7Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, 8Clinic of Infectious Diseases, Department of Medicine, Azienda Ospedaliera di Perugia, Santa Maria Hospital, Perugia, 9Infectious Disease Unit, Ospedale A. Manzoni, Lecco, Italy, 10Infectious Diseases Unit, Department of Biomedical and Clinical Sciences 'Luigi Sacco', Università degli Studi di Milano, Milan, Italy, 11Infectious Disease Unit (I Divisione), ASST Fatebenefratelli Sacco, Milan, Italy, 12Infectious Diseases Department, SOC 1, USLCENTROFIRENZE, Santa Maria Annunziata Hospital, Florence, Italy, 13Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi, Catania, Italy, 14Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy, 15Department of Human Pathology of the Adult and the Developmental Age “G. Barresi,” Unit of Infectious Diseases, University of Messina, Messina, Italy, 16Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, 17Infectious and Tropical Diseases Unit- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) - University of Palermo, Palermo, Italy, 18Infectious Disease Unit, Sanremo Hospital, Sanremo, Italy, 19Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University “G. d”Annunzio’ Chieti-Pescara, Chieti, Italy

    10.26 - 10.31

    OP 99

    First and second phase viral load decay in real-life using Nonlinear Bayesian Mixed Effect model
    D. Ceccarelli1, R. Lolatto1, N. Gianotti1, C. Muccini1,2, D. Canetti1, C. Maci1,2, C. Oltolini1, B. Trentacapilli1,2, A. Castagna1,2, L. Galli1
    1Infectious Diseases Unit, IRCSS San Raffaele Hospital, Milan, Italy, 2Vita-Salute San Raffaele University, Milan, Italy

    10.33 - 10.38

    OP 100

    The effects of switching from dolutegravir/abacavir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomized study
    B. Rossetti1,2, M. Ferrara3, L. Taramasso4, F. Bai5, F. Lombardi6, N. Ciccarelli7, M. Durante8, F. Alladio3, I. Rancan1,8, F. Montagnani1,8, A. Di Biagio9, A. d’Arminio Monforte5, M. Zazzi8, M. Fabbiani1 for DOBINeuro study group
    1Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, 2Infectious Disease Department, USL SUDEST Toscana, Misericordia Hospital, Grosseto, Italy, 3Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, 4Infectious Diseases Clinic, Department of Internal Medicine, IRCCS Policlinico San Martino Hospital, Genoa, Italy, 5Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, 6Infectious Diseases Unit, UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 7Department of Psychology, Catholic University, Milan, Italy, 8Department of Medical Biotechnologies, University of Siena, Siena, Italy, 9Infectious Diseases Clinic, Department of Health Sciences, University of Genoa, San Martino Hospital-IRCCS, Genoa, Italy

    10.40 - 10.45

    OP 101

    Dynamic of lipid profile in HIV naive patients treated by TAF-based regimens: a multicenter observational study
    S. Martini1, P. Maggi1,2, C. Gervasoni3, L. Onorato1, S. Ferrara4, L. Alessio1,2, C. Bellacosa5, V. Esposito6, G. Di Filippo7, A. Masiello8, A. Maddaloni9, S. Madonia10, G.D’Alessio11, V. Rizzo6, N. Coppola1
    1Infectious Disease, University of Campania, Luigi Vanvitelli, 2AORN Sant’Anna e San Sebastiano of Caserta, 3ASST FBF SACCO of Milan, 4University of studies of Foggia, 5University of studies of Bari, 6IV Division AORN dei Colli, 7University Federico II of Naples, 8AO San Giuseppe Moscati of Avellino, 9VII Divisione AORN dei Colli, 10AOU San Giovanni di Dio e Ruggi d’Aragona of Salerno, 11AORN San Pio of Benevento

    12:15 - 13:05

    Oral Poster

    Immunological efficacy of COVID-19 vaccination in vulnerable populations

    Oral Poster

    Immunological efficacy of COVID-19 vaccination in vulnerable populations

    Chairs: G. Scarlatti, M. Tavio

    12.15 - 12.20

    OP 114

    TNF-alfa expression is negatively correlated to seroconversion after SARS-CoV-2 mRNA BNT162b2 Vaccine in lung transplant patients
    M. Guardiani1, M.A. Zingaropoli1, F. Cogliatti-Dezza1, A. Centofanti2, C. Carillo2, E. Tortellini1, F. Dominelli1, A. Napoli3, A. Gaeta1, F. Venuta2, M. Lichtner1,4, M.R. Ciardi1, C.M. Mastroianni1, G. Russo1
    1Department of Public Health and Infectious Diseases, Sapienza University of Rome, 2Department of General and Specialistic Surgery “Paride Stefanini”, Sapienza University of Rome, 3Department of Molecular Medicine, Sapienza University of Rome, 4Infectious Diseases Unit, Santa Maria (SM) Goretti Hospital, Sapienza University of Rome, Latina

    12.22 - 12.27

    OP 115

    Different specific T cell responses to the third dose of mRNA COVID-19 vaccine in multiple sclerosis patients under disease-modifying treatments
    F. Dominelli1, M.A. Zingaropoli1, M. Tartaglia2, E. Tortellini1, M. Guardiani1, V. Perri1, P. Pasculli1, F. Ciccone1, L. Malimpensa2, V. Baione2, A. Napoli3, A. Gaeta1, M. Lichtner1,4, A. Conte2, C.M. Mastroianni1, M.R. Ciardi1
    1Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza, Università di Roma, 2Dipartimento di Neuroscienze Umane, Centro di Sclerosi Multipla, Sapienza, Università di Roma, 3Dipartimento di Medicina Molecolare, Sapienza, Università di Roma, 4Unità di Malattie Infettive, Ospedale S. Maria Goretti/Sapienza Università di Roma, Latina, Italia

    12.29 - 12.34

    OP 116

    SARS-CoV-2 vaccination effectiveness in Pemphigus Vulgaris Rituximab-treated patients
    C. Fenizia1, O. Utyro2, S. Salanitro2, C. Moltrasio1, M. Clerici1, L. Ottobrini1, A. Marzano1, D. Trabattoni2
    1Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, 2Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy

    12.36 - 12.41

    OP 117

    SARS-CoV-2 antibody response in solid organ transplant patients after mRNA BNT162b2: data from an observational prospective study
    F. Cogliati Dezza1, F. Dominelli1, M. Guardiani1, E. Tortellini1, G. Savelloni1, M. Garofalo2, A. Centofanti3, C. Carillo3, A. Gaeta4, R. Pretagostini2, G. Russo1, C.M. Mastroianni1
    1Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome Italy, 2General Surgery and Organ Transplantation Unit, Sapienza University of Rome, Rome, Italy, 3Division of Thoracic Surgery and Lung Transplant, Sapienza University of Rome, Rome, Italy, 4Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

    12.43 - 12.48

    OP 118

    Durability of SARS-CoV-2 mRNA vaccine immune response in people living with HIV
    S. Cicalini1, A. Cozzi-Lepri2, A. Vergori1, S. Meschi1, V. Bordoni1, S. Lanini1, D. Lapa1, D. Mariotti1, L. De Pascale1, V. D’Aquila1, M. Fusto1, C. Castilletti1, A.R.Garbuglia1, C. Agrati1, E. Girardi1, F. Vaia1, A. Antinori1
    1National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Roma, Italy, 2Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK

    12.50 - 12.55

    OP 119

    Decay pattern of Anti–SARS-CoV-2 Antibodies in PWH
    J. Milic1, A. Tili2, S. Renzetti3, F. Motta1, M. Meschiari2, R. Fogliani2, F. Ferrari2, B. Meccugni2, S. Mimmi2, S. Borsari2, S. Calza3, A. Cossarizza1, C. Mussini1,2, G. Guaraldi1,2
    1University of Modena and Reggio Emilia, Modena, Italy, 2Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, 3University of Brescia, Brescia, Italy

    13:15 - 14:05

    Oral Poster

    Immunological complexity in COVID-19

    Oral Poster

    Immunological complexity in COVID-19

    Chairs: E. Focà, E. Nicastri

    13.15 - 13.20

    OP 126

    Development of SARS-CoV-2 IgM after 1st vaccine dose predicts longer immunity
    A. Ruggiero1, C. Piubelli2, L. Calciano1, G. Siracusano3, M.T. Valenti1, L.G. Delle Carbonare1, T. Fantoni1, L. Lopalco3, S. Accordini1, A. Beretta4, Z. Bisoffi2, D. Zipeto1
    1University of Verona, Verona, Italy, 2IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy, 3Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy, 4Solongevity Research, Milan, Italy

    13.22 - 13.27

    OP 127

    Affinity maturation and neutralizing activity of anti-SARS-CoV-2 Spike antibodies
    S. Caucci1, R. Longo1, B. Corvaro1, A. Valenza2, K. Marinelli2, P. Bagnarelli1,2, S. Menzo1,2
    1Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, Italy, 2Virology Laboratory, Azienda Ospedaliera Ospedali Riuniti di Ancona, Ancona, Italy

    13.29 - 13.34

    OP 128

    Correlation between clinical aspects and serum/CSF cytokine levels in early versus classic onset SARS-CoV-2-related Guillain-Barré Syndrome
    S. Boni1, L. Benedetti2, M. Feasi1, A. Assini3, E. Blasi Vacca1, S. Grisanti2,4, A. Parisini1, D. Franciotta2, F. Del Puente1, F. Massa2,4, N. Bobbio1, T. Vigo2, R. Prinapori1, D. Giunti2, E. Mobilia2, D. Visigalli2, A. Beronio5, P. Rivera6, F. Bandini7, A. Granata8, E. Narciso7, A. Schenone2,4, E. Pontali1
    1Department of Infectious Diseases - Galliera Hospital, Genova, Italy, 2IRCCS, Ospedale Policlinico San Martino, Genova, Italy, 3Neurology Unit, Galliera Hospital Genova, Italy, 4Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy, 5Department of Neurology, Sant’Andrea Hospital, La Spezia, Italy, 6Department of Neurology, Imperia Hospital, Imperia, Italy, 7Department of Neurology, ASL3 Genovese, Genova, Italy, 8Department of Neurology Santa Corona Hospital, Pietra Ligure, Savona, Italy

    13.36 - 13.41

    OP 129

    A real-life single-center study on the impact of anti-SARS-CoV2 vaccination
    C. Leanza, S. Covino, R.A. Valia, A. Destro, F. Petrucci, E. Motta, M. Aneuchoum, R. Donà, F. Cancelli, C.M. Mastroianni
    Department of Public Health and Infectious Diseases, Sapienza University, Rome

    13.43 - 13.48

    OP 130

    Short course remdesivir in early Covid-19 as an effective and useful option in both out- and in-patients
    C. Del Borgo1, A. Gasperin2, R. Marocco1, D. Di Trento2, S. Garattini2, M. De Masi1, A. Grimaldi2, S. Corazza2, S.G. De Maria2, S. Gismondi1, P. Fabietti1, B. Bartolozzi1, G. Bagaglini3, G. Bonanni3, M. Lichtner1,2
    1Infectious Diseases Unit, SM Goretti Hospital Latina, 2Department of Public Health and Infectious Diseases, “La Sapienza” University, Rome, 3Pharmacy Service Unit, SM Goretti Hospital Latina

    13.50 - 13.55

    OP 131

    Dendritic cell maturation after infection with a clone of Leishmania tarentolae expressing the SARS-CoV-2 spike protein as a vaccine vehicle
    M. Garziano1,2, I. Varotto-Boccazzi3,4, C. Conforti1, G.M. Cattaneo3, B. Bisaglia3, P. Gabrieli3,4, M. Paroni3,4, A. Manenti5, D. Rubolini6,7, M. Clerici2,8, E. Montomoli5,9, G. Zuccotti1,4, C. Vanetti1, S. Epis3,4, M. Biasin1, C. Bandi3,4, D. Trabattoni1
    1Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, 2Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, 3Department of Biosciences, University of Milan, Milan, Italy, 4Pediatric CRC ‘Romeo ed Enrica Invernizzi’, University of Milan, Milan, Italy, 5VisMederi, Siena, Italy, 6Department of Environmental Science and Policy, University of Milan, Milan, Italy, 7Water Research Institute-National Research Council of Italy, IRSA-CNR, Brugherio, Italy, 8IRCCS Fondazione don Carlo Gnocchi, Milan, Italy, 9Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy

    14:20 - 15:10

    Oral Poster

    SARS-CoV-2: from in vivo to in vitro

    Oral Poster

    SARS-CoV-2: from in vivo to in vitro

    Chairs: V. Micheli, M. Santoro

    14.20 - 14.25

    OP 138

    Characterization of SARS-CoV-2 epidemic and transmission dynamics in children over the four COVID-19 waves
    R. Scutari1,2, V. Costabile1,2, L. Colagrossi2, K. Yu La Rosa2, V. Fini2, A. Granaglia2, E. Agolini2, V. Lanari2, S. Chiurchiù4, L. Romani4, A. Markowic4, P. Bernaschi3, C. Russo3, A. Novelli2, S. Bernardi4, A. Campana4, A. Villani4, C.F. Perno2,3, C. Alteri1,2
    1Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, 2Multimodal Research Area, Bambino Gesù Children Hospital IRCCS, Rome, Italy, 3Microbiology and Diagnostics in Immunology, Bambino Gesù Children Hospital IRCCS, Rome, Italy, 4Academic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

    14.27 - 14.32

    OP 139

    Rapid change in epidemiological and clinical characteristics of SARS-CoV-2 circulating variants in Italy in April-December 2021
    A. Bergna1, A. Lai1, C. Della Ventura1, B. Bruzzone2, F. Sagradi3, F. Ceccherini Silberstein4, A. Weisz5, N. Clementi6, G. Brindicci7, I. Vicenti8, V. De Pace2, L. Lanfranchi3, M.C. Bellocchi4, G. Giurato5, R. Ferrarese6, A. Lagioia7, D. Francisci9, M. Lucente2, M.R. Cappelletti3, M. Iannetta4, F. Rizzo5, C.R. Santoro7, C. Fraccalvieri2, S. Testa3, L. Carioti4, T. Rocco5, M. Clementi6, L. Sarmati4, S. Antinori1, G. Zehender1 and SCIRE-SARS-CoV-2 Italian research enerprise-collaborative group
    1Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy, 2Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, 3Unit of Infectious Diseases, Azienda Socio Sanitaria Territoriale Cremona, Cremona, Italy, 4Infectious Diseases, Tor Vergata University, Rome, Italy, 5Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry ‘Scuola Medica Salernitana’, University of Salerno, Salerno, Italy, 6Laboratory of Microbiology and Virology, Università "Vita-Salute" San Raffaele, Milan, Italy, 7Infectious Diseases Unit, University of Bari, Bari, Italy, 8Department of Medical Biotechnologies, University of Siena, Siena, Italy, 9Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy

    14.34 - 14.39

    OP 140

    Higher viral load (VL) in nasopharyngeal swab (NPS) of individuals infected with Omicron BA.2 SARS-CoV-2, compared to Alpha, Gamma, Delta and Omicron BA.1 Variants Of Concern (VOCs)
    I. Mastrorosa1, A. Cozzi-Lepri2, F. Colavita1, E. Lalle1, V. Mazzotta1, G. Matusali1, C. Cimaglia1, J. Paulicelli1, L. Fabeni1, F. Carletti1, S. Rosati1, S. Vita1, G. Giannico1, P. Piselli1, E. Biliotti1, S. Al Moghazi1, S. Mosti1, E. Girardi1, E. Nicastri1, A.R. Garbuglia1, F. Vaia1, A. Antinori1
    1National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, 2Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, United Kingdom

    14.41 - 14.46

    OP 141

    Dopamine reduces SARS-CoV-2 replication through downregulation of D2 receptors and upregulation of Type-I Interferons
    F. Limanaqi1,2, D. Borana2, S. Zecchini2, G. Cappelletti2, S. Strizzi2, D. Trabattoni2, M. Clerici1,3, M. Biasin2
    1Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, 2Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, 3Don C. Gnocchi Foundation, IRCCS Foundation, Milan, Italy

    14.48 - 14.53

    OP 142

    Developmental safety of nirmatrelvir in zebrafish embryos
    S. Ferretti1, E. Quiros-Roldan1, F. Castelli1, E. Massardi3, G. Borsani3, S. Storti1, G. Tiecco1, I. Zanella2, D. Zizioli3
    1Division of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, 2Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy, 3Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

    14.55 - 15.00

    OP 143

    Peptidomimetic covalent reversible inhibitors exhibit broad-spectrum inhibition of CoVs Main protease and cellular activity against SARS-CoV-2: design, synthesis, biological evaluation, and structural biology
    R. Cannalire1, F. Esposito2, I. Stefanelli1, A Corona2, C. Cerchia1, E. Cassese1, S. Improta1, P. Storici3, E. Costanzi3, E. Tramontano2, V. Summa1
    1Dipartimento di Farmacia - Università degli Studi di Napoli Federico II, Napoli, Italy, 2Dipartimento di Scienze della vita e dell’ambiente, Università degli Studi di Cagliari, Cittadella Universitaria di Monserrato, Cagliari, Italy, 3Elettra-Sincrotrone Basovizza, Trieste, Italy

    15:20 - 16:15

    Round Table

    Preventing an fighting emerging infections: the monkeypox paradigma between information and stigma

    Round Table

    Preventing an fighting emerging infections: the monkeypox paradigma between information and stigma

    Chairs: A. Antinori, M.G.L. Cernuschi

    Discussants: G.M. Corbelli, M. Farinella, E. Girardi, S. Nozza, M. Pavan

      Preventing an fighting emerging infections: the monkeypox paradigma between information and stigma
    S. Nozza
      Preventing an fighting emerging infections: the monkeypox paradigma between information and stigma
    M. Pavan
×
Chiudi
×

×

Password dimenticata

Password forgot

Inserisca il suo indirizzo email. Riceverà un messaggio con il link per effettuare il reset della password.